<div id="page0" style="width:595.3pt;height:793.7pt">
<img style="position:absolute;transform:matrix(.47984082,0,-0,.4790448,658.14669,203.74797)" src="data:image/jpeg;base64,
/9j/7gAOQWRvYmUAZIAAAAAB/9sAhAACAgICAgICAgICAwICAgMEAwICAwQFBAQE
BAQFBgUFBQUFBQYGBwcIBwcGCQkKCgkJDAwMDAwMDAwMDAwMDAwMAQMDAwUEBQkG
BgkNCwkLDQ8ODg4ODw8MDAwMDA8PDAwMDAwMDwwMDAwMDAwMDAwMDAwMDAwMDAwM
DAwMDAwMDAz/wAARCABDAEMDAREAAhEBAxEB/8QBogAAAAcBAQEBAQAAAAAAAAAA
BAUDAgYBAAcICQoLAQACAgMBAQEBAQAAAAAAAAABAAIDBAUGBwgJCgsQAAIBAwMC
BAIGBwMEAgYCcwECAxEEAAUhEjFBUQYTYSJxgRQykaEHFbFCI8FS0eEzFmLwJHKC
8SVDNFOSorJjc8I1RCeTo7M2F1RkdMPS4ggmgwkKGBmElEVGpLRW01UoGvLj88TU
5PRldYWVpbXF1eX1ZnaGlqa2xtbm9jdHV2d3h5ent8fX5/c4SFhoeIiYqLjI2Oj4
KTlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+hEAAgIBAgMFBQQFBgQIAwNtAQAC
EQMEIRIxQQVRE2EiBnGBkTKhsfAUwdHhI0IVUmJy8TMkNEOCFpJTJaJjssIHc9I1
4kSDF1STCAkKGBkmNkUaJ2R0VTfyo7PDKCnT4/OElKS0xNTk9GV1hZWltcXV5fVG
VmZ2hpamtsbW5vZHV2d3h5ent8fX5/c4SFhoeIiYqLjI2Oj4OUlZaXmJmam5ydnp
+So6SlpqeoqaqrrK2ur6/9oADAMBAAIRAxEAPwD7+Yq0SFFT0xViHmHzv5f8s21x
darqEVrBbIXmlkNFUAVqTTbFXzhrf/OX35cWNw0FjqEmocCVd7eGZlBU0I5GMD7s
2+LsHXZQDHEaPeQPvNuuydraXGaMxflZ+4JfY/8AOZH5fyTol1Nc20TGhle3l4iv
ckRmgyc/Z3Xx/wAnfuMT+ljHtnSS/j+YP6nu/k784fJnnaBbjQ9Wiu4mJHJQwIIp
UFWUEdR1GajLinilwzBB7js7GE4zFxNjyeqRSpMgeNgyncEZBkqYq7FWiQoJPQYq
+Y/zu/O+DyRANJ0mE6j5gu1/0WxDFBwDANI7lGCqv3k9O9M7s/QT1mThGwHM9w/S
fJxdXqo6eFnc9B3vzQ89eYNU1q9Gqeedbk1C9kLyWliaJHGnIBuCr8IC7DxObztH
t/s72ax+mJllPID6pcruVVHn5e5xuyfZvtD2jykAgQjzJ+mN3Xpu5cj3+95vJ5q8
t23JRDzPL4WDUoKdDyVq557rP+Cd2rnleGEMce76z8zX3PpOj/4EuhxxrLklM94H
D9ln71MedfLz1X6vQnZSzAge9Aik/flOD/gkdswmDPglHu4eH7Q35v8AgUdnSiRC
U4nv5/Yyny7q+iXWp2kulXsmjauslNPuYmepk4s1AwoR8KsTUcaDc53HZHt1pe2R
+X1WPgkf4STIGu6QAr408H277A6zsP8AwjDPjgP4hUSL74km/hb9DfyS/OzU7ee2
8reeJ+V/K3p6fqlAq3J3biVRKIyqPGjfPbB2r2YNOfExm4E/GPl5+/5ut0OsOUcE
xUgPn5/sfbdvcR3MSSxNyRxUHNM7FXxVhHn/AMyQeV/Lep6tcSiKO1gZ2Y+30HHm
r89fK+h3n5l+dLt7m6Iubit/rWoMOf1e2V1VLeJarUnkIlO1PtnpnTZJ/wAn6YRj
9R+/v+DpoR/NZuI8h93d8XyP/wA55vH5T/NXy1pel26WVqnl2GK3tIz8EUcLfCgJ
qTTluSak7k1Oec9v4/E4Ce+X6H2P/gcxBln90P8AfPhSXW76U19QjNEMMQ+qCAUh
q18pr6px8KKeAPY/yD1e6u/zq/Le3laqnVK9v2YJj4VzY9kYhHUgjuLxnt3Cuy5H
+lD736t/m75WtfJ95Zarp8HHy9rMxikteq2t4AZQEJqwWQBmUdFKkDbiM9M7K1Xi
A4Z77be7ufn7XYuCske/f9b6i/ILz5/ijy99TuJzNfaYwtrlz1ZlUEMaKB8SsG28
c0+rweBlMO7l7nYYMviwEn0TXMdtfIH/ADld5mk0nyvb2S8uN/dwxMytxpxJlqdj
UH0+JHvmd2bAS1EAe/7hbi62fDhkfJin/OKWmQXPlDzB5rdxLc6rrJs1FCCkdhEO
AJrQ/FcORQCld67UyO2cnFn4f5oH6/0tHZsaw33n9j88P+fjLMv50+XlBoJNA4sP
Ec1NPwzjO2+UPj+h9e/4G31aj3Q/374DCE5oOJ9W4XcDg4l4HsH/ADj4zL+d35bx
1IVtV5MviRbzgH6KnNp2Qf8ACB7i8Z7eiuypf1ofe/dv819KXWfy684WZiaaWPTJ
ry0SNeT+vaKZ4uIodyyU+ROdlpshx5YyHQh8Izw48conqHzx/wA4h+aZ7nzRqlnE
wME1tDK57lgxUe1KE5t+38PDOEvePl/a63sfLxRlH3F+nfI/8LXOfdy+Fv8AnNm0
ux5Mg1CCNmisbyCSZwPso3KOv3uBmx7Jr81C/P7i4PaV/l5V5feFH/nCzUre9/KD
ULWOQvdab5kvReqQRx9eKB49+hquWdsx4dTI94B+yv0NfZUuLTjyJH23+l8A/wDP
xNOf506B8QBXQAQCSK/Guwp1OcX26aEPj+h9i/4GYuWo90P9++C1i9s5ozfWxFcY
fbHjXhes/kDFT87Py3fkBTVqcKmprbz7gU6CmbbsaV6ke4vEf8EAV2VL+vD737xf
mHqjaH5C86ayrRIdN0S+lV5zxiD+g4jVjUfaYhQK7nYb52eIEyiBzsfe+DZCBE3y
ovir/nCCC4k86a5KiM1tBZ28ZehoH5saVpStM6D2hmDwR67n7nS9hwI4z02H3v14
p/xGmc0794v+fPkoed/IOu6N0N1auivSpVuqkfC3QgHpk8WQ45iY5g2wyQGSJieR
FPzN/wCcUPzOX8rvzL1fyH5xuH0vSfNcg06b139OG01aB+MMkgelBICYqjrVK7Db
oO1sQ1GKObHvX3fs6/F0fZuQ4MksU9r+/wDb0eaf8/EYXH52+X0YEFdCXkN/5hnn
PtBL04/j+h9y/wCBiPXqP8z/AH74w0/Qri848UND0oDX9WcnPLT61LIIor9ACe2F
1Zzx3du9eFxC6yRsQaGjJUGh674ykYSqQIPcdmjDrcWaPFCQkO8EEfMM0/I21lh/
PH8tkKMWOq8QorufQm6CmbzsKV6ke4/c8h/wQt+yZH+lD736df8AOZ/5oWvl7yxZ
flTpV7HJrXmVkvfNiwyBmtrOBg8UEnBqqZXAajChUH6PSOydOcmXxDyj9/4/Q/On
aWfgx8A5y+56d/zhN+XF35d8lN5i1S3MF55ll+uiKRSGSGgSEEMBuVHL/ZZV2nqR
nzEg7DYfp+1u7OwHDi35ncvvSn6qZr3OULm3juoZIZBySRSCDir8vP8AnLP/AJxk
1G5mn8/+RbIy6jFWTVtKt0IkugDUSxCNN5gfE7jvUb7Ts/XeD6J/Sfs/Z3uu12j8
X1x+ofb+3uflp+ZP5jebfOnnDTLT8wb31LryZpcGmnVL/nHdshd6C9klb4pFKhQW
APY1O+cr7XaYceMYQTxcVAb93Kn1T/gWa0Y8eqnnkIiPh2ZHhA+v6idn1b/zjJ+W
n5f/AJi8PMHm3zz5d0by/Z8qeXbzUra1vrlqlAZ4bihSM9QKVO246Zh9nez/AIB8
TUC5dB0HvvmfsafaT24lrScOjkY49wZcpS6bUdon5nrQ2ey/n5+SH5WW1hB5n/LP
8wfI3l79GiOLU/Lr6tYxWV1FtGSqwDks1AOLDao+IEZsO0ey8eujuKmBsRz+PePw
Hn+wvaLP2RMcJvGT6onl5mPdL7+r83Y/zBTyb5z0TzV5TubG91fy7qTRLC7eqsUr
ia3ErKjKSu/JDsGFD0zUdidmZtPrxizAjY79Dt0e79q+39N2j2BPNgkD6oXEkcUf
VXqAO3l39C+6/wDnHz/nH/zf+dnmiT8wfzFlv5dJmu/rU89/6n1rU51YEFjKjVgH
2eu9OI2z0PU62OKHhYvmP0efe+IabSSyS8TL8vx07n7RaFo1roen29haRrFFAioq
oAoAAoAAABmldunOKuxVCXtlb30DwXEayI4oQwB/Xir4m/Of/nCH8r/zUvpNbn04
6ZrbEO+o2CxQyuy7gy/uWElCTTlWldsnjmYSEgBY5X0vmiYMoGFkRlVgGga5WORr
pfLo+J/NP/PvHzjBfOvlvzFbzWgRgrX8MgkrU8RyhiIIpSu2Zn58kbhwfyIH0ksb
0X/n3h+Z8txCut6/pUETS/vjZxXUpCU2K+rDGOVfHH84Adgo0ZI3L61/LT/n3d+W
HlzWLLzH5ijn8y6rbBWpqAhe3LLQj9wYApodxyJpmNlzyyEE0K7nKxYRiBAJo8/O
txty8/e/RDRNB0/QrSK0sLdIIolCqqKqgAewAyltTvFXYq7FXYq0eh/jiqFk6/7q
+nFVi9f90/RiqMXp2+jFV2KuxV2Kv//Z">
<p style="top:167.5pt;left:42.5pt;line-height:13.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.4pt">Alpha-7 nicotinic agonists for cognitive de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:13.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:13.4pt">cits in neuropsychiatric</span></p>
<p style="top:184.7pt;left:42.5pt;line-height:13.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.4pt">disorders: A translational meta-analysis of rodent and human studies</span></p>
<p style="top:209.4pt;left:42.5pt;line-height:10.6pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">Alan S. Lewis</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">a</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt">,</span></sup><span style="font-family:AdvTT5235d5a9+20,serif;font-size:12.0pt;color:#2e3092">&#x204e;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, Gerrit I. van Schalkwyk</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">b</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, Michael H. Bloch</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">b</span></sup></p>
<p style="top:226.3pt;left:42.5pt;line-height:4.5pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">a</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> Department of Psychiatry, Yale University, 34 Park Street, 3rd Floor, Research, New Haven, CT 06508, United States</span></p>
<p style="top:234.8pt;left:42.5pt;line-height:4.5pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">b</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> Yale Child Study Center, 230 S. Frontage Road, New Haven, CT 06520, United States</span></p>
<p style="top:265.7pt;left:206.9pt;line-height:9.0pt"><span style="font-family:AdvTT0f485e03,serif;font-size:9.0pt">a b s t r a c t</span></p>
<p style="top:265.7pt;left:42.5pt;line-height:9.0pt"><span style="font-family:AdvTT0f485e03,serif;font-size:9.0pt">a r t i c l e</span></p>
<p style="top:265.7pt;left:107.3pt;line-height:9.0pt"><span style="font-family:AdvTT0f485e03,serif;font-size:9.0pt">i n f o</span></p>
<p style="top:286.1pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">Article history:</span></p>
<p style="top:294.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Received 10 December 2016</span></p>
<p style="top:303.3pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Received in revised form 24 December 2016</span></p>
<p style="top:311.8pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Accepted 3 January 2017</span></p>
<p style="top:320.4pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Available online 5 January 2017</span></p>
<p style="top:286.5pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">Cognitive dysfunction in schizophrenia (SCZ) and Alzheimer&apos;s disease (AD) is a major driver of functional disabil-</span></p>
<p style="top:296.0pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">ity but is largely unresponsive to current therapeutics. Animal models of cognitive dysfunction relevant to both</span></p>
<p style="top:305.6pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">disorders suggest the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">7 nicotinic acetylcholine receptor (nAChR) may be a promising drug development target,</span></p>
<p style="top:315.1pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">with multiple clinical trials subsequently testing this hypothesis in individuals with SCZ and AD. However, the</span></p>
<p style="top:324.7pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">translational value of rodent cognitive tasks for predicting the overall ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:7.2pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">cacy of this therapeutic target in clinical</span></p>
<p style="top:334.3pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">trials is unknown. To compare effect sizes between rodent and human studies, we searched PubMed and the</span></p>
<p style="top:343.8pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">Cochrane Library for all randomized, placebo-controlled trials of compounds with pharmacological activity at</span></p>
<p style="top:353.4pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">7 nAChR for treatment of cognitive dysfunction in SCZ and AD and identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:7.2pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">ed 18 studies comprising 2670</span></p>
<p style="top:363.0pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">subjects treated with eight different compounds acting as full or partial agonists. Cognitive outcomes were stan-</span></p>
<p style="top:372.5pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">dardized, and random-effects meta-analyses revealed no statistically signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:7.2pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">cant effects of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">7 nAChR agonists on</span></p>
<p style="top:382.1pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">overall cognition or any of eight cognitive subdomains when all doses were included (Range of all cognitive out-</span></p>
<p style="top:391.7pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">comes: Cohen&apos;s d =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:7.2pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">0.077 to 0.12, negative favoring drug). In contrast, analysis of 29 rodent studies testing the</span></p>
<p style="top:401.3pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">same</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">7 agonists revealed large effect sizes in multiple commonly used preclinical behavioral tests of cognition</span></p>
<p style="top:410.8pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">(Range: d =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:7.2pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">1.18 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:7.2pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt"> 0.73). Our results suggest that targeting the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">7 nAChR with agonists is not a robust treat-</span></p>
<p style="top:420.4pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">ment for cognitive dysfunction in SCZ or AD and necessitate a better understanding of the translational gap for</span></p>
<p style="top:429.9pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">therapeutics targeting the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">7 nAChR.</span></p>
<p style="top:439.5pt;left:436.3pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">&#xa9; 2017 Elsevier Inc. All rights reserved.</span></p>
<p style="top:338.3pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">Keywords:</span></p>
<p style="top:346.9pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alpha7 nicotinic receptor</span></p>
<p style="top:355.5pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cognition</span></p>
<p style="top:364.0pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Schizophrenia</span></p>
<p style="top:372.6pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s disease</span></p>
<p style="top:381.1pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Meta-analysis</span></p>
<p style="top:389.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Clinical trial</span></p>
<p style="top:481.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">1. Introduction</span></p>
<p style="top:502.4pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Multiple lines of evidence suggest that alterations of the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nicotinic</span></p>
<p style="top:512.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">acetylcholine receptor (nAChR) may play a role in the pathophysiology</span></p>
<p style="top:523.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of several neuropsychiatric disorders that manifest with cognitive im-</span></p>
<p style="top:533.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pairment, including schizophrenia (SCZ) and Alzheimer&apos;s disease</span></p>
<p style="top:544.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(AD). Several brain regions important for cognition, including the hip-</span></p>
<p style="top:554.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pocampus (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Freedman et al., 1995</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) and cortex (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Marutle et al., 2001</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">),</span></p>
<p style="top:565.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">show reduced availability of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR binding sites in patients with</span></p>
<p style="top:575.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">SCZ compared to controls. Many patients with SCZ demonstrate im-</span></p>
<p style="top:586.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">paired sensory gating to paired stimuli, a de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cit thought to contribute</span></p>
<p style="top:596.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to attentional dysfunction, which is normalized by nicotine (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Adler et</span></p>
<p style="top:607.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">al., 1993</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) and by</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7-selective agonists (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Olincy et al., 2006; Stevens et</span></p>
<p style="top:617.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">al., 1998</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Substantive genetic evidence further links the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR to</span></p>
<p style="top:627.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">P50 gating-de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cits in individuals with SCZ and their relatives</span></p>
<p style="top:481.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Freedman et al., 2003</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Similarly, individuals with AD demonstrate al-</span></p>
<p style="top:491.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tered levels of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR protein in peripheral blood leukocytes (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Chu et</span></p>
<p style="top:502.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">al., 2005</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) and in the brain (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Burghaus et al., 2000</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">).</span></p>
<p style="top:512.8pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Given these electrophysiological, neurochemical, and genetic</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nd-</span></p>
<p style="top:523.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ings, treatments directed toward normalization or augmentation of sig-</span></p>
<p style="top:533.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">naling through the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR have been proposed for SCZ and AD, most</span></p>
<p style="top:544.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cally to address cognitive de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cits (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Freedman, 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Cognitive</span></p>
<p style="top:554.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">decline is the hallmark of AD, while impaired cognition in SCZ plays a</span></p>
<p style="top:565.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">major role in driving functional de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cits (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Bowie and Harvey, 2005</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">).</span></p>
<p style="top:575.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Just as cognitive domains are diverse in their fundamental neurophysi-</span></p>
<p style="top:586.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ology, the mechanism by which targeting</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs is hypothesized to</span></p>
<p style="top:596.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">enhance cognition is multifactorial. The normalization of the P50 de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cit</span></p>
<p style="top:607.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in SCZ by nicotine and</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists is arguably the most studied</span></p>
<p style="top:617.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of these effects and believed to be due to</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR stimulation of inter-</span></p>
<p style="top:627.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">neuron populations that inhibit excitatory pyramidal cells in the hippo-</span></p>
<p style="top:638.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">campus (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Freedman, 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Additional pro-cognitive effects of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7</span></p>
<p style="top:648.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChRs are hypothesized to result from regulation of neurotransmitter</span></p>
<p style="top:659.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">release through presynaptic mechanisms (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Wonnacott et al., 2006</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), en-</span></p>
<p style="top:669.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">hancement of synaptic plasticity in circuits important for cognition</span></p>
<p style="top:680.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Gu and Yakel, 2011</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), and initiation of signal transduction cascades</span></p>
<p style="top:690.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">through calcium in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ux (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Bitner et al., 2007</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Thus,</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR targeting</span></p>
<p style="top:701.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in individuals with disorders such as SCZ or AD may correct an</span></p>
<p style="top:37.7pt;left:187.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">53</span></p>
<p style="top:659.6pt;left:55.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">Abbreviations:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> nAChR, nicotinic acetylcholine receptor; NOR, novel object recognition;</span></p>
<p style="top:668.1pt;left:42.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">WM, water maze; ES, effect size; CI, con</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">dence interval; SCZ, schizophrenia; AD,</span></p>
<p style="top:676.7pt;left:42.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s disease; PAM, positive allosteric modulator.</span></p>
<p style="top:685.2pt;left:48.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x204e;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> Corresponding author at: 34 Park Street, 3rd Floor, Research, New Haven, CT 06508,</span></p>
<p style="top:693.8pt;left:42.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">United States.</span></p>
<p style="top:702.4pt;left:54.7pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">E-mail address:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> alan.lewis@yale.edu</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (A.S. Lewis).</span></p>
<img style="position:absolute;transform:matrix(.47996626,0,-0,.47937019,632.1267,24.28933)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAJ4AAADHCAIAAABnZn0TAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAD2jklEQVR4nOy8BZAc17UG3MOzDEJjbMeO4yQvjiHm2E7MrMS2LGlx
GJp7eJZ3RbtiZrDQYlgxMzOvFmaHl0QrllbSf0635CSv7Ff1qvL+l/fXv3Vraran
p7vnfvf7znfOvd0EQcgI/JNe//+//2/9ffjBH//61Ruffv7yF1+89uVXr30Kr1++
8ukXb/x0+/yn22f40es/ts/ELZ9je/0n22ef/zfbF3DY1+BVfINbPv/yDWj3Tyee
XTopts/f+Pxz6ex/b5999trn+BPe/PiL1z7HnV/94qs33vrwjdTnX0156c2MF6G9
3unF1zKxvZ754huZL72Z/tIbmS+/mQmv0HDj6xkvvtb5pde7vPxGF3h96fWu4uuD
929A6/TCq51feK3LS290huO88HLnF1/t/IfXO/3hFfhu+guvpr/wWoZ0nBdeh+N3
eumtzJffSHvxtbQXXkt/6fW0F15N+cMf8f2Lb6S98Hq6eLp0+PQPr8CbTi+/2fnl
N+GMeGQ44B9e6fIinrTTS3DZb3TD072W+fwfU156PfN3L8o0yYRSm7B6ZU5rS34o
Ym5psbU064IRY3NTVmtzzk+2lubsn2xNTbnxphxosXhWNJYVi2dDizdB0/9LWnOz
rqkpP96UBy0W1/29xXKi8T5wIul04nmzYCO+xrPhSsRrgDe4HXdossVjfzvfrItG
DPB+0saSNEcx4R6oKhhG+KoIT3/C3U/uHqD0D5EXjZAXDiP8gwjfIKWvSukXX32V
Sn+VsmBwon9IYsGQ5MKhyQVDEv2Dtb4qrbcyET71Vaq9lcn+IUpXP7mjKMHbP9U/
JMnbT+4dCEfG5hkAp4Om9A1RFwyT+wbgRldfAnaAj+BbnirCN4TwDyM8AwmhmIDL
c5QQ7v7ywiGEF65woAovqYrwVsq9VXJPJeGBSxqc4e4Pn8JlECUjCZs3+bk/EIRc
sXZtblNTdjBKNwat0VhuMKqLhPMbIpafbPVh80+2YMT6oJml1hg2BULGYMTwr2lR
XSCc3xjJD4T00BrDeml7KGr58YzQAmE4rxk2wtmlawiKO4jbTfBRbcRUH/w6HDc1
hAyxWN64VV6CLNAKA5L4MhVTKKN9CtqfxJWkOPsnOfslCGUJfEWCIDZH3wShXCOU
afjSJHjDlycIfXGjo69KKFfB1/lSDV+mcJQTXIlWqJBTBTK7oKJ9cDQF7dWwhSra
r6ILVExRAl0ILYktSYNvsQUKpoCgCzRssZophPcarlTNlCRwpXAlMptDRjpVjD+J
L0lwlCnYQoIqINhigimCJufKCLaUoIvhVYPvYZ++Sk+V3ORIevgpQqZKWLKsV2Oo
dyBK1jbYGqOmhqg+FLaHIrqfbOGo4SdbfQSaEVpDxBSIGqDBcbD9zBD57zZpADXG
bIGoVfq3NmipC1ngFPVhPFF9KL8umF8f1jVE8D28ih/pAnBV0kZ8NTRG9eGwvjFC
1Yet8ahuxFJORroUfInM7tYyviS+MEUoThKgp4qx8cWIsaNfktBXRLoCwNOwgFy5
nC+XCxVKoa9cKCf4MoIrJYRymVCucFYAtApHX9giZzwyFqAqkVFuDe2HlsgWJnNF
qWxBIuNLZH0prBfwTmCLNWxpEowMpkBGunF4UT6ZmZPZnRoGPi0C1GFAqEiPAi4V
duZLVVwJHl86NVsCF0M4+sFBAFq1qz9hdqU+8SwhV2qXLAHt6h2KZjWETI0Ry9nG
XqEwAGz+mWb9ydYIFIEGIyNsgFYfNATCRvg3AJ3732nQ9T/ZApG8xmj+/ffing33
dzaFYuag2BrEMz64BunsxkjcWh8ywKfS69lQdm3EXBuyxJqMF5tNYxazGrs7hSlU
ky4169PwgEShgisC9igYv5YvSnBUaIRyNSDqqFAjhCVAGjlfhoR2QCuHV41QquJL
oMdFlgNOhcBpLVui5PwqDoEB5skoL2LGFCRwRQlcoZbxqGmXmhIIuwfGCjAV9AA+
RZpSLhnlkVk4/BYNouIj6CKCLiRsTtiSII45OKxKkgHKp6ELEvhSuLAufEk6iIqz
QmbkE37xDEK7srqPKMi9wlEMtI3RnEDQ0NCg/8kWCBh+stUGdIEQyKMJGh7kHwTz
X9UCMPJgzIXgFJZwzF4XMNc3musajbC9pk4fidug1QaM9UEjbKxvNMLGuoABNp6p
1cEXawNwPeZIxHa2gQJpgXh8Lp4zbCFNQD9yBUkCwOkFohCkh2CLVEKZiisGIVWx
fmgAs8ZRAr1JsCCefpVQms4XpQtFqUKx2EqwQc/ypamOkiShBKWbKlRxfg1fouJK
ZXYXQXvwyJRXCSzkixFpu0NOOQmrA3BSssUKFjQWWOuS0R5AVEV7FXBh8EW7B7QX
1J7AHXywHeG3O+FTApsX5FpB+wjKlwChBOgulCr0jObJXwG0mhXVvSJRED0bhKWz
jeZA1HLwiGHn3t4/2Xbt7/OTbeeebw4e7V1Tny/xBmQQWjAG7Df+ZGv8mRYIG36y
4aHCIKd4TKApnGjLtr+uWPXJytVfrlj1xaIln+7c0wta9cov1q7vsX7jX9dt/Ovy
VV+uWd9j177eK1Z/uWnbN/B+07Zv16/5bOnKrw6fzQ3F9M1NxmGLnUqyMIEtTKQ8
WgoI5NewRWqAlgPRK9bQvnTKkcG4MllvN2dxJ86PQkp7UvnCdGdRqqMwhS9I5gqS
WWiFqXwxoJsCHwnFyaDPNo+C9QOtUagBMBBnEnByKxjgdAlAorA6VQCejU9yANEL
QIQVGOkRUcLqlMGnpFtBucSxhTFYBiHZDvsLMjMDw0IaiPeHgt2lgUEg/gTCUarI
t2mfeBpirXbF8l5NcQiTGJzCoqju2NOnriEPjUnUHIrpUPEiVDBGgZcJx20NITso
WyMwMkYHwpZQLA/3iRo3b+l18owuGMsVldAsquvPQvjfbcEYRFC9iD1cFTDPvHjp
52PHvTVyzJ+gjZ/47tjx765d33Pa9x8MHvrGoiVfrNvQs3rV18NHvrmsusfU6e+P
m/DuqDF/mjDpz+Mm/nnUqDd27OoVilLnWnLGVrvlNi6V96Vw/nQXMK8oifFDnyop
VzLr7cx5EqxMEsgg49UwbhUlyGmnDKjDFkPUTOQLExkvIK1FJS9K4opTHOUIA1eo
FgrljBv6PYErSXX1VVJuJYBhEzS0NxGjbyEwG8gqY/wID6quRw7QsujjEDwLS1ic
IPJaGGSMaKZsDrWdV5IOmYVW2ni4PJmFR9G2I+8JmxsMmoz1p1M+QihK1pEJv/jV
z0LbEMwBaI+fNtQ0GA8czV23qefO3Vlbd/TcuPmbfQdz9x3M2n84a//BnJp688ma
nEDEAJ7zP0ErBsJ/GbTQANpQDPUADAGge+BwDlzP9l29t+/qdeRE/u59WWfqzDv3
9N6w+Zv9h3PO1JtP15o2bPoaXuEjaDv39Dl0NP/gMd2O7T1r6kCirS1NWaOXuuSU
K00o6Oou7eQqTeUKwEwpIe5SrkTGncG6UmlHGuNJYr1JjBtCo4Z2KFmfiilIApAY
r5Zyq0mnWuQQMB7YD0ioGJ+W86tZCK5uCI2ZznItBdqADb6iBrHlipIdpRCSkaYY
XJHfCr4YG0CLA8sNlioB4EfsEUXYTWFFLNU2Dk6nAkG2Ckq7oKSA+m4F7YGQIaOd
yTBQOF9SvjXxiZ+HNhyzrd+YM2TYB1WD/zKg6p3CkjdKyv9U0fdPhSXv9u3/jtP9
x4GDPiwue7uk/B2X59UVq3N/hBZIjJoc+ddDCw2hDRsbUJ/vW6dg1FQX1IfjZmR2
1CxJNwwCUbdNdY068V9Jz1HMgzEyGEZJh5gtQuuWA/M4X7pQCPxDM0W5QdZSOV8G
7+0u+NJYbwpAy7iTWNguaEheZRcUZlZthS7GnoVBoKWAnZCfwLDwSoqazPqSOW8i
74cYnOEqT+B8QDU14wY9V4Abon0itAUK0qPmIFKCVnsgC0LGg1CjEwZr7QVfjYYZ
0KLcKA+sH8Q/hfUlwZCC67QBwLzcxmKzsgi8ldFaOQA4MdeoefyXPwttY6TPuo29
Kwd/UNbv3coh71cOfq+s7zsDqt6vGvwJ/FsOGwd/XNH/3X4D/1JU9vayFVn/89Ca
xGZsgLwWom8EGpjkfBDqhlB+APKf8H3/HI7BzvDv3z+txx10mBGF888G9RHYAb9r
bGvOGrPcqwQPxRekcL5E0gkshJwkkfWmCwWdOE8G505mPVrSAVxJoYRkkkuy0il2
LtHKKGyM0sYCuoBrIu1O4gFa+KJHw3hUJGzxJCCQ8HV/Bhgr1qumHOCKASGQBAix
oPwQnhMxC/IgeIAT4xPB9opBF/BGuwTXliAUpjqKtLQnEWIE400ihQQ7r7FyCTYu
0cZqrbTcQslBpS2szEIl2hDaBID2sSd/FtpIPPfAEdOwkZ+UVLw9cPD7AGpJxbsj
R39e0f8vfQe+PWzkB/0Gvtuv8q2Bg9+tGvKXpSu+/p+GVkqlpHAL5JNQbEC00GQ1
PLBa9UGA8L7bahAFHDgdRK4bpOPUhfMjMX0wihfZ1pw7ejmIYUEqet2CVEg0AWMB
uhtQcSXYOQi0EImh4+RWGv5NJbk0kuvMOjvTQirNJ9s5rRUA5kAYNaRDC51OOyAk
w/hIoD0pQHTGJXquIqQa51OTDhgEWhayW38SiDbtTYHzAmyg3iDvXAEE7AcVDPTk
wF3APhnDuRvGlorkEhiQXCbBSifa+SQSLyDRzmkstIg0MJhJsvESa7WPP/Wz0NYG
8nfuNQwa8gGQdeSYz4aO+Nzte6Ok7O3Sio8Y4Y/+4neKSv9c3v+9fpXvVQx4d/6i
b//fgTYQMfwYd0WAjXVBA0L+II0GIBsQWtjTJG0Rddhc9+MO8BrSgR+E963NOWOW
+8DLQKKZQruRfIwb2AYgaShHkp1Ls3NKC6MCdpJ8ooh0KilkMI4Mik20s4k2RmuB
XuYS8VNeZWNUdjaBcWkooKw/hfelchChvWlCcQZYG4QWYq0HVQFwZTwaYCHtTgYv
Bh6b8aSyXtBbDYf5tBzSJIsgszqU92M5jwpBcikgGwyvIdkU2pEMJ7UxErSJFjYF
xZlOAkGmnAk5xqTHf94hY1kgZP9+1scjx/55xOj3hg5/b9DQd2fO+byw+F2KfXnk
6E8mTfly+KiPFi3ptWT5X1eu+fp/2kY9oJ0kyyKWEaOYDkH4NEuwoW8XKxjSe2m7
tBHNl/gK0AZDOvxixNzanDum2o+mlPamIa6eBMqppSGGcSqRECl2Vg0xkuS0NK+y
0moTqbWyWiCHnU6wUEk2BnlMO1IpAV4B3QToWVJQ2WF8FCSDRHMelGtQBa5QBRIN
qiAUAbqgrog0xGkbm0C504SiTGdxugOyJtgTXRgEV4VddF52iAUCiK0ctZfRWCil
hUQFxvhKa60UxIg0SoALSLdzCjuTYmUlQU76xc/H2oag7fgp++hx782Z99XMOX/r
X/neyNGfLlj415FjPiku+9PosR9Om/FRWd/XD5+w1AaN9Vi2/Z9NfhBdwDIEiEpY
goGyiAMIt0vAgwKDIIdEWYb3jVgu1sFrQxiV+YEgm0Ig3XiFlhZgbXUh5JqQPyTa
BBBMIIeGFNR2sEjASy7ZzqIam0kgCjBSYWEUVtRnLQWE5jvRjk6ssxMjpNgY5BDJ
ayHjtDBAOEhA1RAXWTe6WTBNfBEkQuC9ISHWIrSgEC5gOQRskGKAtqtQkMl503g/
DAhMWAFUEFi7AP5IA6MNIrqN11oYtYkSkx9ObeXlGAvoVJrN4BzpjKOLnVWRAC0j
owRttl7z6BMI7erlvWJxLB03iiXfcMS4HW2Uacu2rKpBHy6v7r1lW07/yrfGT/q4
74A/Vw75aOyEr0or3vYXvabTv7x+fR6402DEHozqN2/uefI09KxOFGQr2Jx/LbT/
ktYQMYUi+fVBU0NE39KcN7baqbSCsrEZtJBJ8V0FTwotaM0k6G0S9BEmtVwyKiGf
DvGV4lPtbBoShc9gnCkUfjEFyS05GibBQstMtIp2KMzALVptd2oor1gZdnWCvBlc
NOXqzPkyGafCZFfaeYiyabCR8WBJhPd25b1pjFMDUcDOwungRHA6OIt0AeiH4Zhm
CmQD46uFwsuDa8BRyGbA4DODkHAa3pOeb9ZKrP1paKNGSF6HjXh734E+NfX5c+d/
sXnbd/MW9agY8MHEKZ8tWf4Ny7/9/vvPLFn2WSjaOxSjEdot96EVU89/X2jDEGgj
Zvi9TbGckYs5pYlOsEFXOtIpPo1xAJYQUxMfOBQsWQB9SR4cMkhfihjwAGPoa9j5
RzWG1yQxGANrIUECzYT3AK0WrBCET9qTzhem8YUplKur4AfvrQB5twvJkFmxvgTa
lcEBrr5OjAtOpLEx8HWQehg9cEkg+4AuBFewUQBtkng9YNHRTNlw5MEO4NvB2YFb
ho+UjDMtx6CWHPJPQltTb66py20I2eoas+uDxv2HrKE4WxeyLFv5t74D3t25N3fg
oHcY/vVNW/4WjVsaQj3+r0BbH0ZoQczh98aiOcMXsgAtdGiaiE0i9DjIr4goNA28
2lgMohAUrUwydCt2Lp1sY5OAKKwLGvR7Ko3FSEA3EQMeop5kY+GYSXYe0E3BSiTk
RX40UJQ7nRWpiZwWID1NYb3grlMYVxfWk07iEVD5rXiWTPH4YMUBv0RRGOB6MNKD
N5YamHZagH06857uvBtkBq5ExbnTcg0aySH/JLS1jRDGIB00R+Pm5Su+GT7q47MN
5IFjfRYt6zFq3Iebt/eqXtXbRr28dv23DSF7OGYIxQwStMFY/r8ztA9YawlEDU3x
3NFLBRBk6JEUsMSQvYhwagFIG6tEq4IeWGPFPhW3c4kWRoI2BSnuBOImo2LzqUho
7G6tSPdUUbRT7UApDsDL4AtktEcr1p+TaZdouNgk0pkE0DIeiJ1w6kzamQYXYGMV
okWCN2iOWFc654ZhpBVlAAeEBQX579BSQife081V0JVxoO8jBWBtarZe9V/E2oYg
dabOsmlL7vyFXxtN/2Ej3xw89MMZsz+FjNZoef3Tz3/NCW9+8dVvPv7k1zrdqxMn
ffp/CFqItejyogaIteNXusCFIjYgquAtIVaJKColaCGwWfBfiHBqcE+2+xKdbMdu
FXUbUiBWFEZeIg3qsIUC9v+DbnsyHMUQbiHnAQMMWVYyKaQzLtiebHclUhDsQQN4
gDadciSIJ4WWJFI/CceQAOcCdMGmwdnxsHC12Lj70YHkQLe7MPhdOLKKdaXlGjW/
+HnWwo8/eCRv0JB3hw770Ot7y2p/raD4TciCisredPveoZg3zbY/sPyfv/jqub99
89sBle9L0J46o5egBf/5bw4t/F4JWpVNwC6jncnYs5waLTGlQsPJAXuAUsBdSHvA
pGhEEkvRF90WyLWdlSgF7yVLBZ8qYUCYSMAbehzIDflPhqMEMhktA5HVm2RH1c1g
3Qk0+GdnIo1pK7AWcAXAgM1KKw3OGS4Gxoo0bpLFUQIQJphJiAgYF0TFBgMPDaGl
hU5wIhxhgpoVBfm/gjb03c49X27akrV9R8/GCLXvkGXfobxNW3tv293zTMB08ESf
bXs+374n99RZ0+p1WcfOGMIx45at3/2fgPZHG9XclDtmuQOghR5EUmJ8FUljoQFX
JYAEeaQVZRkTHqwBcZISArRSMQgARko9sF3wkRqsrBk0nBGpjLRW2oRUoVhNuRKA
vqw3wYbVj2TWpaSwvpggQgtsAyVAcwTCQAlKklea8RoSxYIXHArkHYweoJgsemYY
BACthDcMoM6cuzONhuA+tDn/JbRgeufO+2LqtG/mLfhy4+Zv5i38YsasT0eN+WTJ
8q+nzfzbqnW9J0//cPykL5av7F3W973F1Z/9I7Ri2c8iFnX/97H8T60+bAxF0EaB
IMdjOQAt8CmTdSuBlxaMcIAippsILY0FJhtmtEhfqyjFaJXRtSagNvKZ4FkwTvPw
miSWpRIoB6S/CXYRfhutsFIyG58qlKRRTjBQnYUCkH0YEClwRrsgszsBWi3GWpRf
DXAdwjDtlAYTCAacDi5JbbIn29BVpYvxG2sUMDisNLwBvqaLmRhCCxsphxKcV45k
o3AqPisazQHrGBLr7/URy559PQMhcvPWXkuX91i6rEf1ym/Wru+zanWvefN77N6b
v3Fz752782Hj4qU9Vq3+dsnSHpu29AnHmc1bvz1xOk+sV2ABQaoSBB4savnHJm78
X2Jt1BiOGkSMzS1N2WOWexSkM0GsMUmuGAMq+CawLTYWAAPWqiGjEC2V3MphSRm2
SFSWGo4GjI4KTFoAfg4bui0M0goTpTAzKtKVzBWBQ05gC7W0Q2OHfAb0X8hgvOmM
G7UXiEs5IC7AETQUpLBcgljF1Nw3cXg9iTYqjeEzIeMSFVjksZBsYwDmDNoBX0+h
WEx+YATk6EXWKjUrV+TE4/mgVEFcGmGoDZl37fkWyFcXzD3bkFsbyDtdm3e2Acvu
kOmHcJERTqKdbcg/U5fXEDbW1OcBirUBy7Yd356p0wMhGrG0i/MzUjn3Z9r/PrSt
zTmjl7oUNrAnaD6THiQ8GtGLAtiQWqgkBotsFucJGIVYsZKIhe3BR1ietIkjA1hr
oZIxTLJKC2S3AhpjcT2UhvLK7YLaxoB70iK0vkzWm0q7gLUQ7IGygGsCJYAUa8WI
niBehmSGQRsyOSfm1mJBI53iUux4IvwXrBZAS4Mg8wBtRq5BLFko1QBtU5NOgrYh
rK+LWPYf7L1h07dbtn23dXuvzVu/27Kt15ZtvaFt25G1cXPPzVuh4Udi6y292bbj
uw2b/nqyJl+s3yJy4us/MfWfGfy/DC2EHoB2xCKHwkSrTeCDMLuVyhRitZaWwAY1
FmmE+CmRpoiuElAkxblSibg4p4afooESPTb0eCrqNkZuSFuTceWiT0F7CLsHoFVC
vku7NJQjEaFFw5wkOikARgvRWpyng4OgYxfdGQLJoOyDJoP3TrJQwN0MUHURWjiL
lGUlkfATMPlJy9apHntCEuRsgLY+LC5Xwx9vPX02/8QZI1ikoyd1h4+BVzKcqTMc
P607ejL/2Kn8kzXwJu9kjR7asVO6E2d0R0/kwT7HsV5hlaANiIsapfL9vxVr6yO4
tBbECaBtac4evlCQGymAFhQv+cH0DniZBMm/gAUlcaYWywViZgkjAN+gz+Il84w8
toohWaQvelrsaAa6Hl7lBhvYokScV/fg+jTKC1mQknSoKWjORNYvZVyAa4qY+ahw
rolWYEGRBiKKcztsJiNkcC4cahCJUQ+YDNYJx08l2URMssVaCko6JEiCnHb8CK22
enk2CHIdLgc3opOKmgMh0NJ8aYloQzg3EM6WWjCWC1tAqxuj+dKrtIYUXtE3hUzi
9JlOXMyA76VJmH8raOvCCC2uZhWhlVj7Y3CVKj44yy1NlomlCZDlRCzbUhKHtGI9
QZpo+1GWFdIbMwn7YF3QjtDCsIAtWkireFwDpeGLNIwfMIZMGgvIlAtn9Eixgs24
MB0Sl0ygJ4fjm+kkHCU4tjpzzkzejWUyKyMVQ9IfVLNTsc6M2W0a40plMGAraQfE
WkmQNcuXSazFlf4AZ33E1BgWs5ewtTEiLTAG2HCZcTBqFad0LLgkX5x4kWZgfnwv
TrdhztOAyx6MtY36fzcb9Z+gBdYCtKiigIFU8ZGgRZrSUqUJpwFEEieJ2Gul6iM4
LzHH1d6v1NMiobEBy4FPaWJZXwGsYnEOWGZmcX0y49PQXoBWDiRjfBlCIVLcznWC
7IX3JkjaDsIuniJJGliUAJ9msC7JVaWKOS4Y5iQLmYZ1Zkc6+mRHGg0OXEhj3WrO
nZln/CdoRdZC0qLDGU1RVAGewP31oWZp1rNOhAoskgSPpLcYRCNG0T1J06L3vXHo
wTTqvxVrJUGWoG1uyhqx0CE3g3vikiheyl4A5gSx0IimVJzaSxJzVumNOAEuoYui
nSgWGSTPhWDYOTFGOgDXNHGaAVQ6iRbzHBOVxPhxlQXjA76CT07h/JmcLxFLSFw6
48zg3FLqJRbCII3hkLLinEQa40wVJ2XvV6NEVUiygoFipHJmClZOuFSaS+c8WsHX
SWe+D+2ypVnxuKE2aJBYC9CGxMWh0lp+DEsh/YMVC9L6MWnRKEYsceJTXKkUxslU
cNHSaMBlK9F/gvbf0EYBa0cudiogV7GDQRUkCEVxlvhH3Q+c4mzdgykgIRFLzawK
0xIEWJohF+fnObHQCKEREmUXdDpsB/+VCJS1cuCrE7kCcE9aGhfEpIEPwkDrwklD
abpQLFJKBRM5Qsgm2BlxOQCWMIHBmbwHQ68N0QVBTgY4rRQWpMQqmAYvj8KSBZw9
3yRND6iXL+/THIHkx1YTNjdEssLB3Ka4MRLWnw1bwjGqJmSIxnJrgubGmDUYhB0M
9RGqLgJZkL6mkaoNW8MhHUh0OJzfGLOcajSE8LYcsjHUJxghT4dMkCUHG3vXBu2Y
OEVz6iLG2mAuhPMILkDPP9FI1kV0kaglFCFj8e/qwvb6iD6KHsd0OpgXiFJwkEA4
PxrLCkfzTgeYeNzeEGHiTVl14fwzIWtjzIZzcxF9QyQXdm6M2OPRXoFo/ukQFQgx
waitIZgDVuBsQA9w4mq3sD6EZbL85oi+vtEWimaNBEHWk5k2LC4CV7Si5IoxlYHu
BsYkULwCy1KSVELSKQBaED4h/4EGVlmO5WVKhZVFJFkSBk5HZ94D38VkF8IwOGTe
j2V9nBvwJTPeBMaltgnprF9m4dJod4pdADOVLJaI4bw4cQQB207BEdQWBDsBiYvl
yWRRpRFOKyUmtWyiBcuNmTSfiEaMSbQyat6TkWeUShbq5dV9mprNjWFDbSOw0BiL
60426i+1fheN5Fxo+fZyW8/2eO/GMFkfyo1G8+KR3LMha0MoSzSZuY2hHoGQtTZi
DUX61ATt55q+Ph00nAGwQ/p4MAsOGA1Bp9MNeNieoXBOQ8gWjZP1DSAD0OPWQNRw
MmiqbaDrI3k1QRw0Z0N6SKzDUV1TNKsB2W+PRXIBpNNBUxDvG/vuRBAd3Mkgg+Wk
cJ/2piwYUoHI3+obIFWla0IwVshQKC8a7VMXtmKAiJFnQzYQJJScqKU2YqnBeT0Y
glQsljt8His3AmAO0X/eLxZKkVWKshqIl1iLQKnENTQkroFS4mw5LrJJEqtFEnGx
VkVhDQFn9Tk36KcS0xgsKuHKCiuN0wPAVMajBsxsjnSuUE0BuZ0ppCMF8x9OrGWi
PuP8MYXCqxHttxpnlrhkUXhTSZT6dLTNjjS4QsxxHZ1ojCZpDGZQKgjMOXrN408S
coVmxdKekTjIVFZ9Y3Y4Ym6KmdYdZp4fVJA6qDxlQIlsQME3EwqP1VKnQ1nBSG40
rmtv019o6nkxlh2LUZGY4XLrN+FIz3MtpnPRb2Pi4tDasAlGRiyae77Jfqnlb5GI
rqbRGo/nRGJZoWj2pdae8SYzmLVoxALjpjnau625F7I/1jsatbS39gpH8xsbc5vj
WaeDOmB5Wwvk3PnxmPFyW1ZLU9aZoDUG5jxkaY7nHz9lfmlE6fRtQkNjbiyeH4n0
vtBirAnmnm/+OhjtGYjq6hv14ATrQuDVswOhLFGTe4OTr2vMBpVqa8odv4wH75rI
+4Bq0FnJYs9K9lhtZZVYiJASEjCuEDhxml0pyqYk2okPpk6xuisSTvQ14hwfjTxD
gYW8mXQkkmwyC76pKBVXs/JquyNdvF8vBaBlXCkIHi8lVwlifpUurphUi/qswCNz
kP+k4mIPXLXTFTwzXC1OwrMg/p1ZDATJdjTwKtYFNkoDsVauTlxd/R0uKAFzGzE3
NJpbouY5Wz2EuZQoqiD6lhG+EsJWPn5b8YWWPgeOmUeucwyoLhq5zr3jJIieIRzL
3XTUNni1t3iZf/ja4poGS7wJBDyrehdbuqqo//KCuTvdB8/SLc3GdYeco9e4Bq1y
D13lPFJraolb6xvZQeudE9Z5h61xz90lAMb1jcZFu/iRayomrvcs3eeqDfe51Nxz
Tw01aK1v8KqicRv4mgZdNA7DIh/cUChiWnuMJSxlhQsKr7Z9eqieGbaeX3qIPd9q
WLmXWrTfA1fSGDbVhckQuAS8xTavLmJpBP2PkBBWzjZam6NZk1fycsqVJHgeEtzd
WSc4WwkqnO2xcTIrK4VYrViuSrD9ffWFFmFgAFpIQkTp5qXZmAyxmCC5nmTck8KC
FOlIAuMjzu6lsB5QdVzFzhRoWT/mo6IapzJOoKzktOGk6ZQ4NyBOQykAacbRzekT
53n4TqyjK4+xPAG02oy15c6Q9VohlFC4P8TaPBPaKEKpXbvq20g4PwimMUqGQ3nt
rb1nbqEA2k8nuQYsdv91QhFhLBhR7b5x/qP3RhYRpRVjVtN/GVVAFPUDG7LrmJFw
lBYs9FbvzH11cPmvB5Rcb/t4wgYX4eg7ep2TXeAgqkoW7nNcaf3bswOLH+5fMHyV
kFlZ/puBheeaPll1wEwwFV9OK/p6hjBqI9MW+3bqFi/B9PvrDNdb47y/G18QgLgb
MyV5Kh4a5M+b43x0hH/xTqq1RX+iERfpRaO564/AEcqdC3y32l7pu9BBCP0JvnTC
CvbT0WX01IK2aF4YnEHY3BzLOgNjLppdF7GdDUKItTVGsxsjuRdbvx6/jE00QUZL
P8S7unPONCxQoLgpRacqt4qL3yDiWrkHU0PY72qRtdI6G4iLErrJ4vLVFBuTKc6f
p0qzCBiAwTG5k0kG3ZNQlMJ6E7AO5U0kPQrKg24cK8YsQIuCAV8RF1QkkejSpRo1
ZFAZrOMhpy/dxoAIdxZZC6NQghYcMowDDUYQOBSWLDJzjQl4O5dCtXpldmtTTmvs
u2jcGo/pLrdlz91hIczA1wqiqJjwlhFFJUdOcnfb8z+bUEj4C4wz3Il9/Z0G9792
7m9rj7kJj+9AnfXe5VeEKf6U/lV3z306doWTKOzbGvnUtYglKvrO3+24fanHY1Wl
RHlx9uwCoqQkZ0r5nfYeW49YCGex6Qe35Qfhh13cnYu9qw9zXaoKdLMdH092/6J/
+YEzppamPu+P9n82sdQyVyAq+k3YUHy5TReOWpqajC3NffYf1xHWskFLCu5c+kvZ
Qt+rg0tyJ5apS/r+flgROa3kSltWvCknENG1Nn9bGzSC7GPFLWqDQBuNf9PW3Kel
OW/wfHdXK65b68QI0CBfFJeZ8QkStLiQTEyEzLQ0LyTBmSDWoVQkFnul1FbKl6QG
UgwGOP3BujigbxfBB8mMFhwTX5DMehKBprRHZcWbtMTFdbh2IkmU8SQRaalYgbMF
VlyRg1O/jNCNx5k7cQrP1VmcJECdEKuMIBVo8hFaECGhU54p8clnCIVS6x+qH1/t
nbCIHLWYH7FAGLfExU3iCVuxfxY/c7V1+jph+hpm6hJq/GLbCwOLHykvmrqM++vo
QsLpGL+Yn7ZCyPR4CGshsI0w+7LHOWeuIP1zOEIoxJvy6WKCKxg4k5qzlnqkb8lb
lQUjljo/GuwmiktmrhaK57AE5SOYEtjtP0qLJlXbBs5l8OkNTj8h+FLdhcMWUhOX
WxLLgMp+hQ/3tE/wTF9umbiEHrGIG76EqZrDEFRRn1FFC9bR2WM8Kq93yRbyrYF+
QleUNbpw+kpu7DJh6GLXmCX86KWuKSu40cvcE5awY5c4xy5hJiwm+8/iPy3llUZK
bSSTSNG/QLIo5iHSwnEpjxRXrjBSmSlJzCDBPclAJ+3cjzVkcXqA1YhrLfD+EXGJ
JKgoEDqd5LuwbnEVnANsVDLeGeYEnwz/Qi4EsTMRzLOZhCS1E0RTO3pgoCYMBSVO
KOH0Q5Loqrqwjm6cC/bpwrszGQFibQpWGblkK5NGY0qWaMU1ITKSz5RWNAJtn9Rn
JfOeR2kug4ZwTT/OgCOg5Sa2G8f/XuAeExwvC/wvKeppnlcyXBfe+Rpve5LHYfUw
RT/Os4+xDsLIECYa/MivHI4/2JnnBLQPhJ4ndIyM9jzDCc+ynEooeZb3velyP+7w
d2Gdv3P5nmIdMjuD39XxhIn7teD4Dw4yDfgWSxicaXYSjvNbJ6/Cg/OEniYsjqcc
QhLNPcmxT9HUUyz/MOtIYdlMwZPJsN1ZJtNR9KyDel2wE3ZvEs38UnA85fR1FQq7
cJ7nnG44/lMO/7MM+Qjv6co7f8nYUyiBMDtlpLu7jVaYSTWEuvus5ZIslCSwkrsB
aEUL6kh5MA8vM1FAKRl0vTh7LzOR0vQfrnqRyGpnJJebgQ4WHDglQluQJgC6Loi7
uMSC9WZAiAVoLQhtF8EjcpHBNXiMQ1zvgYMGYnYazWdQXDfW2YVzQ6qTasOgnoKL
HYVECwN+Sgu2wAZhAgScSce1UU8CtHJ1tgGglkm3BJmpNFxxycryTITeqtXbVHp7
so1Ph59hZYh8E/SCDJwbznPhNIgaDso6H2EcMhOdAV7AQsJxEq1sBk5s0Qr8F9ft
ac000DedLSJILzC1E+PNIHFREt4FrLdi01kIfGOXGSk4+8O0A5N0waOx0jIL9TDY
Ueg+nBOlZeJNVBoTJbPzKpJ9hIFcRVCbaJXJ3tVGygAMcUo1iXRmUoKM8attrmSq
IJP3yR0F4EG0kJja2IcYt8Jkf5xkVYygtlLdYU8r85AotpnilA7wFY6fYSa72Rkt
BDMSWOJUk0x3O6M003jDK7xa6IdoJ2RBnaBDTRT8aqWJfAhSI1roRrKJFN46J7cw
cFJgmMoGiYqTYAtklPc5R3Em7dZwfjneMsvBiQjoB6CahYQfnmymU+zgxdzQD91t
TCc7C+gkMk4tTiSwcoDZRj1k5WWUE9MwK/MoiYgk4CCgkuA4kEflmhIf/+UDaCWb
DnSG6CKuk/68bICucth3A4Y8bOdgSMJVPu8p0g0Z9UvWrTDaYNw9QvHdTPbuJIo7
NIBEAVEdPgW+mhmFCWyhACfrQrvgZJ1s7KOs91HGg0vjGU8nCnDFNO73gjuraliv
yiHZg0d8N2TU5/0GZzoKFQbbk7hcQdDY2V/TDhl2HElYgdDsM1a6k5nUGEiNFWdL
EknuURbHxzPO4uyqEQ87PCCPjxjtT1m5R0mcBE3mCjV4R2UJYCBjPY8w7qft7NPA
ISMJHaq1Uu8X9+1ROVwJn1LOJCunIh2dLHRnAJLESkVnC44k6L5HKIcMGutMYZ1g
mzUmIDertIFgkuk4w0MnAAAmvGWDoBxPc65nSQ6u8ynalWJlVQbb07wn3cY9BzrM
en7J+9I5XyoHSuNIovlnKE4Bsm9jvx006o9OP8o79Lbd0RWwBNqIZcXuFPu4nepq
pZIt5KNg0xhnF7tTYcKxDhcDw6grGD0sqsAOLFznj9DK7rMWhyFCiwPWQK47fPzq
7Y579+6NW7NJqbcocvT+mQvu3bz1l9KBcr2VMNjkBhvwTGEiIeyrjXa1mXnYyiqM
drnRhqQ3kITeotUjF9WUW2YVCNJNmHm5gZRb+WTWr6V4ucn2Tf/Ku7c6AvGWJfsO
rj58ojnWAv/SIycQWfkE9L7emmiyy6TyW47pYUzdONgux19Fw2UkGKwKOy3PN+eN
nHKv486HfSuJbB0gnWihCb4ogxRghEEjjLyK4p8F/ExINdTSPDMBOqEzf796U7Dt
OjgmIs8sM9jgu1q7AGMLGu5gsGGtB5yOwa7MN0FwTTBafm1jCINdgb1kJYw2GArg
sJTw9TxLqo3vQjogcBJGOzYDqdbbnqFdBMkTdhdqElyYoyjJWUpYBYWZVphsIGyE
zvRhYfnVG7dKZ8wjdEbCZMffCAc3049aeTUQ1Egq84zSATHS6cyEASf4cNDrrGqT
LdHCitCSyRJrc4wJjz2F0KoAWuoBtOLNmjKdbdORE2di0RPR8JmWc684fNBljulz
7ty5+WbpQCLP8BjjfI73ELQT71azMs/RQqYZeaCkhOdZh1ws6CRZyQwr04XGFUCQ
tstYH1ikx7wVCt4rpzxPIdHtn/YddPv2nbLvf8ig+BTemzt4NCBUPnchYbCkcu7H
OM9T4P3M9sdoEC6s26GoiOIpM9oAD1xdLbiIHP1XA0d03L7zTnk/pcn2C8ErhxDO
+kGiZaz3aU9Jd6FIRXMQhLpxHsDmdyT3EOfB+JKrG7V89dFAPNPO/oZ2IHchiIDA
2piHaOH3Dj+IoQpUmnVnWiig7+NOHyRIaoM5kxbg4Ol4h7xbHM32ThQ+HobINQHV
IGxnMMJzniICBM9gl2PPMDLG1xWsgKdIjvNuHpB0LeV4ye0H70LkG55w+O7dvctN
mEJkZYOBeIrz/JZ3yS2swkARedZku/AE54bjqEx0F4f3F4wzDcY6LuLBTBqyHcDu
H6FNzDbch/bvrDWL0FppQmdbt+/QwZMn9cNGAI1WbN9P5Bp8k7+/fffe5xX952/c
WtPWvnDz9tMN4eode/9cWNp08SozbRbRJ69n1bCLN+/0rhy2ZMuOO1evVu89du3W
zdFLVw/4fm7b9Ts7TzYcrmu8eePad0NHE3ok/UdlA+GYzPhpRHY+MPU3joLmK5fX
Hjy041TtvtrGKSs3HDob2H2mbvX+Q4GmdjXJdmOEY7UBuIBVew6ELt3Yf/x0a/vV
6i27eg8efvFy+/HaswdO1ly/dGXd/gNpvG/d/iMt529sOHK6vvnq/vrAB30rj9RH
Ixfatx46fqI+3H75eq8BVf7Z8+903Nlz4syO+uiNGx0l3899wVdcGz+/+1TtqGWr
GlsvTVix/rcu38Ubd44FIruOnrxy4/aYlevqm1oDsciuY8fbLl8+2BBcunvf4Zq6
S1duwFcUduZs/NzZcHzUspWBWNumfYd/Y6d/2Lj11uUb646ebjt/7sDp028Xlx88
VRu70L796OGL5y6u3Xf4w7L+jW3t3MSp/WbPu9B+Y9fpxtONdefbr3xVNcIydsr1
azdPNwS2HT0eunBlT23gdDA+b/NOIivvncKyGzc76LFTCUhkAVqw9+KtggDtP8Ta
HwVZvE0YoF195OTRsw3dWMeRhtjN67df5Jz85JlAKfuose0XL1UuWKwkGc/kaS3X
O6zjJ8NVuqbPInrn9xw84mZHx7vlA1ccPVkTCX9Y3H/l9h27zkYj8ZbtJ2teLRzw
8YARly+0TVqzMdFG/95dkDNo2M2OO5NXrXvXX/xZUVnZzAU3Om5vOnDw6rXrwuTp
CovNOGrs4EVLBy1beffG7ZcKSh/iHOeu3lizZ0/HtavDFi1/hnfPWL/5VGPUMWnq
zY5b41ated5XPGHl+vNX23NGTbzXcXvq+q3PunyFMxfdu3uHmjD5RG2gpqn5nYqB
3wwcfO36rfI580tm/3Dr5m168oxXispP1wXWHjr+lr9o88EjPSuHKPJ1kzZsjbSc
f9FXdLe9fdb2vT3K+0fOte8+eRpCVfXufb/zF42pXgVDv9+c+e+VVKw/chKG3VMu
34a9++3jJsjMlso586NXbn4ycFDs0qUpKzc+5vANWbQi1HqxaNYPd+/d88784WmH
e8zKNS3XOvKHjjrbdN45Zfr+M2f3nDj7qq/0q34Db3TcGzR3wZwtO0/Fz31Y0je3
csiV9mvb9u9fuPtAXW2dQmfoXTUUEPlz6QCQ6L/H2vvQPvV3aFGHf4y1Otv6g4fO
xM4RFuaT4n6Xr92o3rVbmDwNRKNkxpzLNzsOnjyz99TZDQeObNh/yDVqbDTe4pjy
vayP/quKgbfu3PmgvHLFgaNLdu+W6aygok+4yqKxttEr1hO5JGH3rNp/5N6du9G2
S5FL11bu3nvv9q3WluZTkVj8fPvJhtDIhcu7UOyU1evhmIFo88lQbNLKdc873BCP
+89bnD905KmWc+U/zLvU3v5RxUCgvsZsJ/KN2UNGdnR0vFdSTuTqc4eNbW1rK54x
9/LFiz2GTyDM9pcL+1+4fr1qwZITNbUTV68jTBbCaNlw9PSiLdvHLVle2xhRWCH6
6qZWr957suaTwpJNh44daAht3H/oUF0g2HTunZLy1kuXHROmyqEHTfbPyvrDaMgZ
Np74LoscNu7SxRuvCF6iZ59xS1c3hluedHgW7dx3oiGw98SpHQePNF++WTxzTvvF
898OGSeHWEu6IE7zsxe3X7n5kreYyDV/MaAKiNtv9vxAJO6bNiN87uK4xSuAkaCg
aw+f3nToyIlw07S124kcI5GtX3vo5JIdu94prrhy7UaPfoOqFi6LtbQqjXYsiAIz
TfYkeBWh1UrJjzZLL0Gr/AdoVxw8UB+MyXFlPbXj9JlYa3Tqlq2gDP7ps9rbrzln
LXi7rP/X/aqM46f2qBxy8coN++Tvia+zPq8YdOfu3S/6Dl6zffeavfswZ80zKmx8
85Wrg1auJ/pYIDfdW1O3+fCRvw4e+d2AQc7J0+NXb32/fMVrZf3e6T/kg5J+kGYQ
Bmv24JHWUeOMYyaNXrHu1p177xeWzdu2a/7WXcMWLt96/Ezu8JH3bnV8VNIPfvCv
nIXfDh7rmDDtzs3bn/argmhnGj35/KV2dtIMYMbnlSOJHMPzBQM6bt0unT3vcF1g
9tqNMBTA4m2tCc5Zs2nI4hWNsfOQjxJ608Q1m7ccqxEmTocRbBwx9v3yASt27Q+E
mz8pqbhw6So3ZTboHhzttw7/7VvAs7FEjs48fNylW3df9viJPF3lstV7axq+HTL6
9o2bJd/PfqN8wMSV6yLnrvDTZl2+dq3HkFFwtQ85insMnTB21brb16+85C4Anfuw
74Ar1265J39/NtxUNnteXShcOX8ZQKs0khC8Vm7fcipQP3/DdiLbAJZiy/6DGw8e
AdMQbTs/YPbCJTv2zd+2CxwrhF4tQmtDaClHYo4R769FaNFGCUDZJHHqChftGckD
x0+eOne5E8Wq9KZHPIUQSOAHd9y6qascsvHwqaYLl8sWLtt68HD7jTsflQ/YevTU
zRtXFuzac+Rs7Z3bHe8OGFK999COw8flehO4DKVNmLh+O8TU2Ru2rt936O7d2/Yx
E+F3ghV6r2IgHNYzeQZcdzIpdLbzahPzuqfk0vXbm44dZyZPWbJ77+Wrt59zF/Uo
r7x6+y7gVzF3WRcrE2pqC55vnbNuXezChTMNAWHaTFDsbwYMIfL0wqTpN65d+ar/
0MM19QFQwtWrAvFoS0sruISDZxuuXL+ycs/eLXv3whDMHz62as7CcNslDQmWyjB9
/Y79dUHLmPGXrt+YtXFrxYw5B2pDLe1Xvywpg1HCjZ8q05mV+eb3/KXXb9+1jppM
ZOcx4ybe7rj7l+K+YC1nrd4UiLZ8N6Cq48rVpXv2e+bM37j/YMedux/2r1x74GDr
pXMzNmwJxuORqx3G0dNi8Zb6aHDq6o0NreeO19a/VVJx+8o1avyUsctX3bt9Z9bm
7SsPH7vdcccwfBQzenz7jY6dJ2q2HTwKIX/dvoOgTMVzl1y9ceXW7ZtZVaOUBjTe
SVYpnjKQuCdA6JUEWXvfIUPOgHoN0EJ6MK169cjqDY8yDoWVTqOFEQurV+07vO3Y
qd+7CrJHTVp36OSRs/VgoocuWKq10dZR4w+fqdt4ombi4hXVO/Z/UNS3/7zlJfOX
QwacBEbUQH7Vf8iKnfuPh88fDrZMW7vpD4IHl9hb6b8MGLzl8HFm5DhIJCDf7855
1HYWnMjwxUv3njh24OSx7SdPD5o1Twkmk3Eu27X37s0O49jpAAM3Yeq2I0f31oeO
1AfJsZNfKBu4dMfBj4v7AeO/rRy65tCxX/pKbaMmbj5RVxuIH6iNls5apLBRNU1t
mw4fnblpW03zxe/XbXuEcdrHTJmzcWcC5jO2qu/njlq+9lcOD3jAY6dqVh04PnrN
5rnrNn1V3m/Btt1Zw8cR+RbCRP7GVbh6/7FPKgbJcvVZg4ZV7z/yvL8ELKF78uzJ
qzfJGce01Zt2n67fcPD4nNUbF27Y+kd/Uc7QkXvP1Ow/23DsbF3h3CVa3lc+b8n2
UycON4R2nao1DR31LO9esPvIlwOGfFzcd8X+o/CjDpwJQGL2W0YAsz1+xZqDtYGJ
q9buOH5q15ETkB39qbC8MRa5fafjTW+JKs+cSOLqSXTBkLyRfEIOOOQnH0ArVs6k
igZCa6ah+whIH41kJu1OtrKJePsYCRuVJrvCYFVBkqczyXQmjd6stjG4dFZvleWb
CMxo7fB1LQQA2GKmH8ObXngZODcLdB8FkQazDis+POAxEhJiS2ejJcFMqkkBzoJ3
fYuPZVDpLfJ8LIdBugkhCoT9cc49e8OWtvarr7gLMHGEoQC6mm+S5xogqyasoKh2
tVgSUhus8CtUNloNSaTdSRg5wsBAVE4kuWsX2seu3oRuPNegyTfjz4QcFwAzM93g
h4tnlEGOATkl5I65ekjoVRDLjTaVyQbJD+yfjMVFSpWdDwk9QTlkRkuq0SLDp2hy
Wh1cjB5+vtIuVu6MNrg8DVwM/AsXrKdkOlIGSTZTkEb5lZD34842qUvFuqxVrrNg
0Q1+u84sF6uBcIShS9esOXTiBbf3T2UV7RfOLd++F3b4oKj8RG39mt378MiQBGOt
kRWhpTUALbAWBVmu0Gbrf4QWrltpxT2UEHGt4rOm8KZxzJoxm8QpTJzeSjGRkLMT
oN5G26OsW2WmkgEAMyuj3TIbVhYhkcXa2/1bRXl86hztI/CxOd5kmwAfqU1kJ5JT
YeGQUTCuNNLRHRI+G5NhZx/Fe6SwfvsQ7VDrLUozlWkiBy+obr7SAX5YaSWBOkrI
oe08DhQLlq/xjEa6G+XMsFDdIaW20F1pRxebQJBeGVOcwRQSeRbI/5pbL45bsxWu
WW6yq4z2x+H32gXCyj9qZdPEPBu6KcHK4gAVbYfMjrlEAi6Dwp5JsHJdxEXL8MNT
LHR3GwP5LvwKSItTxbuq4QgaC9OJdslZr5zGZ1CoTGQGKWih30iPHPqHdBNCqZr0
qMykgmSSzSRo1ZOU0IWE7F/QWNknpSQFC3lY3oI45Zo0E3zr6YZQfX3g5tXr3w0Z
DQlq9d4jN+/cs4wEITEl2ji4pCSRkAgthdAmImslaEVBFqElleJOyVYmxYZ3qwFs
+EAsKz4qActgZoRcYwZ0KXHFECuz88lmKt0E2zkYPuJzBNkUyLIpXmmwPmQitdh9
ji5sIcEVExZBpRcrNXoczt0ZB1wKDKBMG9fZzikMFjA44Lw0MORNWM/qBqm6lVYZ
LJ1trNLOyo3WTJLRmsiuNl5llAhHyRhPMuPpQjrllIBPixFvnsSiKT49uPBxZ5mM
9WOpUmdR6M3Q+52s9OMUT4hlfVzTZKK7Ipw03s9jw4o/obOqDPZHrOxTrFvN+7GO
kauX5xmRRqBwRjuWKaxMhri6X2Vj0sRVSwr4Ovx2K/sc59HaeY3B/kugNRbDmcfh
RGYWhz7p1HB4r21XklOSLAxTsLUpVhpCIc6iG+2dbZw47YMz+d3Fx2jADgq9pRPt
kNlZVA4IqzamuxmkEe/ihU9lOJGMc7dYobPguh+EFmPtj9Ba/glaMMZpJhL+TRXL
y49baBhiaiv7KEKL3AUIFRYWOiVdXOShJAWl3pqKNxbyMhbwYDRYhcGewmo+UNbu
IWiPjPM/z7iehp7VW1JMtm529hd4p5vzUcbdycb83uH5Fef7nbPo95z314I/gXFB
FPgPh/9Xgg9kA8RTZbB1ooXulJACQcUmPMs6cTUJcsL5sJnqamfSabg2SilyEZ84
yxYpHCUplPAMxT/p8CkNNrBCKaiWdgLJTQEpZaQDp61Aruw8HP8JUvgt7wMJgfH6
S1ehgnY9w7lfcPoe591PsK6nnQXAUYh2afBd2qmATrCxCRYqw4o6pwJ6mOxdWRfB
uAic62XEtYn4eKI00vOEo7C7s0QplKfZnb+G89q4F10Fj7BuuIzugJmVTif5bsBm
CPyMKxMnX2kNI6gYlwy12oyFLQiRpCMDOWCV55sVeM3ss2ig2CQRWmi4wivH8PPQ
wpAX72+BEZEuzk0mSt+04MPNxOIZnSqFVQsDJ+hECaDPD8NvgP0Zl8pMp4kTnAlY
AeY1JkphgR53eGcsvHDxRrTlcvDc+eilm66xk4l8QwLjBN7LdJZPygZAnnP18pVo
rCnS2na9/dKNW7d7D6gqnDl3/padiIEZQqYYwoGCRvqNon6QsOuGjUHAbBiqCeCr
0drJZAedgAsmDDRBF8i4YhjL/Lgpaw6f+iXvUehBjSlgMKD4iJlKhYhjIEHM5Xob
jp5885/8ZVev3mQnTAdjBZiBtFTv2Hv3+q1QtKn9/KVIWzskBfM2bkmEbhFnxpQ4
pcoooAMNtm5GMsmKS0cBNi1QQmfWouRg/IauaGxuXr7zIAYscKZ2oClpGTl208mG
ZNoB54Kzq3QoQl2Ar2b7S8V93/SXAClV6BvEEAlMs4BeMhqAGYaCTcBIZ7A+YqWA
aThM/xHaBzbqPrSQG8kRWsCVTTIBX8XFBpAz2XlRbNlkMwNR6nE4LqLFdLIwqRa6
G3QoGAGTPdmKC3m6kY5k2qWw4j5qFBA+HXQJaGR3LNx7+Pz59j5Vw3sMwTLKAgDM
YAZp6kI7oRfeK+0PidP09Zu+rOj/ddVg3w8LIeUYNG/JU7z3NU/Jo5h6ohkh8sC+
WWTZxpeL+t29e9M4bCwaVwM4PgrIBM4OnwEDoIKk59kIi5uw+2RWIZN1wvEBKlme
BXJfGCJ4HAOptHAwSnAQmBBdMDW/Le4L6QeLw84IUgnHXLZtV/DS1T5DR/SuHPz1
oOEHahuuXrqUwTiILJ1MLwYOnUlhtoHzgmQUzq4C6TJj5MJZBMBMnGmA4Xigpn7+
7uOEzY2TEzDCrNyjvPdDTzGMBrgYjBewJ3BRnH2Zv2lX/wUriD654koPNGWggjhn
YKTBRoFEd7UJALPSYEmxkIkAjYWWbBTe2Q02SoJWA/EDWA+xR/RKcrP9/vPEcJKE
lO48vH/DoVigl4s1dPhIfIQcg6sALfT9EjQYThsYHIcWF2qjDGRy/kQrlUqiUx1X
vfH8tdsfl1dBSv5eWdVv/OVdzWS6GGth9H1WPhAy175zF0LqnUJyPYeMbLt0jZ04
Y9jilYu3bfu1w7d8557zbecaYvHm802+KdNfLCi/dbOjV+XwnGGj2lqbz4bqo63x
7cdO/NHh+6JqDCSQ9ZHY6uN1O06frZy3lB429mxtfVfaM3zR8ljLhRPhptbWi/1/
WPQswx+rDUDbebz2RLDZNX7y7/3FbVeu60dPABOeKhrvBdt2BeJx6HR5jonolV04
ffbNa1d9M+cePVu//cSZ/afO1sfPlcyaF4w2Zw8ZSWQZ8qtG1sdbqSnT9x0/FW25
cDrafDrQ+FJhRfX+o8fDke0njzc1Rc9Em98uKLaMnrDp5InfODyLNm0NtbWtO3Ck
IRjqP/eHshk/3Oi4ffHKtUAwNm/zjvK5C440BDYdOhg9d37NvkN14fCQ+YvBYX3g
Lz4dixpHTwApEn0PRHRGQwvddObEJ575EVqchkQp/xHaH5eGSHNq0qp26Y0ZgRcX
BOF63RRxAbvsgdbjk+/sDvGOVbx/5iG+IAEiq4FUO0rGrNwIYBw8E/yNy0/k5IOI
acAhU05csK+3vFc24O7tjppIZPmuffAjD4fCl9vb/yg4p23YvP/MScO4yXfv3p26
agMzduqRhhBg81FFZce1a/qRE9YePhlqbWenzxm+ZCWIATdmwqytu2/cvumdMW/E
6m13bl4fv3RZwZRZ529ce7mwLH7h/Lojx2wTp9bUBWKx5p6Vg1taW91Tpr3uLdx8
9MyWQ8feKCq70n7JPm6SzAgjzAn0WrZjT0M8ruJcEHdTbMz32/dGzl08dLomev7y
e2I5esfRE6OWrYxcuDpm+Rqidw7krPHzLQs2b7x1+3bf2fP7Lll1u+PuoLlLNuw9
2HT+4tAFy4bPX3L3zt2iGXM9U2ZevnzxlcKyM5GW0dWrHnUXwjCKxeOmcdPrgsEz
oRg/fR4zdnL/RSvuXr85YuHS5fuOXL51tz7evOXYKRCVngMG3b5+rWfVUCLfKqGj
gaDLuR422u5Di3ktGDAremjMcMQnlYmL5fHOXwlLfG9DpqJhNlPi/S24Yv3+vU12
fFqVQjTMgKsWzCq+F586CjoPWYqenL1h142rV37r9tnHTQMI563f3HbpKjNmEmhL
OulIMpKfFFcAeCNXrn/bU/SBv0w3bFT4wrVBC6rnbdm9fPfeQQsWhVqbuzt8RM8c
3ahJTa2XDcPHtt+87pk0vfncVf/kOWBrIQrURdtW7t1/JlA34IelRLaZsLpONrWN
WlzNjJpy8vwV36Rpt+/ee7uwjMjKhx8FNuJJ3jNw3tI1ew9M27i1eu+hE9HmF0r7
3rl6xTppuooWcPmE3j5t3eZ7t241tF48336rrfli/PyVghk/+KbNamg5v/X4mY0H
joxdtvJpmvPPnBdvu5RkY3eeqp+9fc/Kg8fW7j6kAF+db1aToGTcgVNnl+7Yi6lz
vjkYbYJv8dN+uNx+6XnBWzx11tpdexdu2jF78/YrN2497y1Zu3vvrE3bgQDEt98V
zpzfce2mnGQf4tw9iiuMQ0dcuNHxmr+k3+z5Fy9fTbbYleb79wlqrVyqwwOh+j60
CVl6CVqVNFNtJu/DickP++N7fJCcGW8txXWadmmRgyAVJnGFOz7SCBoDuEK7/3QP
CNK06yHQ+XzrrI27IudaiexcSMXKZs1tbW29dbsje/AI+PdhoQCCzQel/e/dvWsC
//LV19D1Kp3xSCByuCY4d8P2+Tv3DV24qDYcfEzwEL1y8keMv3j1FjVuSvPFNsek
6bHLt52TZ0PETbYwJ+uCG/cfqA0FBi9eQ/TSAbSnIk2jlqx0TZx9KtbknTT96vVb
n5f0heODSqVbOX7s1OCFGyNXbSibPXdnXePh+uBrxWXnr1znJk2D9DfNxst1tunr
N59va+03ZwE36XvPtDnk8DHdWNd/8I6Ri5Yt3LZrw4EjkfNXyucs/HTgkBsX218t
G1gXiPtnzt95umHNtr3yfBO4rV9w3u6sa9vpmoXb9xI6G8Sssy3nxixfYZsw40wo
+EnliIvnLs7dtrN05vwNh46du3HzXV/J6oOHp6zbAtR82VNYuWDp9VsdLzm9EAeJ
XP3jrOPCjTuOCVNmrtm441StOt+Yhg+iwoeqALRqztXFYMHFqvehBacDma9ZzJcR
WvEBO6SgpvDOflzTZcG7IfDWYPHpCtID0DQifgpRCtSYulHiXaG8lnQorZz4fEj2
Eci60P7Rrmnz7t69M2vd5qJpP/ATptRGYhevXK+PtX5UWIERWm99f8CQux13ToWC
s1etnblp+/bjx27fuTV0waLFW7ftPX7ENHoizjstWNZ74NDNR48faoyALUL5HTt+
26Gjx0Px3FETS2YvAufFTpo2bdOOWPsV55QZVQtW3OroGLVoqX/8pBvXz3/UrxKI
DgcEFV2yY++l9utjV2+4A+NpyOB3PL61h4+H460v+kvu3ergx0zAUhflBCu0Zu/h
2IUrhMECEi3TGVUGM6Rh87bsOhWMf1I+4De+oppIS/X23QqT5WxdY6y19dL5Cy/4
i6sWLAY75pwyTT9+UsfNW1PXbDpY37ju4EmQAYC25erViYsW+qb/0NgUt4yaCFrC
TZ3xhrdw7Io19+7dedHlX7Frd00w6pg2O3bx2qbDx9ouXH6eFSATeRKSe5NtxuoN
LS2tl6/dglEOtksuLnHFmxssrILi0nL1GmkBjQit8M/QYqUC8MOnK4hVC+m2Q+nh
WOLTHliJphrxXgaV+MQs/NeMz+nAe/ftAt6mCBmkhSEgl8+3vV46eMuJmtbWy7F4
e/xc+7GG+OgFS9ccOZVTNUJarfJBxaC2lvPhi9euX7rR2Hb50tWru06d/rSs34jq
tat37/k1591y4Eio9WJNIBQ71wwc+ou/PBi/8Fm/Kn7C1OC59qPBKHy6u6bhad71
cd+q04GG49GmzQePN7a2jVpU7Zww9Xg0AtZ9/Iq1tW3tDY3htvNXR69Y/0XfgYDG
qWBk5d6D+86G1+4/8VZJ/zONMcPIcbI8A+ToSqN97totx+tDnUi+OyQC+LQKBjJ4
8Het564ePVW391T96VAzCY46T9/3hyWXb9yKtV5U2Oj3yisP10MMaTkOF3z+Uq/K
oUt2HZy0YQ9Am2Km9tc3jFiyTD9y0umGAKRb6w4eD7de2HX01I7jp2vCkf/wFnOT
v29qaos2/z+svQd0XGWSNtxJHdWtVrZkYRtjHHDACWcMGCcc5BwlWanTzbGTspOc
c86JOMCQYUgmTWDCN3mZHcbYWMk2npn9dr/99j9nz/lDVb0tYWaA/Zh/fe7RabWv
bt++9VbVU+F96n9+750Pdz77wp9u/uUeHTtDXKLpqI3UHjz2l3//d1g6j7TtALxt
I9ZG2qui2AQ1UFXrvOtO0YIUMcEm2cIZ0bp6KR1cTITEdeZgUDljfrG1mnaeZGjS
bWEJgTFuPYsj646g5kWwWaswqlm0NgyCa8M54LBDMRslSCFu8+Cuhzh2+kAUgclh
3lYvYA4hxGXFIACNwWsnduQqAFktgPvB/kfwBW6xikh3wTl1EPxg3tgD4XVM9MWE
Y6++tee5F8Cr3as19vz5f55+433AcblhriyqZtXAFVTKTMUgloDIxFkToVSahJ1c
gDY4TAiURCkWAJcETyYiWKnvriQqQzjkCPMWTodozUI3jH0p2M0Us0SFAlm/dfuv
F15/z1YT9XIaZrbreSc4MkxvxWDdW8QEJlI4xRGO2SM8eBBHfQRCf2zLAuwDVgH8
ZThaFJXgyvBNXZSKgpDBHopC5JorxUFhIAK2R4V3fvXLn/3md14ILqJKUTjmJs4G
iOVsouarqnOyBhoUrfC3omV7H5wkV2eU9JJ2jNtYkpMAs4eSkdi9Tr2urCPXifss
tFzJzJXjgFMcogESskZUn745GwQcxmY2iNv89RhoeyEOxpSFWiTquXAFigKz6jjM
mdRHvTGhn4DtYbkRHuJjMACA8rMgGOWQ07mYM7A1LiLhLIUauKZo5zQveBBOfPy9
j/7f//s/tz/10pnLvwQvIB89aQWJRuCyEvwh3gMIoy7iDnMWcjcQniLCD8ssW56F
yQFMTlkxIaxj6gYwWhi+uGoj1lQ3rgDFHeZ9YUw6QvgHkhtrpJ+6/JP/6z//o2LX
PlhtJZRvhzUHUXhuTOsH0uJMi9oa4OOuEJ8XwiYFnOYS4mwRFZcywKt6Hjtw4U/g
fXDzUcXCEiywgEJcIW2th1sq4rSWp77///zn/z74wiuURYcwVfBEKFWJuUzNU1nr
KKOiXpBE66RFisAngmFPn711kZkFJ+rC7CNS65BcM4edo3fAaIdFYtyA9cj7OKRW
AHfrFIySKG5pCnBGltpkqQNXzw0QsPYE+h2M8O6omKeYpRwE3aI1yvY6ytgOLah2
/BoQOstZggw+JktEen26k5g3rLmR7U7KwmdtZMdEzEXwBoCDQuoIt1RH79Wby9v3
LNl2bICMPbPIsYYXF52cCJoHh41DAIiMe7SgYelQHA9KZhbxmj0Ki0zzYH4AEIbo
5xBg2olbyhYDUyT1kzQQMyyXvJiYG1Y9YWmokXp0445iJenkRb+UzMY/UaxIV63i
Ps+w5BUSdrXBRlkgXwQ3VXrDuJHEHeGDfByWDt6noPijfF5EA0XKi8BDkDxRxc/B
m7DUpBxOtgqYAZ3e0j4x1eIPcci+HRWy0cvKzJRa5XjOhrB7EBnkINZrsb2dmuRU
ayRzUoaPiuiVmWjdDPdinQC/J8PGTLRwaWZXsxCCI8UgxUuaPRyDBW4T47Bagzxo
v+KqlwCKW8KY33DwZqGQckQNsGn+kGGPYos5mo16yQlaGNU8WADBIApj7pCEhX1a
UrB+7fUiPLLcOsEZ0x31kr1eQj3jsUE1l5d8EQAXqiUat1SHrPUSLlnQmzpY1/DU
VAenW8MKlqfqMUa31ovw6G0h2R4SLFGcmIXNKBDaiVxQkbLrJDd4qJBqq4cVyVnw
D8GoAIzQKAHE4xYE+OK8ZKuLwKryRThKrCpMqKC7Zbj1g++vpAGxw+L2RzFjnMvD
Y4QvAqZIcIZ4F0sY8Cplc6mwFhadIWzqxpIMfGIIHIGJWdsQb6uKWDdEEO3GYJXL
cJqzd3O3TTIDjH4TRJuLca2J6oxdcQoVEL6kv/oyZRGhyDWW4Vuw97KcIRKm3BNS
35A/xkM03CLONoIniGoUM8Y0t0iH5Iqt4uS09tgmdWEbADRxw365fJM2a6e5ql1b
sMWcagpLNmuPtfKLN8rzWpVl7dr8VmlBizq/RVq+WS7foi/dYc5v0eds0mc1iAta
hfmt2qpt5pxWaXaTuKxFWLM7OSmtzGhSaw+o67eI9YeTq7alyjcp5W3q0i3G7JTw
aIO+bLMyv1mc1yws2ijNb1EWbFbmbjQfa5MfTKmxQ/rynfr8lkQA1lyY5w5Lq7fL
a/abFbu0OS36wi3qzLQ0XBLmbFIebJHhfhZs0qdq2qwGeWpSLdVhqcmFsrJ0Izdn
k7l4k756R3xqozE9ra7ZE5/eoM9IKeFT5uTmpgUNwqLN5tyNevkmdaKuTGvWx5nS
nE1q+UZpTpM+UNY9MbO/ooX2qrNb49MauMnNalZMHaXCzcRXbk+s2Gosak883Jqe
1SKXbxYWbtbvT2qWeolpLeqnoGVX1GVRopFEK4JoCTiQWybRkszYKJS+JBRRXtH2
EoVJMYsmLTBTSfQONHkG/DTuWkHm/cKwbKHS/4p9m4UjCfUIFzmUmLtJr92jlkqy
eEip2h2a1ZySj3BrthsrN0nmKSF6SIod4eY0aKGjYnmbXL+H4w7x/CGp7YIcPmCW
t4jKCbFiK790o5Q8pyxskFft5IUTWsNJJX3BmNMsz2qIh/brc1qi8QtGy/mUfDCi
nJTEI9HYvrBwRE6c5mMH+Mh+WTshKyeEtVvk9duF+t3iI428cZxbujVeuV8aLoNf
12IH9DVbVPmAlDoZNY7HjJNCeC+/rl0RjpjScdE8FhNOCBt26eqpZM0+Y1qD0q8u
NrVRTZ7h0+el9Xv0x1pk4Yhe0a6u2NM8p0l5KC2s3G0u2d6wbpcUPyVEjiuJU2LF
TjF2QK3aLYQPytpxsXqvdp8Yuydujk0bjefUBVvUtVu0htPiGFVcuVVKn4FlbdQd
Tyxolir3GbEDhn5ckE+LE00VoICbVM5N+1kClfXOAXf3GmTBQNESFLL2pSmI5cbW
C5pYSpllEBmvDrPVTLQeKugS56vMMs9OcDNIyYS+qiQmjYunvWFhgBB7IBG3R8XB
CthPcZCg3isJQUEfJCgTkvJgVZ0SV8ckteGy6gxrd4mA6ZXhgjI2rs1KqcNUuIg0
NSXnSeoIEx6WPFSGxYdd7ONM/uFU9H5NdgDs4pUyxEpKgWaOSTeNazBHq8qkpDqh
0SiW5ZlpYZypjY3r09LyOFUo46IlUWlSQ2JqkznBTBTw2kjTnLxJzZONUs3sH1EG
8fIQRZ2YlIeqSrEg3i2LhYJ2nyyOSCpDFekeXhgmciM0aWRcGySr/QXjwaR0t453
WCIoI3XpAVOb1pTIlWQw8rkKRPxN9xv8CEWckeJHyepIRb1P1wYoEjyEmWltakIt
jkVHJ9RZzWo/XR9lGA8YwlglDkZrXDpeIOnOqBCQZGeML5Gl++P61KTygC4WgyOI
KkxrsYwoGfmAz+8e0gujeM2dsa4KYTOpV7S9UQ3lHVlqwtPLyJJhSqKt4y6qOjFK
O7YUHJi9ApXVgvCRgmkRmhAH1oqWenDn+OjhV2x5DKnUXmNgQgBcSwh7FZzoyw0f
x8OZNsDGIYIkmNVCJ00bAxVrnYYOWEQ/B17QHkHjb4npFgJEPkBhMQ0+NCuievmE
JYSA3FaPdR4KP+IWnP0L0NSwUmU3X0jACnPE+OyYMFTUcxTDEjU9Ivh48LuaD28Y
0KzmAyfNadlhDf4cUKE1jGkAex0PvtwuqvawAJbcFYJHoThCEp4T1pBcNQZX0+1K
wiU0W2pED219wOHDMewWAiiAXxPvDUyrAp47mzPsYaylImauF/Erhw07PgoA87wF
nhW8g5BFcYUgkNEAhSEYoj19uHUa99d+RbTMv2LXBCLeiMB2CjPfmdn3T/GPl+37
EFQPTwxKtKkbnjJFTb3eF6AyNsQg8wNAebuctMpJG8eDO/cRIsvHDhW5NKq4o6Du
0j1iHILXQoBdUdzYkx2VBvBaf0kvEQ0vIG2kRQQkKRINJkQdOCTAI2s5nAJoNgjA
LQK3Stwwgu4XzECYg7uyqAmL1JIrxvN5WJS8I8QN42Unj7Skfl5yc1JQMvqbZp4o
+0TJIek5WA/HVIwnotFmFsBxAuIaMEgIGAHQ4bp3xARXhB8UYxsbtTLJCGZgjtpP
0Iokfaio3BURyhSsXluluEOQ+4lqES8OFnD0Vw48WOxCoc5h3DQNYboClgbjY/gJ
YR6v407qGGB1wHpCAVpTJTsSK1b0PEHOi0n9OD4nxBfwYqGoZANcl1Wkz47KjGYS
RJu7IeQeOPhL0XoyuQi5V7TY2UTMWBKjtCO2FeT6pCkHNJ6KZ4TOKqMQzYAvEHCm
ZKSi247oDtxymgwqDTaMZVGZBnAxD1b7FWeIy6YGSrcI0JpAXBTCa+zNKICvLevF
1A3jjiDTh43T3VGeypOxACcX80gLgl0KMngBPsBJRYLi5k1Y1FkoOdUrxQvlxrsU
NQeDOp0xZ9px94RUAGEMrG41XipB6IV040MUIxuLYshKHpTlu2LqkIjgRIZ5qZ8A
NkkNoGXC/V5+JMQVcyIYEYE78AiwoHVYOp4oiFP2QJhgxLOiOKPFhlMrdR9vBHkI
AbQBeqNFMnG/LNjFmFDGCwjFaSdWAJcmhA9CVlTxgtXlsBxuE3VvDEGMn8RWArEl
aAWYAcCzPFH+RcA4a3kgS0FkdNsBybBLZh4OXqN6rb8SRKs6EMfj2rEyAYeFLF5z
9Nb1UFkpB017Oglkx5B/xUea7aRBfQFeQxaWmFggG/m0ITyAaRBsOMIp3VIaLS1W
jXRSbvkueF8yinjMjeWBk+BxrA2S6EWVEipIwNfzEY7rDwZD1O8SkTwnR9DBtBaE
ANAh2W0RjwVjUJdhMm2oFTSXaPYXtALJ9JutEEpCLFFA2BBOzlOMIsXsb6RzRT0f
RAsqjkVJNV/GbbJB3IYsuokTJAv3qJtDDBxP2AsvZBrNpWIylcc3wQZ6eqn94FHg
SBjwc2rCK2KSlZjflAxrPa+AewqqLW4h4abJIxjU0k44L5EWIHMMY0/n5Cyi2PYj
t5vImKSyGSMOJY6QxBcnIsDDR1YpYhvUGEkDkpiIukNO5FXXs13xTLTa34iW+Pd7
GSYZcyEo2R1VW8pEKmy4DTaPYWYK2aqCglKALUsGMRzpXsa4JDdkSWlbJlbGbjp4
QGVKwiGZlrqIU0uCfjgkA+4b93CCDQdZ1sewgTLE5YJJxFk6yggRUJJs58E2SgPB
tApysawHaCgLnNYfninEgqKJ5A9hMV9NZsfbHHIKTIIfEyBEVyoqA1NNRXoyh6jd
ce9oVGTTe+BDfaBSsMRDnAswhKQNAJ3WUBJspgRLnruJyt7DkCOXoavxkJDIeeFn
kSOjXASZuqBkgmGD9Y2i5Q2AQr4oKRkJifFRIKcq1b+zkEQBuRMw/9NrL5loUboI
Y0XG/wmaRjklJIPMQeuCHKEgYzsT7YCMaOt7RUsdmky0ROLMeGFZPYBxQNtimXco
gYyM6DiNIaYwdrlcSWNUvUg+yWt+Xvdg16qQJac9ahP4OSwcRfELWGk2wvRUS93+
o2Ba7yIjCQ/aIqgPYU8QN79li10yHmvZfK+s2znswSyVcXsn4CZsHsb7pGmFyLyF
nVxgZvzYMYTmF557lqAUJtqCZgs8KcBEhbxaoiW98XSZmQZ1zKXhOR7iMAigL+CL
1VQeOZT+kjFITRTKZjGvuCQd2XOJbpXyNqIrw9+XeRrZpKxEXKIwxk5PLzsQ/gmd
EJRNLz3JfHOzT2nwiaqfuEUCMj46N2PHZnQZpOiIVdG0mu4MmaDMqKw8AlLQO8FN
MPoxotqAZ8hIzbO5DI1ZlpIsqAGDjDDK6qcW86+Klu0QwbjWdYdonWhAFDRNUSVD
sEP8stjZSrRYTLTEj6X4OBIt9VvhcFa10UXvu2MkWjDvYa5696EPP7kinzyvHj/H
HTtXc+Rs6Pi5HU+/oJ9/+uwbl+9RzYPff3XTxafrDx7jT57jj5/WT54zzz81ymx4
NN2SvPSMee6JRTsOeql1sjAm3yNosK7hWZeA9QPnZDQGtTQ8l36yMUjUypR4vqKX
6ckhicZiJQ4+vkDUcVxpTAoSmxfacyVeqCWLiJKiH6gakXJ5+ub89OouUzI3DnbQ
iVIX1Y6oO2XGJ8XCB0RDNIrHQ2FkvrHRj8Ng9CCYUE6BBQcGPPN4sWIGT0ZhSUA0
BqLBsryMHgVF28ucwmjD8Bxkd5DyRKQb8lHekKZzgWjD3oF3ijb6d6LtyyH3RrFo
hMnxZOw+fExEgFgKyQKxmVYAg5wDKyiGe0z8nJbD637JROCqNnqVND4LZGdBlmAn
0i8IE9LNkSMntz77onnmUvjEhar9x8J7Dm84dDp28mL02FlPVFzcvjty+BR/7Gz4
6KnQwWPikVPSifPDk83z29qF4+eEY6fnb95ZFhFATl4A5CBg8JqcAra3QE0WJdr8
StKJBF1oXcA2ZtWFs+pjHpoLjtk0mmbmQPeMIw+LiIgegSHgiYiQQ6QWjB8+82RJ
L5Fuj9QOLHmBlsxXTJbERpYoGniXES0HMpOY0fZQ/3BAaQKD7CH+TCSnFlVWKnVS
it4dy2gLXhzn+slZ9JB9RNXKuLbZlT3oBdRsQclGkK8XafFCxSzS0n4JtStLNHOr
632sy+LvRIukFn3Gx9U7fwwzTb0EdkzkPjKqcLl8MmtIp41jS7BRFM6kjjg1ADCE
k704ATLliggBAb2IFzSJeCzzjNTs1s2TUg2lMd7BS1kbat0R3lsXnqjFS9U42NIC
8HbwxMPcffGmB4w0hMiumogtxN+rN7jDfIlkDJGxhxssNpxTaqTKzIb7zIYJySYv
XEdJDDPShQrAbEzuF5iNw+LpYkHxRQUsllETqIuTysxUUFJd1PCN3CsQfmhJlmTN
Y/xCYIHY9+0di4jIhXB1kZYAVOHDwgssLxCtwKATzWVhwSGb4abYBTWAMCruJWCP
lVARYQosuMyoA1zrOEgA1gpoIRZComwalJyDpKsS5pmxzqF62Ng3YjEH0Raq8ULV
LNZTOTLYAxVQZEF1HdNa298Z5IxomSFyExzw0FAvkFbGAgsa4yMEnwp4uMRIFqnJ
HGZnRN0dFqiiglTRQZznqgQMmpcRFQM8MrLA+sqOKva66OLNO9795W93v/zGsz/6
2es//9Uzb1/e8uxL5y9/9OHv/vD8Rx+feuv9l3/48fn3fzw+nvrhtc9/193z/M9+
cebNd87+4O13fv2bJz/64Ys//8Wrv/6k7uCxmc1tj795+c1f/X5OQ8u2773Q8cVf
z733o/ZnX3npx794/n/86sn3P1zUuqXp/FOv/vJ3r/zqd49f/vDoK28cf+PdE2+8
e/iVN1757SfP/Ognp954Z99Lrx9/872FLZuGavF8WE+wbsDYUic2G+aQQ+zEXvwW
KuMiLtaTxcQIlE00mMjECgrQS+MJ0nUSykU7CU5Xa/HKaS9OgdCIF4jRQmSAi5fi
iwI1UWKm4JoMgWMISqJlHH9I7YdajvFbnppg0zLzZT1PiYNq5UlqsRbPTTSXhmPZ
d9/7jaIlWjOtz8uyCWBeukuamq4x7w2iyoV4XANgYnppAy+oKfyEMxG7yhBgAMyW
fGo6W0HGM6JmRp5QJK+qiy3fvvf0a2/uffHVQ29ePvbaD06/+4F+8sylH358+OXX
EhefuPTWOyffeGvb8y+UxZP7n33u6cvvH33plYvvfXTgtbcuXf7g0g9/suOpp8+8
dTlx/omJzRuf+vBHR155PVuUzQtPPP+Tn+1/+dX048+8/PHPT7791uPvvzch3aCf
uXD69R+ceOnFM2++CZ919vIHJ996Z/vjly598MGTH3146LW3kmcvHn/7g1mNLS4R
Fc4uaeMUgKki4zdGg0SE8B4C1XkY4On9tEQ/PQna46NJa37K6jDR+mlbh5MGRPix
iiwHwSCLSXdMYFydPkFxEiu+hyaDsEl8INRSEK0Kdhtwg0hzSxWa3IeBMmJpzNjg
2gJMwFQLHzLh1jxZg/thovVQ8GP1omh1KyIjFC0jA0VHixPnVRb2eLErSgSFA6DE
LAZcpdRI5sl6Di/D18uhmTOusOCLgSPBLShIWwUn0zrwaE0uuRFcWg5SiGJoVIgF
OG2kYq7ftX+YnrDUhnHvA5KsRIZpcaugzt+8Y9GOfdaosGL77mXtO/K0uA1TykjZ
ZakJl2mJ2W1bJ7ZundDc5ozESuBPwrH+erz20LH7mtosYW5SU6tNSliEJHyRh5ta
qw8eG6+nsMBM2+LoO/IOioMBK4GFB/ObTVgXfBiYNXhYbIqOjwxvAY1xyFVMxglP
40dxQlO+pPdPNGB6i2j1aJat4g7x8BrXhKj7KIrFiWoAto2NWUoDpnooBoFI1xfG
NAWSVckG2NV8SQPTWmKkyxJNhXrST+VkH9EdF+to+ZkU4eNyya3CZxUoBqyGAozX
jf5mEsxnfrKlLMoHBg/tE63WK1pKGkeQ9dFJnoZ1ydDoPty3BDdBYasJtwKfB98Q
PgbEHMBu5IxokXgbsAAnBTixUMJBGF69xaU02glw5Yr4XEDMdkmvPnj8ex//MnHy
bPWeQ9Lpx6sPHJePnGx/7pVHUs0HXnzjxIuv6yfPP/PeD5/48c+3PP6Mcuq8dPrS
2gPH74mJ9YdOPPHhx8deffPYKz8A5Nz4+HPl23bPbd748adXo8dOS0dOXXobtPl7
1UcvysfPXXzr3Rd++su1uw7aJGT2YiR9AFzBpnlZrhRr7MQGDwpKNrafkUKoj9qg
s68Mos3v/VlAg7JAnPAQ4EzkY0X6aZymRPTTFK3G5EIlwRBTNiEjFC3ASQHTT9h3
gKV4xLo+AiuAhvKI0g0cXKGWgANjSNQlg30Kfrps+mgPY5CEyt4vUOOw4AokrcRM
FmuJvERL/wgXIIP8pWipgYaVBJRM5NNbk/cRWyEmceBbEXUwoLI8xQxk3L5BWksL
Fr6GgK9puK5RQBx2br0ZtNYeFuD9fDnByJrhg0AYTZeekk+fF849kXziufD+o9yR
U9yZx0dKeujA8fiJc9FjZ4xT58OHjidOXxBOX9iw5+CiLTtG6olVO/bGj51KnDqn
n7uUOv9U4tyTK7bvHZNqUo6f5k6cbbv0jHTyjHz+GfHiC3VHT1cfOLRsx577zJRb
T5RoiWLAk7A6wfqp8VI9WQRmjSOWaso/ABgBcMQ8KKNaZJE6Re06/tqrN+gacYmb
fkRGNLaDPDEOEyaeRZwiDYaU8CYotE9tzhKTPsyb0q46QJdhKYgTcHEeUz4SKas4
0ppHU5GDVH1moZ4GfARSL1JNeGJ+zK7jBr08ySg20nAC0joKVKfSk3clGkDH8uJg
kDmmtTYvsb19VbSU38eUCjmPKFLAkTUGoZpIlC9qcFHG/VuEbJAGYwP20k4hOHzY
dCLnka9F+KfDt0rZECGDSwBd1/IhGEXGYHmoYuQZyYAWH6YlRqvxMjXuFxQwD3cJ
6kDFDOJHaIMV3YXMpFowzOUDiFWT8H4/gP5mOlszh8CC1TDIGZhocHDiaC3uFbVB
glwGca3aAKbCLakFig6ePh/wkawXw7oEccakIjU+KNk8ABa+pNO0ANzXiyZXwqgG
2RnphnNoAkgQnZnBxEwRPNJd0qx4w08TKWk16xmnS3AS1IDNNfRRGOpRmrOosYa6
haQsbIuRsYOM+gOJoRw/vW9wBLwPCCaPBJ8r62wESQGdnC8ZALhoMAyGbWBF7jIb
yuJpWGoBLV1cF/EzGNUrWpk1q6JocQwcACuxj7CdxqRjh1seDb1BR6KAAdFLTFhW
6M9pMKOOTkjKfFU/We8cfK2CaK1CMovofLN51ABk9iI7XwKWCuMc2YePVfNrxJ6o
xIsoEwQhik02hicb3WrSB6YJVqho2OS4C0dyaFl6yqXFs0S1WNTAWQ5QzVwVuYKt
spkN0U68zR9vC8pmqaiW0XQyr5HspyfyYDEpSOqONLSwegSmfIlc4gWnKToqygyf
ncYQBj0+iB0TzBn5e/FU35QsXNbI2KmypYCjSDk28EFhA79BNT1qs11K5ZAUbTRj
LYfagXMxbEX6B9BOuLiPcDJdU2bqhOBc0hhLLvWPyiDafhq6DFiCGNqCE0EmXRS/
S4oX1oYyvFG9BlnOwCjiasVYPiKyecpeLIRhjglDWIjQeYV9K7DD/RONxeQVmEWi
FY0myM8mVMGaimHtzEuiddK8IQDSgFOKODWAJTn1blEfqCRK4TtQIq2floRAtoAK
D3QDqod0BVbSECV+N68W0ZiyAkEv5ZViLdlfMUrUxEBeGaQmAEoMU9AvDhBUS0zN
NVsHmy1lIlrRLAivceXpOYSGctV4kF7gQDPQFcUsBtFCNBIRmGgJLpl4t8SfCb/C
c0eHh3eCI9zZvFEy0RobFwwelJGc5iKtMcb07ojAOnkxbQSYA0Qro2gDOLdN9SC1
g+Yk/faRme2fbC7SkmAq8mV06jShlhl5Aaw02Mscmm0AHwfWuCTeCMpaSF+kgIxH
roh675YTRbWRXtFWZZhVnWGxT7Ss5pPJk9HqIwejF7KVTtYJYBRgY+YJ2P2xUcj4
TQSkT0e/G5NBb3x6s11M2TH2R3JBuE6/mDRASYDPAHwPYitCKE/whGxgfy0Ff+uu
j92Ny1aHJWmjTyyF9STHvRTy+8GFy8ZQzbTHkCzJoaLXLKXsXR4O/o3nGc15Ghpk
CKPz5TiYhyEyxqOwFuFgWXXwlAVkUQsQ9Grg4cDRIDAh8WD6nsIYujeToA3eBkM0
8L3g/oM0ygWWr5tCPhBMLlHTkz3HKMUbwdGJOKFJb3PKaTS8nJzFY5IkQAlLH+2E
h0cH1w9SLg+lSPPk3SQCd0wMQPCqJf04lN5gZ6IUENMZBXTD+RSMwX95lWRxXdTH
ROuprLMJ6ldEix2j2IhKnNyGD52HDJ4jj74h2TFcI+hlebkQljNakjhN0aYx2DEI
ewwIvwAvBEHjASkYLeBr4ZqesBAU4bkYLtQVw6fG7ZSXKYVoCmKbqEDbwqRcwJZa
2smj9gQ5uchMByUVgqLB8TSWKgVYanKppN2jaGVYM1AHhniHkR4oqk491U9NFPNq
AQ/2tqHIaPRAlIJBfQI+rljTAbGDi4WvAO4ZXgdpiFmugFy5IF1cHIShKH2ImYRs
Dnclg+SCAqvhY3QLjxKcEaINEVWfOVfMJVG0A98dLTA9BxxwSKIthMWqtTrEhBcJ
UkUklhXR9vhpSxxSnmNxXiBLYGD9QNRYugOzC5j8wZSImwav+aJCPvP6BGbhbkG1
wOaBaL1Ys4oX1YaJo9FmxxbzPl9LwY81THkQ9LJYOfLQfINsypH6KA+CVOoxCfOL
mMmUaVY5wk6Gp1i1xBEBRIYRYUBJ+5VGt5JCpB0W8gSGNk1m6PLJhBJwQK/sxR1j
Yl+NIZdABMD6oKRlYCogSRyRhem6YkoXwOMoNNI5vYOY2VoOyKmgks5VkriDgfwI
YR+qIgsKxTBxBhHYnCY/TYHNI92FOylCa5RCRSS2a6YrZHLgoYNFRcNbajYwGAXS
QsssIx85uzEErmQVCJrJsA7AfoAVcSOJqJDFSZjvxRWAcwtYLslLNRwwxX4q8cLi
wwkgGCtjbtlLozLdMSWfkDlmkLDID3g+nkPzvQAbB2V4AqobEH5txIfbufpEG8nA
KKrIZgq0bMl4qCiLGWN0IZS9pCgWFy9aM4h3ZYSdmThB8/fWOpw85jf8akNAa3aL
cew1RwhA0xsoHmBXYzFcgPJc3hhxh9P14TWhEq1QwSsHRCY8Mjv4nWUwp+g+Zb1/
ogmerJuox0GupUYyGz5UxkI6XK2gtx6Vj+4KL8jCU7w3Gq3GqihBiiXoGykE/jE7
zUKaXHJ+iA2FTHwSxPAjFcwEIRmzHKACOyGSOMtKIgUJE7zRkh9v9chxR293CpuZ
lkcPLZsGzqOfJgfPwio03ZTddFKNllJdErs9CqhwJwRqCAXTcH6ORBkFxehXH80k
Gv9WtBTXMn119w5Rpw3weHWmFmxKOSZQSFNBxhAvYuofJ0Di6EgqJ2CnXBC0Sk5l
g2hlnBmXK2B7g58CfC+EVQQ0Mg+UQx5jiB8ClBplJ0AcBU8cRFtIekBRhEqJGHg0
KuhWUMGOjjKzoYBmnRVgIiWJaTKzpchsKVCT8Fj7IzBGTAB6BlCIAV1289ms1QH0
ICrmkI0lR4szBgg2auQF8StjVg/HCZiZAaOUF/QirAXIjdASl6moE3OPgqIlmIZf
igTmldM5WqNbxDQIG63ppwFMbHh0HwgFDSbJiWwKCSVGNJaxylXihGpBW+KInzkJ
0ZMazyYglgvQT1LB2QWMZBmAwSHDvyJaN5Gu07xO2tRHfRSeWKb5DcE9TTBgsVc2
DYiCmAEdOD5f9ENo63AassKaP1gVD2cu6y0eJYn0/Rz4ToVZUTC8rjCfzZIeGHvg
gw4KONcRZ8ZRvcUP5xNAQPspYXDixxkLGksaFKqIaFgyIUgTChEKwEIR1WwlVRhv
xhmSGPWic2XwpyzR2CdafOIoWjSzhJUMOsfI6c0/5NIELJQWDt7RWIoxh+JaNgDN
HRVYHoMspMqqCLmk5WxuFktVgpycOFO8wSuA7WEpTIlGvisoYHqYND8NvqnJgkw2
8ZItYmeER6CnxcE3ZdOwmTwJPJ1erMeZLcEYGq0XFsi9qLUxP0tZsN4oFC1tnWZa
64xmWsZpRyWmpXy0tFmQh3P7kEZFQdGS0+qN6PU80toATW9FNwaoQYyDQfYpScz1
UMyTIzIUrbK5dQx751I7VV+h0MexWIKWM7o3tsABvsFHGCxEARBRQlqYh5BVBwsB
OKi/kQLp+sHRmo2gZCCnYkB5KikWh7EjC12YIgZojGk+BbVkgbAS0JtNZH5X9VLG
JkgjBIL0KJmue+ixeGKZ3iXWS8QiUXT8EZHlQGick5Ylp3ONZo+It0EVboTioIgs
8+OmoSEMQ0H8DfFCPhkPFmdnI2xU8lS4N4OFUmCEBqSbcdoPhy07cHuA84MKrDDV
JSqF1fWeL3ujhAwDDTFG4TZNJ1NZLiNaD82r8bOsAt2cB0GgTNnOJM20wQQsLkCR
lr+ayMlonggKFACtlROAtAOYW0bfHOBlltyhMWWZDo0gpngwH8IyPoQy0LcVaigh
qjUZpDoGzalSCinZWxpvKDGSIOMCGVCuxnKHgFkK4y0AjJlBLmb+glAbSxrQYtdo
ebEReJjqy6URPbmUrM8gCTDXBB5RiSWDjWry4yx3iSUmWR+hl6yiF+8Wx36z7BJq
bcawq/ZMCxFCJ1CJPITZCfhclirBRgb6iCBpLSh9PyOdx6y6lBn05Ue7jSYE9Aq+
9aCGVljTpP0a5ac08E04qFMxECF/jWgzG2oV1hzjozSCjyazknoZgb6FTF+mGNPW
cQ9NW2bTuH29xtZLPWCgW0EdWywcuMMAvxUJScECMsUYAbJINDRFo9H2qKAsHY/V
CIpV7ko29ounMG7jcfwVS9DAswjSPHbK66olmpkvgTFUCkHw8Ji0xhytAVu3eKUf
BWxs1mBfQjg7A5GwWOah2S05VEbN5vsMPuZQc+jLEgiA29MJ3OHwSRcNR2QZ4Dwc
PYu+E6EJxOU0aJb1OHqpbA4fYVWa7EICzCFIrgibKQkxsGWNw2NkSgVjegAeJnxi
kOVDCILQRCealUteAJ+qoBVKZpGaDAhs6cfhKeVqJhNtcR1DyNhA83WipZ5yP3ZE
6FR9xH7uTDYEtJZVCyQw9ykwHdg+Qp1BoMo5ZOVQ2BHc8QEfCYjGLaVsMVB9OYAH
FoUKyT0HKXvF8iGY5REUWu9yPmkwuhCqL90VTw5MNfYzMrnAIHopxFk4cBlhBZaS
ILYuAq2VtH4AuOAmlbRPTnpouDrcQwlA6Az2UZi18FNDCDp4RBXwNHk2eh0fMaod
TnYuViG2QQTgxa7jjMViYsAmThA2q4ErcRc1JlLLi+CnighTBuohRZuXpbdaORMC
wqBo9FPwDtFrqgnmaBHHZQaEYy6PGpJEFqFl0z581qrh4XVWM4bYAVBIsZZmmB8s
c6mZytNw6IlLUotrIxmEnI0pCySo9yDxEytnYlxL3UAy+RIMmLD0iEIVmanBVCKE
toSQA1SIzaHgjD4VliHqOsJaSS3Qm3LVJrwaL7OyMxYgwd0KSJcPInRSge+umOCN
qPmiXiCbBSKuiQKqz+Rjn5iCM34RIipU4dcBM/eXtRIJzSnuEIR1g0sHD1AFcEtB
o8UtJ7N4jTwFWCqV6HAyzoxuXqG/wu0L3iiqew6EHLxayGt54OOpNg4fCqFgQFTu
4sRCGQeSlmB3tJiPYQbNjgV4L5s+smG5NJfLT9lBL7Xx4nA9anPBJaW3enkjT0tS
1ho/C75XIaFuuD1XTHSEOdJIXAp+6p/NRn+XJFXWKLsJjw7XjZ/kkk3bICDgLIBA
VsG8GAArTIDI2GKeMch9ovViykJwU1qKglolm5o8MCMTQwbOXEIZrAgMN+HFrBMu
fJZ+wqIQuWEvnQ+anYv9Zko+2EYpTU1D1KSBiS2jUNDLJN3OKaWcehcsUlBTHGel
oWEkmJ2HwSg2heQIYIRFFywLcioQxeaqgHF0PGRyMGJmCbLh3AAUCzQj32j2Ij0A
qgIBS6m3OxAsEEaWbg6DOtr6jTNiAaEEmV8QNaJikVhLsJV2ygajfI6eyAZgIek2
QXXyGLXbaTO1T4nDCrDHJKRb4GQHJ2UJWKuAmN5Pk3zgtr0S7hy3CqYbsAJ8kGIw
bAy3AcvaJehsvwUsRCev05QvfOwYICEa1XzYcoSVK1dUcGPyGafq+vCbGvA0csjR
Yrwu0yA4gIG1kQwDjb+y3kYGmbWDe0i01F0s+fCpYQrNHQaUiBWJ/IyvUhl+o5pi
Cp4FTmgEcy9p5GXR1lFYphYZDSVmS46Uorovrm4wpGBXi2Eh07YI5GaNKhZ4gnUC
bRxSrLjdWLPGaIqMlIQX9phmq1dsEThfx58RFYybVUwiAwH8b0i214p4wIuoauc0
m2Da5RYLl4STHVHdHtUcdZK9TraHVPzbMG7HtoVkawh3QLPDVifZqjncHB3B/VuW
iI47zGqJEzCi5WPraxKWVDGP/d+glNlRMGC4SSRPMoMgxahUpFDeEaw0GLmIBAg5
FxtgNYjji5VEvrnRxxuesAAQr0xPFsbkImorA4XJiUFMCP4OTgbVBFtNrwUsHuDB
4Z4U0nKKDjDOAb3Hako/KoXhvQHoEUGDNX9EcsKbNREfa6AJVNUzrfVR+zjbdsda
XjN7e0AqYWTgRFAnYLqHgZFc7A1IsoIzExioWnZMpNeYQM/H0lBLP6MpAApEfEQe
4iHF/gRJh+d7tywtbE0s3JSavylevlFbu01btFlfuEkrb48v2mKUt5tLdyQWtxuL
txqLN5vl7Qk4MidsSyzdlV601VzSbi7apC5oUxZuVOG/lmw1lrYby7abS3c2lbcn
F282yrea8P5jrcqCNnXhJn3Rlt4DrrNZX7BJe2yjiscmY36btnCzsWir8dgm+FWf
26I8lOQCuOkd1FQJqIZD1rJFGZ5VFugWcTMgq49kgOJirl9LgI76AXlIho24S0C5
3aAbEAVoKY/RjOwAYc6vGgUGFeQpue0Ba8TB00ZvhWaSBhrjxgL8FLY/HVO/Dhp4
7abcu5NOBtuDQ7Fjojsmou7i6C/swLKBX9hQn9kVD1pLPCuSP4ZzjiiKZT122PaB
nXMQ2lO4SS0HOitWo4AJu+eRoyV4JVMobVAaXaW+S6Of0RyU45m9mpxKHbwKdrGg
1ZKSp6Rr1zf03Fj/xc3l/3pzye0b6764QRNXb1bdulF560bF7Vs4aRqO2zfX//lW
BRzwgt5Zd/vWui9urmUn3OxZd6vny5Pp/Q23b1XdvlX51y/W/wXO7FlzG/+88s83
K/7yRWXf8Wc4jT7u9hc19BouvuaLm6v/8gWcVn37VvWDaROUGxY3mJkc3igDjeGN
3IjiRX5cVAbUMAUiPQAHmPkirQIXixQteZR7CeDE2ZRfiDujCMTKjAY4CiSKocFB
gisF4ww4JiqiaopGHhX7sjmAyhAH4pHNg1nGmBVeBNjoSw6MsJkrGmAbssMCmQ2M
2n1gsUQjWAVx7RC2dbrOzUQbZaTj2MYOCNBPALUAMXCCxSRscGemXk1ddBR1MeyO
MSJgn37YMIVuGHUXILTZSvUpAROWEcqdYoYyUaaYFj7R/rj5r3+uvtpVf+V6TVdX
6J871c86op93xa51Rj7vwoO9wJ846T2ER1f99S54Eb7WGfq8M3S1K/pZZwR+XuuO
wQGv2fGnjvrPuuppgnjoWmc9HPDiKvx5R7ijM/x5Z/g6XL8zcq0DX9MRwQt2hz7r
wJno8KKjJ9zdE1m6LW6pjUJIU4w7eVTALAERPCWifYoPsQYVhBAOw0odMCPWzAFX
yjo49aAMr/HXYrPRJZnghuHXIiORr7LzjRwNC/5YPQzzHjbDGgEUOlpw3qD3dtra
BXqPOxljyLrviYnOCI/pI9RgbNZ3REX0EZzi4gQ42Q5moLKG0ZTYQLRO8rV+moRJ
mxow+AmQaAMsZsCNbLAMcdsQJtUEnWWxCbyxCB0j+tJ4Q7GepMKywkKLfvFNRWYj
YAeaw41IJ4dKOrBULbH4licSf71ddaWjEp7mF93Rnhvi591hOK73ROBAqfSK52pH
HZPQ1c66ax11IODObjyudYWYSHqlyH4NX2XvdOI66OzCRdBB73TSr9d7DziBHXBN
OOAE9rmfd9V09dR199TMaTMtVbylTrHXK5YayVIv0DADhbZvq3jEDIuQxF/BK9eJ
sF6RRCikWGoF2vGt4f/qmy18ylqvAJ5AB18nWjdwOI0gpltiYBVUaw28DwhAo3Nk
a7VgqeYtNYKlVrTWobPHi9cQZzBcGSl+VbyNOnqzVsJN3LX0iXXwVA17RdjSf3Cv
aEUduc0x+BF8NKWUphhrOYqB08tDPEuRU0rBwI26MZqXi+0yOuUajewYOvayeCOI
1k0b9yCAK1DiRUZb/2QLLFWAec4IxvWsfwCgmSWsbb5g3u6p6uyu+Kyr7rPO2JXO
yozwUKJ17LjaWXOts/YqihllAxLqvBHpvhG5cTN242a0+0aYjvruGyE68Ff4r56b
ETg6u8I9PZHu7khPD7wZpfMjfQec0HUDjhAcPTdDXT145c4bHJgEeH3jZt0Xt2q5
gxAvpoaayQmGcW8iOTJtDkukhsQTI01jTCo5Km6Oa2qa2No6Kh4fnYiPTibGNTaN
b2oe29h4fyo1rjE9rrFhQnPr1C07xzW13p9Oj4mbY5PJ+5PJ0SaePLYxPbYhNa6p
AX7CcX86BdeEn3DxkXBCInmfacJPuOCYVGo0/FUiMUxVh+n6cN0YqmplkjxAVu5W
tAGSMkzWhsjSUEkZaMaHRyIF9xBCDqyvxZFOAIxxwjJFcpRDwKAesJKI24/Yjo9C
JckSvxAOYdsi9kuYhZTMy44JBVRLyadCN030VfLUBo/R5lIbHYJJFHAGxu+40Uyh
FnN54wXj5o1a1JjOWlCXz+7Qv785roI2X5f++U+rI8KMen4qJ86IxGby8iSOn/7d
DmFajJ8GPzkBXk+PcVPhV16cwQkPCuI0jp8CP3lhqiDOCEenxqQZijpVN6ZqxtS4
Ni0en6ka0+PqJFWfljKm6PEp8L+J+GRDmxI3pqrGTEOfqenTDH2qpk429alxY5qu
TTGNyYo6SdenGHSYBh7stf61h4GfaJrTDQNfG8YMTYMXkw1zGs9POXh44b//edGN
7tovbm241bX21s0NAFBudFfevFl562btrZurAU+88+rq8eOp8pNDlGDuiJBFDeUQ
5AVxC3A8U3ygaJKF55hEpSIXpXapxklggaqqKgXjaJ8LjFRQiYNy58qADFucStrJ
G1j0kFi3kYhJBl6z1oit5/RbN2vuEG34m0Vb131DevuddXkFfltWlsPlcnt8dqcz
y+3++sPj+T85HB63g06GC8Jrm9vt9HhsTpfN7XL6fHaHw5vtc/k8Lr/H5/N48LXX
63HBC3fQl+Vyufzwjt+Tje94fV633+WBn15PdsCf7c+Gd3zZPk+21+X1uOF9n9dz
x8HecXu//qATPHAp+GCXB/4cXnitdvuiJWNuXK/t7ol1dNd2gwHrqe+5UdnTU919
oxbMFby+ebP6zVfWjh0/AkvxwcoQiNYV4hj3LeBsjFa1RJDykywh7qFCMdU9MOnP
/G4OVmcpzMKMiUqlG8rgY/pN9wngqhucWpNXSXulBATKAB3zsZnIQPIwQQcP0XZe
h1u5er0WrC44yGvdkW8S7Wcda27crH3/w2oL/rNa/vv/3XlN2x3vWP/utL73bXf8
79ee/N9yP9Y7Lztt5pi/fKFd76n54+cbOrq5TzuiHT01V7uqr/eEEXh214Bvev3l
yvvH38d8bQh5o1BriQ1K0IogpibRsm0grBSaRzVOAFCgu9jwZiQLFEwH5mMNS6f0
OpWUaZAJQjhez9ewMOBV0z4p4SFFB++bqyRAfXNwYG9q65NJEO118qyfddR/i2g7
uis6u2suf1Btd7osVofF4SQROL7xsGd9/fFN51vtVoeLXtML+GfPssLhcFkzf2XH
d7I8+MJqtdqd+ALvAX614TlMAPjnTjgB3rTAOVY7XdyGL9jR+3Ff+fXrb4n+Cq6M
P+kdi+XReZO+uFV3pXPZnzo2fN7Ff9oR67oR/fQ6gn+ILEC0nTfCr75cOQZFa7Oj
QZZMH6gsbRR3YnnEzOvtly/SEoVUh2H7IwI8pVf0RLEeL1RYfznWKzCzj3tmNEyL
y7jFH3BTrpJCucrJbEFnfRqYMaf2GhQtnwTRgkHuE+3Vrm82yF3R613C5Q/Ddo8b
VzI9NfhptTu+9sAn/g0HnZDFzqHXTpQlPEH6CUKzWm12hwdPQAnhb9a+NYGfbctI
1O2y5DktDi/JwMZ0Hf+Kzsn8Cf60s4/7Pzz+7m6dfT9JtBO6OlZc7155rZu71sFD
jAey/Kwjdr27FsK5691VYJlff3n9/Uy0CKMk7Gx2Uq2KzTIOEIaiHtd4b1kY+7Jy
ROyswO4TGcJzhXqOkNsAC42yiZlnEJuM+5RdgLPkVL7RBKIF84tpZyqrYdyGe8h1
a60Evha0FqOarlowyN8CoyBU7egOf/DjOvCL+BwzymH7RhF+k9aiMjH1tdOfZ9Qx
Y+9sdpvTixLNmAQ8M6O4KGZ8uPaistyBI6xZPjgh+65gYEIp6qvNtnT/1Nb9qwOF
ZSTgLLYO8Ca/RS//xrp85b/u+CIZ0ZLWzp14+wZY3ei1Tu3zDhEwyjW0zGESbaiz
u6rnRu0bL6+7H30tIuQ6MMhe0lpXDDPdWFjAuBYRUz6lDDPdxdTtRw3QWAzIpyNI
EBr8K0jLw7YuiTruSgZxqukCsxnMr4/4XYKEt7FnHaQrGBC9tZxVma8F0QKMutLx
jaLt7Knu7K68/OE6uwvMZq9QM7L5egP79QcqkBOf1B0vmCKSUbXZABf1u7tXES1k
M+mwZgy1f/iEsrHz+w97yGp1Wq0O9/giX0l+0ZC7qr7/cNOOlVnZhcwy02qwoRZ+
ixf4e8fxd//FhJq5T4tl1pwH/nwTtDNy5brQ1R29CgYPovyeOorF4f1q8rVMaxmR
n2Ri8MNjG5SNNiT5qHHeR5Aqh1p1csgm+ygKoj0tBsRC/bR0Pz3Vz2wI4hQyJPDx
i4ZXNl2c7BGNHLUhoKbcxE5C3Byotb3tOCoi5POIkJloO741+LneWXfzVvTdD0C0
WRk3Bk8QveM3Gt7/8sgYQNLRSbPmj1+40JLlhdf33TdvQU383uFjwwtmMuNvB1Vm
zs9iHTh9ydDZ+uDplX3QZuTMoY1HFx19ZumDM2f0Qh9bIJCfEyjImO5vNshfuSW2
nvoOGzsnq9e8o82YNXfiFzfAy66/ipq64UpnTUd39EoHICmweTGII9DXvlQ1ZvxI
vIncKpwYgrT1GbpkHDHFtrIEYlK+qOeLODUPy4dE4APiKaTSHuIpoyFfSfQ3m7MF
zUnDCWj/hYGcB4Lp0lu9SooxYziRuN70cpm9CF5OstYoJNoKTAZ1hiAE6ksN/v0B
lqe7J/L+D9dDlNL3tdlyttp6jZ49s97JE9usWe6MS0Zts6J17YVIVhu6RpKrzUra
ubZOGNqy0zPiPpsla+io+Ss27Foyr6IxsibLVxosGeh2Z2dMtNXun7Jo2sMbJz9S
f/+I4R5LDi6F8cEL56a8dracC6+2OIJoVGyu0mDxXf1dXp+n994Q99myXLiSmMGg
BcpulXBZr9baCYVlTHGvce41LSDa2zerroM4O1FHP+uKft5ZRxgljOnYr/jaPqrr
sGQPo2jtuD1UCaom22KWj42Q2JsDBzZJIU0X1pYzPcnY8KAVqsk8NRWEUEeKe6V4
HljgqOLmDbvc6JWTmRETyPShs+E/LrT5IFqZ4loULSYXu+qvfoNc6agD0b730bq/
EW0vZul9Rr3YkuCMlT0yay8QtWZ8as6AghlgTjP21mKZWjlvbdulyRsPDp+wYuzA
5QsWK8tXnGiSj55dt2nfzHAvPnJaaFnkjJk67uGKNcsubFMaVq4rf7R8eWWFEF2o
7ju4/NLjs422irI588aMH/zYpAcWjlgzsewBiI2tGdtuszA1ZUbe6WY4nA5HxqHS
HWa0mWnql6K1f0fRAkKmBpqsMJIFejBlARJV3IRjsf2VXKkPe7qQIQxr8jgYk3ow
qS+Q5YpBbG4h7uANJw/vmH5O94pJEG3QaHVLCZy8iWMqNXcU2w/gyBZVa53WdsEA
0V7rQNGCgL+7aHuX8x1wg1APqDLB3SxXRjUdbloHGCMOvnv6yKJKp+Mei5WeY8Cy
Tm1Yrx8tatw7aYFeu7h97artj9Ue2K3sPbx8z5GHkxZbtsWW8buAnG2lQx8cuqSq
ZldoZXXSXLH3yIawpurr15zcV37y/IyN5xbFj1Zq6tqqh+pHDnzQ6SmwQbyUiZHs
7CJWW1ZGUyncsjKHygInCq4yq/YO0TLz8w+JFp57RHZEsW+NtFZ2Ir8gTtv0s3KE
aDixERIAVDxPxmYwKvtobFMiIOesEM6ny4zewxBIcwpxi9QQMDY6xYSDRpWAF2cs
eMjHJxvWkLHxotlnkK9eh3DtGw3yN4kWZUaeiUm011FZKTRyZzwfex/edQcCxSNm
TAlFxQOP1bfPrZAnL5wdW2gkxVMTUpuKmk+kE3vVyFZjdeu5tVsOr2zdsvKoUfEk
N3LetAHDfLlDMpGrd8jIsfVbI5XHtkwTq2dtTK/cn5AEIb5jW/WlY3MPnptvxja2
bTFq5LXeASWZ1WNzTSgeP2zSA1NGPJztLmQ2IOPmmdeHm3e4vgxkbf8torXaSGt1
0lqZSDjRIONoPGIwIwpArBeisOVEAMCRZNKOT52RPLDkBqWxVOSCo00GOQIosZkl
N2RrrXbe7J0xgxvFAnARCbvFrPX6naL9/6m1mdiUEIeVmTiMPdCEZucUOxx+BLdl
906tbBm/PDE/eWZt6yWx7Wit1t5afzGWPDo7sa9Ca29TEjWRM0f5+BsLlrRUnG6t
fKpywc7I/WPqJy8cXDSTGdXhhVNKBi2ofmzB+ZaqJ06uOdBqHlmzr1Fq33Ss4omL
5ccOhxM1B9M72qL6hmmzKsrKpucU3Gf3lD7oeXjGtPkbVgkzpy6w5gTRyFsRBvZF
NRmfwkz014qWTvtHRRtG0dqxcUtj4z+omYh4RlCPNbcYR64v1ijaW69FOgUtmZWZ
uweqLxHRDeDkpMdoC2itWULChhTYyMUPFwkqSdzbw8l3wij0tYCVur8xZfGNWssw
ZG8gdGcwYwv6lifmDR4+7ZEpswZhJcRi8xc/UB5amzgysf3JkHluU3pvg3CAW3Ww
vulwtP5we2Lz0dpNRuzYmZrlP5rzyOaVh8RVJx8pm324vDw2dsOgu+eho3UHv79w
8feWTJtx/+R7Bk2YP3rOlvAObuv+7XUXzq47fO5I5cWNmpw8lajemAjr9fq2abNr
R1c0W9zuUt+9j4yes6h+Ha9J4yZP+0o2ERdiXzBG65KBA/a9vhrXfhfR2h3BO7WW
OsECyBBGxHCcQh1POhuO6JUSHtpEy8ry1FGmleipIj0Fau3gNCfYbQphAVvZOd2u
NHqVJocQR23m8B0np7tohIU7JlqrMzAK66Yg1K7Qt2SjvhFG2eyWXvW1MmyJMiQA
7HSv2zF/0vTli2Y+XDywlD1K98S589RDk7ZcUuJHBP60WnkiXr1/TXwPX3dqj9K8
p751u7z12dUrvreoVoud0Ffvrxpb+71VS2MjqwJj65hxl+as/JeaGXOmjcQEwgML
avWWpRt3ahtPHFp88nFp0+ONLYnkMaV6qyK3rpUbplc33ztzNZzpcxXPnbxs0tKK
+ZHKqY8sRrueX+J1FnrdOV+iPwa1+kKdL4Pdf0y0GRiFvpbBKJp9oviovxwkV2qk
io00tqlS4tBHu1xyWFke2/KwIzUXaWY0ewxEm/CK8QIlVSAnnWLSo7e5lEa3mHQC
vBJMt5jAiXuS6cQpLyTa81+K9tsR8jcFP5aM1pIFJmXNCvj633O3Z8CIwtyRs6VH
tPSWiiULGVqGE+yenNnSkahxckP0wtrq06nFB83IgcN17XtX7t5ZczCZ3nlRWdVS
35Lkdp5s2BC9r7xlwpRn169cdc96a+H0XkRt3Tp21L88NHr3g2P3LFGbdhybsatp
YdvereqTW6qOVyeSiX1t4uZtq7fuXWPueqjxqVETZ8PfuSw5j8xaPyu8a8qmA2u1
2IIVy2uXL26NVcqV4SE0kyeTRcnEaY4+0Vq/FO139rXW0vVVFuTPxpkiOZxqCcv2
kOQO4/D6bF60Kw0WrbmfaFgFc4Qez5HihbxUJEhuDreWWjk1IMpWPg4vBkakEkxP
Jnw4MVGxiA1ZeotFabWrzVYp6VRSGAhxuk0w0G7HFEut2IoIuQZuDiT3OYS231L5
6azovBF59/0KFC0LRTJ5ecIXEKiynL4zv3DwsMFTJg6f82jZI/x0Tkm2NaXrQj7K
/6HSDRy6IX04wR1cGzkfXX+mvXzntvpNF5Y3t1fuT9eebtC379eFtZGd29ItL4Tm
Vt434eKGx15b8dD60okDPUMzganFsn7aw93Tx19ZMOLy4iXHxePhw7um7t8qJi62
h4/PjKvVe7ZsbWtYe+hgza5N69uOzQ8LrgA4V+/iKn1Kw8l5R3esaquuq5urLVle
OXv+xPvGlOQUk7o6WFCUMch9KWjrHXlTFO0Dt29VXO8JX+kMXe+u/aybI5Wo+zrR
WmzDI0JZMjnK0O/R9CGaOVqTR+pqiSrdbxrD4vL4uNzfMEemmyc3t05JJ+9LNgxP
NY1PJLyqMSEZn5nUJzQ0Do/rw5PxEZqarajjUvGxyeRIQ7GorTZ5i01psStNVtJa
sMYOZMzV2RZeS43Ycj5Tr8WGim8V7bXuWEdX9P2P1js9PlrXdmvviv4yrrdYh40f
tmDZ1JkPjppX/tCC1Y/VyPVrW7enD0tSmC+8Z/iMAfOGLpUaE3tb5GN85cVVNafq
as+ayumdVS0VxsnkymOquVVMbdbN1ue5Jd9buvBJtfanNdM+mTJx9cj7g3mlDKOC
5tdXrn2ysfk3D4z7ZP6ojxZMeDy8Obbv+MRdh3Xue41VB2dv2bqqbVfNvv2p3c1L
jh5YXXEhIhwu35B6RGqeIuyr2LsxepgfWEYLJWeAxR6EyxaUDvB6AxamsvApGKr1
JZAd/6BobVnOXSdDT72nPvOW9PTb0sUfqM++zV96M/r6e9FLl41Lb2pvXpaef0d8
9i3x4rvCpffkp99NvfaB8sTr8pNvy0/9QH39A/W5t9Vn3hHPvQ6nqU9fVk+/IT3/
nvb4a7J+aqNFSFmEtF1qQMp+QGHEC4skwDgcC+Jaqe1iRmv/S9F+3iV034i9+8Ha
LDdEfr1FNxYX2nqTwFb7XWUD7hkyxl96r7NoaMnwhyc/NGuJsVm7sHJPa3r58hpt
2paV+pEWY88O87C2+uzcmvNh8VxYOr5ueUO5eaJl/aV4escyc+c2RX29fu3Tq1d9
XLf4n+fOOLBkQVluv94ks8XtCCyZMuOYKf5x9gO/fXTUxwvv+cnK5e36nvJD+8qb
jm+tPlfZvmfS9qPR9l3Nm7dM2n8gXH4+Vb1b3d0wK7FlpXRsa8PB8tBSvH93wbgH
1wwf/9iYh+ZW1dWuXrgwK7uEUL27Nw62ZVxsn9P9blprc/zgtcruG1XwHx2dFV3d
1Z/3RI9fNs68x/3ztfCb/6S++Uvp159Gr/eo8Nx7Oqv+0MH96krks466L27VvPWr
0NbX4hcuh35zpe7KNe7a9difOupOvs139lT/5daKTz4TxzYYlogB5tqGVQeZbf1D
EmDGgV8jMK1lou341lI8fI3uG+H3PlpjczgyuTpMBdhsFOQMKC3gZg9OLpu4rnzt
6ClLbWPLbSPnlIx4pOwhflH46bVtO+qOr2xpjG4Nn2qN7TWk3bsix7YJu2sXHVnH
n1kkHrp7cWydcFyrPbq0ZV9ly+GThvjbeUt/PHfy/1j+6PnViwtKB80vzfNgWcJN
tRxfaNTUySPH7Fq/rHPC6Mvl49+pGfPRihXnkodW797/cOPhyTtPTdi0h1d2bzL3
rTy8Y7rydOXyiwlx3/rokeSaY0Ji47hpqyYvkVZE96/Q9nF79un7Ni5rPD1yDt9b
dbfid/yyovePaq3d4Xr1hYrr3Wt7euo7OsO3v6jr6IpUnW3c8nLq1Lu68Vwy9T1j
55vC+R8nTl1O7Hs78eLPudNvS7tfN77/w1jsmcadL6vSsw0NzxpHLje0vKK1vyam
nk78/k/6lY6aP14Vpze2YJceb9pQXzHFCBFzjqDRZEsJKz93GGQAU9+qtVUd3aGP
Pl7v8Lj76mtW8Hx2p92RteqhAYerJzeumytULImtqXjgwSWlD6wY9ODaoqnrRqzb
v0y/ULE3JKcqNstbNkXOb+YOiBWHt/EHaivOlSun50hn5nP7Fwnno7FjkeQepX3b
y1LFL2c++H7lrFdqVq1esHxyXsnSkcUWLEtQJdFiub9//6WDRk8dN+M3M8Zfe3D4
x0umXl42/una5o2tBxfs3TNg38nRm3fXpPY3KgfqT+2dqJ9dUv2EvuKcvuxcg7p1
w8HUsuqNNeqRmuTBhRvbI9vTK+K7S2dpDteQ/NwBxfmF9r78GovlMgU+x3cWrTXL
/dLL1Vc71964sQHLalhJWL//VX3Xm+beN6T21+OHL6d3viZtfUne/Jrw2k+jP/wn
bcdrxul3pZd+Lp9/P5l+qXnHq+a5y/LOl/WmF+Vdb2ov/US50R25eXPtrz8Nj29o
wO0VqLXIXM7mj3hpZxzBKOlvYNS3BD/XuyIY/PxwbZbHy/CklRANqmyhb2KBa1kw
f8WAe+eMumfZlHvCi6c3rp9TNX/+7KmPTn903QOVm5Ykn1hTc3LlonMblp7RVz2u
lJ+pWHi6Vjw7fevja4xLj2rPLtQuNcUbzoZrfrPokV/NXvCEyLVqW5omztvw0MJl
+JgY0PGSL3SMH126Z8XYyhETj0ybdX3ByE8fHfa7OSNejCw4ET2c3npk2v6DD2++
tGj70ZjSOG/3rg3KAX3V4dYFR0MVx+ouyWLDvipx32KlcVlramGCG7M4MXLWtsWz
K1PzHj00b/bhueUDc/ozMPFV0dq/u2jt7jderbx1c3Xntfqu7qpPr1fcuLnuD58L
P/8Tf62T+/3n/D9difzs09o/dUl/vCr95YvqmzfDv/us+pPrsStdfHdH5Qd/kH/9
ydqem6FPr2/47bW6n3/G/+F67bWOKhDYJ59FRzU34uYZDrXWifvpcLM9S4D0IeSb
fW1v3xrXXuuIdt8Ivf+jdU5fDoqWNalY7KWuooqhU80BDzUW3H9kyENHxs7ZNWV8
8tFhW9ZPatnwiLxiyKr584Yv0efKT0RCz9XNPrVswdnVK85rC89qs06Gai7MbLtY
3nhpuvD0MvWJXS3m83Xrfl82+v1Va2LxXU0bUk/MmfVqVVX1zKmTBpX4fD5EUHZE
OsVFuQcqx/x40YMvTyp/fd6CX6wace2hwW9GHzolp/Ynd887vHXhpiPrthwXN+58
dOfOuvju9NL9W2ceq+SPVR1uiOpn1qd2zEylFm7dOTe0ddSCveKy/UdrjN2rV8bK
N6yetKZ//uCMr73TIP8DWmtzOL//wvqeG7VdnYk/dnJXOis/6wpd+MDY8or203+q
6+pc39nJg/d9/7eK8Yxx7G3zd9fq//lP4d9cUd/4Kff7a9W//1PsR/9kfHoV/py7
8jm183dH0GF3Rf54JTSqudkSNa2cQYNTKSEVVbLVpF9NuATDUq9uvGT2dTRe+9YG
GvDE3T2V7/9oLQY5LCFnsc2aUXNi4fYdy/aEK56oW/+UufLsjgXHX3wg+c690tuD
694ZX/nGo+ufW7ho79pYdNW++IqL8tITDfOPNTx8rGn+6dZFx2qrnxgaf3JI01Mr
Gs6Olr9/Zk30zdWrnquoP7E0dXhe9QuLZr47a86zM8avuGvI2EDx3e5gJqNpB19g
m1R836qR47eMHfbxuPGfjJ/z05mTf14+9SVu9VMbYq1b9o7bd7B+06Flew4v2H0o
seSMtvpS9ZpL6dqD8V0NS7YfWtl0iKve377haIOwn5P2rVxdMWX5o4XTR3uHFmfK
+Cyf3FcL6qv/fDetdXpfeGHdrR6AMNE/dFSC6tzurueeSDc9n0i8nLrwobL1jfTT
HwGYkusvxje/qMW/r+38QXLjC8rml1LNL6drv5dKPWd09NR9ch2cdO31Dv6zTuyD
Adv+ydXw6OZWSwxUVrfGtKyY5oipbjFeqKWom9WwhnSq/Ky7er2euvG+TWuvdkW6
etZ+9OE6uzebff9CR8HR+1ZVjp4770F17uLT06Y2rig/Ji8+oi44unfu9sNz9l2c
svHShC3PTzEuzZFal56OLT0vr7yQWnHaXH4htuJCfP3FRS3n5zSdX5q8VJs6MVv/
fuvqzU+Wh86ujLSu2/bG/MW/mPngJxOmnRs6ZDWzkFj2cbFs193u3OrsMTMHP3rf
4PG7xj18ZcCs342Z+9H8+a9WLn5u3bqnapoe23lq/dZd5QePLd1/NAIuYNmF1fWX
NlbsXr93c6V5cNOqXUdr9m/R28rDkfEPP5pdVuAs8WeaOiwWf7EXMH9OYbbF6bJS
tcpmd7NGsK9NWaBoKWVBz/BO0drsP3yr6t9uV165vv6vX6y6fUP46626Zz8Otb8S
P/62+sSHQtPz8f0/0H72e2X7G+nD7ybe/RX35s+0I2+mLryrHnhLP/Ju7Pg7yc+u
c3+mrVTdN6SOng1XOzbcvBHp7K4a2dSGGxqjmhUiWtH0Sgm/2lBkNBQhUb5mrVMp
0bgOc8hdkWtd9d/SQAPwu/sGxLUVVieY4ix7livLnmOxortdNap89rCKXEv2/QMm
zhu0bMLM9vGLzsyfd2Ld0gu15bu0ZTu3LWq7MCd5enZLy7LT6upLDdUnKriTozed
GdlyYXn6Yqp129Z4+wT9+fH8i8rSXXPrLzy1OvrH8QvfmlP97vz6jx+JHFqyYfg9
o1ieEqAJRJ/OrOzV9497t2TB/sVrK5R6LSW+t2Li+8tmv1ix6uWVqx6vU2u3HVh9
Ykf94Z3Tjx1c07IvVrfdXHtupdYe0/aaYJZrjYFjRtkwj5HJJPfPCmRbXP6CgrEP
DLI6EEaNnpi7dECR1+7OlJ9ZP8l3Eq0jy/Xyy+v//fbCv9xc979vr+nurrx1Y9Wt
7qWdXau7uld1dlX++FPx08+q/uMvaz/9vLana/G//3nR/7q9GKDWf/x5wa2u9f/2
xZqObuFfbpX/660N/3az4s83Vty+tfx/fbHw324v+9EvuFHJFguftAsJ0FpAUgEx
ni2ncpREvppAra3TvizFd0Wudv4XHY2fdVR99GGVy+XJZA1ZgG+xzB/xyKqprUP6
zxw8ePmwQevHjaiZPl4fP6Vlyfzj5asfX1B1MbL6/OFZLU9NDu96rEmuP7Ki8ciI
rUdnt+8sbzy6NPVcQ7x9P6/dJ780N/b9+TVPl0cvvfpIzeWHw1sWLksueqTlgeXb
F5vrx83r5yoMOrJZotHiybp73uDz5Ytfmrec082atvSR5KKfLZ76orzg1TXz07Gd
0w+fmnN8j7hj2/oze2a2nVWXHWlYdwGC2sbwwSh3YVKNbLnjX5E3WGIPWq22yTNG
jR46DK+f758zNjinX1mmIsmk6/R+N9HiWuB1S2q7xWi3aK0Wrc1itluMLRZ9Ix1b
6HWTxdxk0eD1RouxGV/omyxGC75vtFni7fhX+ma8AvxqbLov1To00ZSvpC1iq11M
WwUaco5TbE042HwUFG29wUrxfVr7LaK91RG+3l15+QMQ7f/H2ntwt3Vd28IA2ElR
1ZYlq3dR7JTYey/ojQRA9N4Oeu8Ee+8dIACCVLPc7cRxi20pthMnjpOb5CbvJnas
6iR3jO8vfHsfUE7ei+XYuVcDAwMiyCMR86y615ozNdFoTE5K24PLTNz1lfl6U5XF
WCET5gkbn27in+f2nOklnlO1kSI93XEec7OVvoVnbZPVLp9M59ZOPTtxjeRfZHhW
yeYbHZYYxX6VqH6uRHSLz55+kSj99HTDnculHxbWvlLPIhaWgX/gQEr26eyDT6Ud
gCPQ4KNPT805e7ix9OJAPfs3qdIfV+gntAPTEslP2vJ/X131yXH2sMJSMbratrhS
OrdAUq36u8JE0ZaXvNGrnZfbF/FTq3svNYBUMP/Aucv7Tp3Ye+zc+WPlDblnsk9m
4zLOlO7ntJ8fq7+859BT6NkfbmdQZCeN+u7Qgv8oS4dRDGMkfozEgZH3YcRBjMiN
EXowMj9GCl4H4GuJDyMJYEQ+jBh8PYgR+uH3i73wIfJiJOCn3BgJeMsHroCVOzBi
G0Zm2WUdTtI60EV0BB4Aqy2paks23BaFyhL/eF4Ls4D7kj/df/J57T3e3x7K335f
gUMzVfD/PpqS3Z56/MD+C9gDOXk5svZKI7ma008ZcRJHjC1uZZWWnSMWtCwRaFFQ
8Ci7Nnpo8S7Fit464VIFnwmukoZWme4IQR+vdGy2WK/XC56rVT4XJ+t+dbztd4UV
nxZWfJjPGW2dEF5mnczcVbdv/8VdMMZj0UYYSJQPnczounSyj2L8rMj2iws9b3aw
Rrs1r5M6/quk4z+eJr1S04PYZjtnl5pm5kS9iwPkEFUQD7aHOMioQb0mWZy+Qtdd
Sj6GP3uq8MzhixcP5pWeOXb0ZAZm99Pnd3VwL46QKxh1ubiju9D5AeCN4Xwu9gkn
P0+GFtwOfB1GP4RR92FUIOsJYJQeTMCFCQQwPj/G5cN4Axi/H+P2Ytw+jC+ACfgw
/QFovs4gxtaP8QQwdvD94BvcGIUTXkEdgKKRGn2y1pih96UZvBBahSFVa0lWGlNV
cLwmE2UOxUotwU0rOkCD/s/Q/dcnQfufX/L/fF/57p1ubHra0aTM6v0HK7IL3M8q
r57yha4Eh5snEFqsmbBwLJ+SffB0Uw1nhLQYwc8sdyxaGxal7esCSrSHEmvlho3m
OetI396hUE0wxEJiHN1Wo+6FM4qbLuboT8+wP7vA/uCi4KMc+St58rFiUjSnSZNy
vh3zTGP66YsHcnf6JGggOJx9/lq+5rUc68uFmmuXLbeqPe+WuN87Z/j4rOwXRfRf
nRE81+gzyaw9gzNS3toKcVKgXdcTwlbxikayMiNd6LeHGtq7sOlZuKx9uKQDp3CH
67KOtZeccgs7vIVlKtyzZ47vo9VV82r4lWdb0GogcSj0/aDFYQRGDDKMUQUwaj9G
0QefhwKZU1bMiO3YuKl+1UoIWfbP2LLGndmz7oJ5V8GCHePzYPodmHFX4YLl+Lyt
a82K8fdDa9YEMYgX7g7JDbtU9r3mAOR31lghQ4fOnqm1AqvN0pgTGwZYmbVv0/rV
I953gfbBXdXde5qf3e7FpWWeSD3S+2xR1+5qxXlb+IrzuWLRa8e5q3V9fNZVcufs
xQopp9E+iJ9ZbFkdblzsa1xQda0SKDEuKczjh32uDYNvKL8/hPdvsZEI3RTqUN1U
MpZfqVH9MoP58QnRR/nyGNXeJ3SNczQRPl9adfkI9mBjSnP+U5WYxMg4OouDw2VM
5CvfPGn/6DTldmnPD0u58TLNjQbfD8rsn50RfVrIWW+zyvjDGlN/r2h1pXbOalmT
MKMu/IaLs7HB8DrNC0JxX+HpyvxDp2v3ndEdueSvPLUhrJ8vq7Nmn1NfyOtp61DR
PO0tzovn69DhvWT0EBr7faHVY3QAUS9G5cWofRiVD4P0gzAJnTNAWtGPUQ1g5D7o
nwH84GHwwmdFAKPpx0gD8HvAD8J3g/Bnld49OscupRGrtSYZgpDhWufEaa3pWste
dLUrQ2M5YLDvQWCs9UfNjx5x4VL6A9nn3zpA87sv+f/9FeOdOyxsSsrezFxmnmLs
ssdXZJFUjoq6FvWNM/0V/fb2BSU5NF096epY6iVFJJRVPjnCJEXZzHUpLaYjrprZ
Sx71xoxqoccbFikWuqwbjfrtSt4NC371dq40Thi7indNOmpe8Jdo9fbiwWD+lqB+
SctwKOii3iMHzydyZNz+rF35R/OOnhKdZntdKsQmXq8KrFc63u3i3i7h3KjSRers
HxdpNi+pK9TbJf0zPM08szuy0LEeNMb9go2RpuX3c7UfHen+5X76z4u571/mflDL
equ+57kS9uIV/CyZ5aDINNxRdqspc9+zX6daO9NC3xNaLEZgwOiCGCXwpeAZxcnn
xHiCGLkLY+jD2AcghBovBnFilAMY9QDG58LYwE0QgPCDh6ofY/Fh9F6M0ofRDAGf
nK1zYRE7RmM/rvem6NwpOleS3pOkcyfpXamIOU2t36t3ZENlUosPQsuBE4334d7H
n+49sYf8n3fhiPmd96Sg8MnYW5S7r5H0TMdagTKUr7e3Lqk7JqZK/aHmoICzre1Y
t7XP0SnrfPIGm7xGIUUExA1B+7IGGZGZpo3KTY8kpDFe7TUtkW0xkvhmjuwlDm3t
Vo1zszMQ4wuHF9s+UhQ5uOJzY2bq9ZbeFVsDh1FSXlhzuhGLg0PFKRf3PV3zrLgb
P0rW9DsQp6l/nrIYave/wDQ8x3BdrTaHilWujqloUR+NvnRFeoNgHcLb5nwtS4Pa
uE3zQj9h+fmigRfyjC8XGJ4v9G8WB7fK3Jt1to0yrb9Vr+PaKxmBTtFc0YkSUAMk
qrvUpERRgMba1tK/Peq9i+7/370v+OM95Z/uSf+QGAn9JmiNMNYCXwptEaAVxAyO
FC9YMydcu2a8+2edmVPevbPelHEbJuiCWfFw/7EZ5945a8aw68K8u2TBfmTSlT7v
xRhcqCm7k9QIFmTdBt8BWyBVZ0tBHGlGb5rBnYLY0xE4aLFLY8nWQWgDMetXX3ES
GTLaaFQ8MY36UnnvIefVdxhZh84ePHhekKPRVgwYaqY9teNI/aK8YVnTvKRsXu6l
ramFCzLRgpazqBIu6mXLCN9vFnsQ+7hoflA00281T8xx5gOsKFlzjcLZZIniVELk
tPDWNHPiznH6sqvqJSVly45X2dVdK8LK651mK2JgB9mdsrIjdY9NCO0tHHm2Sc+t
eom+Z83jlIz9kCV+iy1dMrYHJPK1Fu/rhRIKebmSEqdSow2UjVbFEkO3JOrd5tHi
TEa8XjXOCWoGhAPbxb6bnbJtpXNZYtsW2RzSRSl7Vcaa6+oc4JMGTfS5PtrkfNfE
ULnv6FOXEtbb1FH+l6+4X9yX/vGu9MFDIdwY+DLh7Z4ELTK4E2thMhWAhY0T2Cua
KIHX1gB8bQF10QBGC/4K3kK/ovPBFw4fxuLFuILQ3FXAsXsAeAc11hSjP9viz9Kb
dyH2TL0HxNpUtSlN68jQOjNBxIXQWgG033HE/PN7/M//zLlzh7HnXNnlQoG4eUHa
GZZSl0y962bOgpw7qxLNiOWTUrtPNKdkz0sFU0rVFFczQe9SV3UoSnvn1dQ1s27S
p+gb8yhXnL3LJOs6HbnBUN6idkVyWdvXSd4PLzEX5BXX5Obh8Ub+OL5+BukMtQU1
mj6xa5zZyyoqv5BzLufs6bPHTp45dbqwtNjHEQlCnJyrIrVp6TWR4H1G85y7alnD
+RFe/aujnX7iRDFju5EeK6DEc2ghNrIuUK6pmXEhI9Zu8xP7BvzUsTBR/nJn51Ua
bVOg3ORoFqnqEEk1T7WtEKxLjJklVswouKHlXiNUSLN2nUx0o+rbyx59xfvzA7hm
DqAFqSVKzfGNVgssXQhiLYDWg1E5oeMFGbLGgVG7MHIbRuHCqNwYpR0+wDdoAzAk
q8FXgIH64E0AXqhc8J6Q++G7iAejtDytsV4wefZZAvv0bqgHAxIonTNZYwH1TyqA
WWtPVpqydDYArT9m+3rEHHZEn1z8fPlAff+B4vWfCC9kHmAfr+cgeMZIU+VYC6Ov
XRoUNt5qp7/SyngeL3mVzHqBQbnFZD/PEL9CpNwidcZbOvtbJX0a24TYOGsP9I0i
1lmJPko3RjuRGIESqaNtkhhRMXHdTJxebTfES82rWo3ZYdb6ELPJttg6+WKTPtoT
eJ2u+4VI8BN5720u8z0p945Avao2i+ZVrTc1e+dHpCH5nIe8qKevqzo/yaH+5iwh
0u4/Tt/Oo8Qq6Ft5zM0m/aJ5ySSXLCh4/WJkULvKCYtMN1v9A9KheblxulcSIuuX
aa6bAs3L3eTX6PxXmOIIiRNmyWzV5IYj5xuOnC47dAwLoG25/Ne/8L58CIKX7N4D
4ef3VX/+Uozy6/xzoxGkUTwpxFJpxioRjNKIUZixcDrcilGA1yas2gy+CJ91doza
gtECjNEXCgNGrscoEKwOfNGFQWwYnQtj9OEQK0iADxhc6da+3Yh9j8aajdgyEXuK
BjysuwyOLMSSJEPSNSCNsiSg3Rl7+1ZoP38g+6973NvvyylJpfjySuJgQb74/AFG
I5nXiZioxBCTc13OvyUUb0slMZH0mpq/pRTcUPdscdVvcbp/SNCvkwJ9iGVe5fWN
aO0TXaY437BFUG+TqZst1FgrPpLL2D5Ki7dQo+Ok2Wt1ioBDoXVZBmjTU43LNwm+
6z3Kt+jE94iUV+nM17tFP+xmv0PtusrvcA1Rqq7LyuenkTnhi92UMLfjJq/ps9PU
3+aSI23uEz3Xaqixy4Rog/AavW/evCzV86aUBp/QPChd6TEZJ4d7Nryibat3zuLq
00vN6nbPUpfgFqX7ba7oTQn1U2HbT3urtEVFe7BZoLZNVPOtbaV/fdj7JRwWA+FW
8F/3lCDo/un+NzlkbFJSEl+MVVvSFbpspRrKCCv1WKUBlCtpKmuyypQMahWlOQ2g
qzHipAhOroKqIkokXW1KV6iz1JDuDHzPSa3hsMKYpHVngpQYLhCYsCZvEiRKhEQW
KWpLitaRojLvNjl2GyF3LJTLFRr8Uct3nWi8L/jrI+Vbb/YeKjycXHEM/J4HDx0w
23lcr4tq5tX0cXvmtLwFN2/Kq5py2Gf6JEsu7pqlO64izzhqAi72lFHpdkq8NnZg
lt+/0ILcpCFRpuBaAylCIIda6Fs0/BqZGK0nrejwMwZBH1OwLGFFHcy1qw3Gd6tV
r+VZ36DJ3lF0vSNteU/Y8gG39qaaGeiTMzYI8tHOIQU9QjRrCGNj3fofVQo+Lha8
lds7Xe8rZESv0DcukqKXhWHG4IzcNaQSLYkdoyK3mzGtxsfYqnmZTDUno0TV2iWz
dIV1SVd3pru2Un/uPL4ku9RTUrVKyv1jz/lfMU67ai7i8/KFZ/PJpJr/7xHn/kMp
utUo/D9fKsCL//pGqwV/Mvgi6C1lWqxMlaw07AeGqNDhtOangP3ByXJIOpQi1eDQ
Fc1kqP1uxsoQAH8qlN6wHNEZj2mtOFRYGaO1pmgsWLXxoNaIBXZs8GcgdsinqLLC
dqNCn6qz7DbYstRGKPYu1Puilr/+BR43fXHvX6RRn3+J/OZPots/7dl1NguTmrp/
/6luUpdf5xSZ3D1BNdONcEYDiplxzcSce2HYOjqkn3Dpwk5xxN3qmiulrlTQZ8rZ
K+309S5xiKKfa+NttYtuCljbBEKISIq1U6LGxpVKUrSDusEnx7Ss7V78mr9tcpo4
HL7S99ZJ7e29mnc6xC/x2eDxQzH3FQn7B2xmwK4gbAqEwZZBpMrADVbQY6zmWVfb
xHTtQF/9AJ0YKqLEimmbdcRYhTDMGx9SuYJ23prCMs9z27huV+eIKTCjV4jnBb1x
vmJdor6OUGYVNXpmhbrwUMM+bE7VniO0yorJtoZPKAWvN+VJ8kornjnfha/874e9
n9+V/BFkyCCNeqD68842zTec/CTv5ong564GftiEUVv3AXtSQjrRfVrI4wUwy5Ij
SeCLWkuGXJOi0OBkcAx9l1T7FCQCt6aZrEmQjBAy3IFSJ1sFIXwa0g1aM4wBcB1w
cYzWmaSzY+HKvQHYdAq6owCs1rdzPCBNFD9fPFA+CdpH95HP71Pee4+VnJqRlJSZ
ey6ntKjo9IkTtLZuHsfkpasH2pW2PJrgEFl0idVbp7AIBnmWAbJzkTQ5Wme/DtKZ
1t6Vuo71OtI6gRAhdMcInGt11GgneYNMioo61lspmxRilEmPNzK3NR1zru4xqXo0
1ql7hSp8t5P+cVvzJ83ln3bW/LSl6rPyK/9RffmD+rqVQqW10WEnuHw0dw9xqZ0S
LqVuHqVtYZhX99OjdfT4Rd7Nht4bxd1Xu2ibBMEGizOpo8wyydFaUqSaFGuixhmC
kFS87GbOOG1zvMkAx7GulF9XUMbE1VpRqYBZwFBRgjnHakBOrik4037sGczO6jT3
Loi192UoQYnq3j3JXThc9k3HA3t4smTEgoWy9TosOuCfrIajwgCt/YgFLuVBxSwD
pI1D2ZKByaYp9HBKGaUS2m+0ZwH3C+8Gc5bWnayyZmhgQzEDcWfo3FiZDqN14HQw
NYNkqSrIS5ylNqdqTVix0Rsxf4U65ITVfvHk1en//FLyn/eQ2x/0JKXB5TtcWjou
fdfBA6euHCxpzMivPJh75akzeU+dLXmmqPloaXMelY13iZgjeHOAu2Bi+tdOy6Ny
5QAL7wVOkoiPkNnXOsibJFKYSIhwCZGezg0iMcrpWmV0rnV0hnXVAyyVKX+5Z1Mt
ep0t/TFd+iaN8Q6RcJuO/wGT9Dat53U27S065QcdrD6ejaEedBKcvPZJVctaM36j
lhKto0ZKKPFc9vUCzo0KWryZttFK3awjRTqJ0SryxmHOjQL6Vp3wuSZOvF58q1F+
gy3cEssW2gZnKboxinRTaIrLtFtKyQCfoWcLdOfyzmFwuJIjJ/jnjkFo20u+esQF
rhiUPfceSP54V/znx4xM6FG88B+34nEAWhwCN66SoeS0Douy2CYrdZmIdZ8O5EGW
TDnkWkWZe41pWlO61rpLbd6tMR8wQOGBA0b7Xj0UVwfopkEJLkO6SpuuA9YcSNN7
UjXGJMSepHVi1I4UtRXUPxlQYEaLUxuwIoN3YwdadAnz26D9233Bw3vin9xhJKdm
Ppt6/GjaiWeTj1xKPluYnF96uCjn5JlsDK7iyDHJlROumsqrDcy3GyTzp2QKiU4a
8zKjlu5byliwzbpeX21apbWHa/hbObQ4kRTNp23kUjbx1E1p0yrStKZuX/XWLlA7
lmp9xguv4FdszT+r6vi0uPXnFeT3Wvg/r+d9WMG/3UT/qLb79WbeB818va4vxz+c
a9f4qK6JMo+Cuu4gbugIYUHbGqdznUqK1VPjpcztUtrWMdpmLTNSyNnOd7x4vn+r
Jrh9dGzizNhIvXs+Z2Stqn+9bmiGMT3Jn+wTjTtVUx7FwECtcTFPPXrY7Xm2shKz
d19r1fkrOUdbu0r/9hfBlw8kwF5hxL0v+eKuFJ2y+FZoU+QaLMpRj0Xl0HfBxUsT
SG7T1ZZUpXGvwfGM0ZGps6ZqzMlKY7bG/JTR+bTJCZ4PGJypIPQqjelaSESfiRgy
Ld4s62CKMZBtcIIrpKmtmSoLMNYsjRnKzIDbSGPEik0g1u5YLUqX+C3Q3r0vefCQ
98HHtKS0rEvpOVVPV7Ycb2i/iG891MCqZPZzpfwLlQ2Yw4YzlRN5rVPFpbdPN19v
YRuDZsm6n7XpEV2lLFqpyjCT7ljtoETJ7C0yOQqibDFz6wI1nkePVVCi3I6QvGXN
1LSqbptiuQSMm52W9baQgPizctJPirs+qe34eX3NfxS2/q6x4WcVHR+Vk2/mSzqk
Y8dMfoHLtNkk38pFnG1rzqYVY9uKpG2d3RXGk2Kl1PglRjyHGiumxusEz12W3jrr
2rrSH7kyPVM9MF4/7JNPOTyefnNfkDUw0Do6wR4Y9Rgmp6R+i8MhlC9qdCGqaqKg
sAOzOyv7yCFK7slOUuXf/ir68qH4j3cVdxNnZXcVn/9Lq00H0EL6bUjMftgEyfig
bqLGCqrSXTr7QZP7sBGULjacXJckBWZn2gcP1e1PmV0A2l0G7y69a7fBt0vnyDY6
dlv7d5lHcOYhaLuIK11tRqnNdRno3m2SypoO/kVJohuFLmF+XXc/KY26q/jige69
93nJGVkgrT9x4mzWwWcxKYkNWtypw2fpJXUWjtBDJvi7yDayWmdx98y4JOtB0Yqd
FZfPLHEnpV3cMYRq3iqTx2VNa7qmxVJStIy2SSFHaV3hfGqcRNyg4iMUQmTsyuRi
h1McFEjX6SNM92TT6BClf7Cnz9NtnaQZh7qRSZpqucym4Tubh/zUSa7YYvfWLmra
Vy3NMyRCBFyESABRPNZJjNDwoV5SmEuLnaFGy3nxU/ab5b5Y41xQMOlg+d09A2pe
SL4h9PyAbv5Bp/B1hjCocfI8U1rnuFXl75P4J5jOpVLl6FnO9gnx4nEq9anSprbL
jx7yvrgvAtDeewCpK/98T5k45/5naLGZj6GFkrkqkPdC/fqjZigWDuWcYJ/BmqWz
HQBAIuYMxIqyPBvgGQ5i24tYnoKG684yAlCdu/We3TongC3DFMg0DSeZBzMsg+kG
XybiyNBaQC0LEmaQauEQF/DMqNXuQJsofp7YZUTHph48UvzkNh2Xih7Fp2alpqbh
9u5OtP7Sj58qO5vfVlmvlZCX+5R23xBlZli8bHMsuXo3zdSXSBE/xa+pRybtVOut
eiTCb1zVtoJqB8S/tXZquJMU6yBtCAjreHJM2rG0dd63WOHs41gCQt5Cx7i7e0vH
ial6rzmYETtjuY867+6e9hJXfbp+uW6oVzDJZk+LuzZ4xLC4fbWdFKXgI91dYWC1
ws4NVWdY2xVWEdZKaFv1rI2T1qsVo5useVPfEl8S4Ss3GYZN6cCCd8WjWTNTbxgE
UcThCYCCSKv069lWA79HTKkmEnPq2WkVouSKU5in65qLHz4Q3nsohQnUA9Gf4CSo
MkHv8k/QYjCZXCkOsT5WDNGhiiHIHqjpgsBjV8jNq0tF1U4P6Cyg0k3XWHchDmDH
WbB3aMyGypZ2kHmBLDpJBfIjC1amAfilmfrhKhjcCrGgCZQZo7angKCbmKcBcV2g
90YsX/1Dy+KLJ2/F//5L2f2HwnfuMHFJyReSnylKO9R15gK+s6aRRiIxGGUtzeeb
G9pUQq5fbp832gbYE16Wd9HUuuQkup0M76id5SWpglz5bDc3SmWECKRQM3mznrbV
QIkQ8WFZ2zqLFLtC2aymbkwU+a7ma+OXTdvtzEiD6K1jzPcKBa9XGK9WGLZr7ZH2
wWidb4A4H672v3rK31c+FahatNcsyIAnb1w1dK4b29ZVHWsS4hq7cx3fGWqkxitp
W5W0CKVrlcSKXzbeyFuYHJgRum9wyBGVbIMzOC2fmvGOGuVugddM1bhNDsPzNOa8
ttaiJ4+UsxerxWsk7YKu0UF5OvcM8E8NrZf/8pUEhVbx57t8AC10yE+y2gyuBKe1
4HYknHSpKBc9TIZ3dB0NCaXjDASaKSxn0REnGIOBBashL0I6qGVVaParsabrQLjV
AWiTDH7wzZlaWyooq1RGAG2Sxp6mc4GfTdWaYVEkNAKr/ctX3O8C7YP7yvv3JT96
vyctM3M/Jrsm5RjxeDGppLK7rFaKb28htHURas267jETx8FhBVjMNWW3bkxPmA/S
FJMk0oaoflncvMToWuvGR/AdG7XdW8UgdyXHGMQovyMs6gw3kiPkrhCVEOmvHrhx
GoldQK6dEr5axX2ZTvrVeepvDnX//BTldi7tg/PsN0u4z5dYX8l3bZTNDVcvLVbM
i1pWOe1rrM6QsiPMIIbw1EgrO97Qs32ZvpVPi4Nw20SLMIA1c8J1jqtXZieX1gjc
69L6DRESFg5M2iem/VND5hHloLZcz2gldVpl1NH1ZosN319DHMbTh/QtiKlahBTS
JUcuVNQ3lzyEHFtiyJF2bwfaBG3pN8RaqKmHLkaiiiGQeh0AmRB8yJBrIeM6Sjif
AvsSJoBritqyw0iiMWcill16B4A2SWvH6pwgE95n8GdCnoNAitYD6bOVpnTIgqDF
gkAu1QJ73aWx7NOYQWWFlVgDm7avvuJ9cRdyWEO+sodPnkO+rwFl3J0Pu7EpqRhs
RjpuH3Io981jBX8qr71fW/Woq/Ihr/QO9cJ7ZwpHUimqmv4eQphJXuF0h7jdC5LO
sJC40UMKschR8MwgbVC7Nloomw3kGJ6yUUPdLKPFxW1rAlKI1rUhal0TtS7F8uxb
l5yvMxsvXyNE6JYf5ut/WK17pUr/WonhvUu6108GQ2Vzi8XTqxWT/RWTb+exbhUL
mPhVUN7QaTBmE+jh+p54CT1+hbJRQd+q4V+n8q4Re7ZYis16f8RmDeKHBxuXLMpV
uWfe7F10Tkz3jYoWGae7K/ddwiQdTmkTd2qnmHLzpWrZ2Qrqicpq3NHzu8/VYY9X
NneU/eUrUNFKALT3Hgi/eCC5+0D1JKvF7YNsb9Y9KmOSXJciQ1JRmdEMVOBjt1oP
hSMM9t0IBBIkUDioVgIs1bQbsaarTZlakBDZQHkDbDEZoKUBALuS9G6cPoDR+VAZ
N12m0gC13hTw4igDjTkdjd9Ymb0v7ngED/XEiVj7LRnyvS+l9x+p33m/B5OCO5hy
RrSr4k5Owy9ZxR+or2xrSyd7CsZFraO9lMV6QeSMYqjaJ2gL9Xau0Ls3eikRZVeI
i4+IOhdBFMSTQr34dRkx2gVwZV/D0+PVzO0OYtRXNdbXMIknrcva14w10xsXAvNd
1lfE5fK1DoPXtUYYvF7e/2JdX7y5/60i46sX+xZLZ8Llc8HS2c0i3U/PUvTNY9WU
mLQzzCOFutvXBa3rJGqISluvokbbiNEGepTAuUZlbooFN6+4l4PDZuHAIMG/QJzw
Wkbk/kV3/+TgoHZeXKDMO30Jd+pKSrOsmT/VrZyo6JTsBYg+cwTyRGYfwuw62tJR
9vWI+Z/vf/umHhZ3AMRanT1bY0oChSmoaKG6F9SJy0L5DFCtS0u2xgihVRnh9JrS
kKwy7tJagAWnaW3ACWPVFshFAgxa504x+JMMvhRjf5qxH35FrklV6tJUhoSUDXDg
aVpzBuRFMCaOB/4O7WOe8m/uIT8Q/eELyScfkzC45PyMp7ynT185dQCblolN3Z25
96mktAwcNi3rRGF9h7Zf7VezVjjUGAcfphMi3Z3LzOZ1Ucsam7SoZfTrqav6lnUb
cSPI2nT2biEtq1zGBo2xVdFz7Qp+Q1k/0V8x8N55/gfJsi2mkhlu0s3XUBbNoSrP
i4f12wXWF3INb1+Uvn5O8maO/MV81VTl2JuXWDbC0gVqpAcf6ekI9VLmxaKQhhsW
da2q2WEJe0HJDjHAbYQPk7vCvN5wuy3UH1Iob/R2x2TmKZXD71X4ZxyugUmN5FZ9
75sdzm3qwFiHf7XGb20cV3bM9FYOE8t8lAvKPclwEbS5vey7r05jDvRKsIg1A/LH
6JPgVCnUNkpFhdR2QfUe2x4IM6hZLclaK4ATeGNgrJk6Owi3WXBwwoGFx0HAZG1p
Bn+qoS9J78swD+0yDyXpHOmwt2UCyReoesEDvtDAE1zokKU2AO1DOGUB/2d3E43Q
J0D7J8jPyfvgDqTPqzpwXFQAf09MctqVopKGppo2TkcruelsWUFFu54vntKqZvn0
ZVbXRm9biFe3ompYkrevS3um9IJhJ21D3zGnaV4bE20buVe1bYsm4jKRHm+iRK1N
Y/3Vrtk86yeFnE+eFf2okiuJtjc/16FcQt4u7f3kMO3Oid47F3t+cZZw5wLt13nt
t/M5P76keiuXW0CJgzqH3xHSkJZY4hWGJC4RXtV2rYo71nq5S2pVRIlfrSdFQBhm
Cm50aZ5Hpuyiq6yuq0LjSs/KgCDYF9A5+oc1tjdI5N/U8X5Zy/ttvfT9NtGLxdLx
Aoc+342c0NUdLkc5dbBNbaV//eo7QovF7edJQaxNhfKmBsj9BLyoUpeM2hmUJdVb
s7SmhKUCVECgBYUpqFNTVWb4rLGmaGxwIlVjw6itOEMgGbhixJ1hHthlGsBqLNkG
XwbIlrWODMQFXqRoHWkILIIz9XaM3BHYtH8Fz2v/NbSPHsm+uq95+z1SanrG7vSM
Q/ufSU1+GuSAqc8+dbymsFnYQ1IE5KZ1lS4k1awMsIMexoK0acnPGI5aRW/4Wc/r
q18VtNzhdk1I+tXy54Ks2ID4moi1ZaSHNdSYkB5nMrfbmKDG3cC3rtua+z4ooFw9
PyCa0pGf76AtKVY4wy8X9//gSt+LNc4PchWfXWD//ATn/WLlW3nitwoUo1UOKmmt
nBgSUGMIe0PIiuGlWwz9dVH3hpQzLxEvmVVXm83XWrRxCu+6hrcW9NhtN7upcTUz
LB0f49+0qd1j5sWghTk0WsARsWqIsjImp7qNXV4ULKuIVbfpcqqp+6vPpp1OTDR+
D2gh/abKmCLTYCE1kAEkUBmwugV2BtsX2Voz9KUyLWxAqkwQWpD0aizwgb5OQZzA
D0PDVVuToMn6QXkD3HKGIQAy5BSdBz70ngy9J00Hu8pZIMkyQFU0DBpr0bpWnGB7
+9PdJ2bIIFP4w13phz8RpaTDWdFDz+a2FvSeO1R+6kglkaIVsqas+JG1Tt8CwRuk
zi12LU8xR82dK5Ye63j/xeFAwXPjRc87a19hFX2gbVpRGaakW1b8hqwz5KRvKolh
CTPUyL9Ww9gmkGKNhA1H3dinhS3vFsuW1KKoqmtJIx3kjWyWD21VuGP14y9cNt5s
sP34rP7FZsUbRcqXmZRXWkSxYi+vdYnTvm4grJnIUSl5na28JpfFGbINkWDKL4uL
5dsN9oioZ8vPWpo32F1xAX1TzY5Ircuc11zI4IRldlJAUep3g3SKZ+SUCUtLO7BH
9j518GlG4UXdufPkA2fPZpz9f9a5/lWsxSVlA2ihPD1IX0EVa8JqrBlonQpbUQp9
KjBfKDSuS7yVprFCq0X3AMAjU+dI07syDF4QVjGgtjH2Ywx9sITVOoFzhhURCMOI
HYvAC0K7V0HZuFQ0Q8ZIbX2o1X6XNOoBpIaV/uTHPZCmBAfn6J85mddB5jlMti05
5w1V3ceqkpetDevTpXZjO/4U/UTSxbojVGIxndt2SdRwvj336M2piuum8iir5KWu
XDnZxWXHhkQ3LNSIhrBmaA9xiFFQko5eGTO0jAtb5u9cEvz2QPunB0kT7g7xlHKJ
bXitxXSjTvlCg+YHjdL/yCd9eIy91tMzLm56gY7/WSX947MqOinc07kiq52WtofM
TWuO7qhHtCHu3ZoWBeMsTVhsiyO+YcbcaG8kyvPbh8y2TTZtU0XZ4jhDlC2vMLog
cRv5ly83N9V1dNF7GqrwhQfyzmRAcpqMpKyCp4/sToUO+R9j7b9Mo7C70OInGT2m
TVIakwByWmsyKFXR+ge6Ygi5GZ76qS04ADkUvDNAqEDs1NqwINbqnBitHaf3JpsG
k4EfRpwYxJWi86VoE2eFIEibYcQF1i/Xpiqgaifa2bAHdqCV/Eto/3BXdO+B9J0P
erHp6TsUSxgMgV276i99w3bhI9eZ17xlSyN1Jn9tWW1+NvZZDDZ7V9rx5JSDgp7L
AVYupfbkxmjlgrlmg1oiaCxu6GTrRevz3A0nKWzviTjI0UZGXNa66i4dNbTOWOpn
bher3ys0RMjdtFDDlev8PknfS+Wet0tML3T436xR/jy/+xcXSXdaml+ntPzsfNvP
T9Jvtg10UyNdnaCC2ujuAFnbipARVYgiSvrqHGM0xDLckEtf1givqnWz2uCGwD2r
8gZmDcpNTmdUS7pGHV5gXvOLolNMo6SXWNZUcrnsSkX9heOFJ1OO71Df45KxaFf1
+0CblJIN0iiQssJaVgcq1ySNLVkFClZ7EgQVtTOQFQMk1GhfQolqHEL2L2uCDQoL
J8htyXpvmrk/2TSSbB5OMvWlgCRZH4DFLngX3R7IRGzgjkmDSbgOZOPJaIacgBYK
bj2UJwYwn+iQQQF3T3j7jgxSXaObkCePHHk+UP9rUemPghUBeUkxsfDE5SPHjx18
LAoB/5SU5o4Zy64jhe/7y1/S4n/Mq3mBVanoLDcxaTLRtIseDUqujXDD8u5YMzlG
I4Xs9TP8zuWZysBrF+XvlqhWtZLm1/B1N6mzKuWnR4RvX5G8e0X6s/P8T4rw/3GW
9fOztJ/mij4t6fn4IkPRuTJT4xY0LdWSI130TTE/bBdEg+TlZa431uPeYDq2mnxL
zf2rrMDNXuktreKWQvEiX7+u0Y1OapUhddu2jBJVmdd044Pyq0u07TlK9fmcf1z5
eky9jf0+GTIWmxCDwck1WICuGkKYAp/NaIMJOE/ogSH/osKQoTJlq8y7UMWeLB2o
aK3gPoDqU1p3msELAmqWuS/D6E/ROZP0LlgIaV3gXazaioHEUtZkNLVOh0RwUGgQ
Kzb7Y7DReBdV5NqJuE94/BGe/Mg+uMNLSt85ErhQkPMTZ8WnmpwxQ9vpk88k+JXS
ktKxSUlpezKfOXOwqblwRF/xA0vhR5r2d0SMV9icd/n4N2kd4ermBSrTxp409Wzq
mJs9jDiNFeMTwk3UOL99lkoMRYvNb1+S/DpDcE3Irnm1I+95yohJ9lka/+MT/A8v
Cn5+QXi7gPthjurdQsUnxb2/vEB9oURt7Fweb+5HmpabeXEOf0svWnXjw8NtS6Od
S4tNo6t1o4s1s8v00U2Z+zWF8lWL4nm7+pZW9ypPeUOhHfHrDWElKy7tWjI3To70
TgVGpg0uLoGQV1T89PGio2fb84uPPXP0H/mQ7z5U/tOIufQfFEP+bz7kZKjVqocr
dUoTCKggdqIwm5NQaIE1w7pFa8/WWrN0jt0Gxx6jK00PEmNrUiKNUkOMkxA3yKrg
Gjwscx1wAxNxANsFd0Ca1g7Z3lBWXVDX4lQ6rNjkj1rQulaaoLpOaKZ94+PLu5yv
vhK9f5uHS0tPWG1RzrGPRMclxjpsVjY6gQ1v6raSC7PjnS9GG38zUf4LY+MLvaqR
zuBctzeuME2p3Qr2hpm6vETsi8v0q7wpIT/CZ21Tu7flPdtO1paMsUVvCzURo5ba
6bfyZD/bL35OJGt8mXDppU7DkuH9ot5PijgfFvA+OiP9NI/xu8vtPz3O/ekl5e0C
2XC1T1G3KO8Kt3FvyOQ3Pd3hYNmCr2bO1bQSbFhcJ01GhSM3hP5J4ZAhENBu2vEh
E9Wt0/ZJvAuWmRn9VYP1VrcrpHMu9fVbZo32DRl1xXR2drogNmqNqadvCv3j0ku5
FxPW+/2ghVarNqK9QAQr08HVK2CyWriog8ZXAIY5OQEtCMOgljVCAms4V4zYULxt
GdDx2gCWSVonLISg6zYDyJM0DtT64QPm1SD0KtHrqE07Vvv1ee2/gvbze5IvHsh+
dJuLxlq4VnVwT7a08OjZCyfQXzkJk5pa3nxJ72kOTdS966x8R8JbIun7SL45gTui
1/lVIwrJjJW5MsxZmhUuTEvHItQFpS7G0EW7xNfV3XETZ9PJiQhYW3hClNm1/F6e
5PdnSG8ySLZxkmO2lRNi/7iJ9eti2i8K6R8V8H9xkfnbS62fFTPfq+j+qID0XDGi
alygUKIM0TUXd9NTN+1tWLXUrUg6Vt2Nq4Ndqz7mxKBoyqWYoU35uxddbROeWptd
xNW4EBl3wza9pIurHK8SrXGea0S/YAsG7REhsiFtXPWXPBe4fE0vWbaerSvbGTH/
flYLMmSQ/YLiB5osTJESgxboTIwBfgWdqgEAg2AJMqNknQNSa6os6XCo2IoyWaPF
LsBSbduJr3BOyoUDf03cHzJ0BgNNsNN18HAeHsXDWGv9hymLb3PId+8ioLR9/4Nu
XEIxBC7N4R6zkmPPnT6kJxZvU1veIDLe6BReZVt93f5ZmXFGj9iFozbiykT98lLX
1CR73qyd9hv1SrGJK96QSa+qJdEB8QYfiRE58YBsc0IQuX4JUbTPvlCh+rS4aw0h
esdJfWYq/lrHNRH5l5Wdvy5v/2U18ad5/M/yWB/UU36Zz/h1bst7x8j+ppFu7hZP
sGVirw7XTo+0rk63ro62rhhb18T4NYS9ataN6Qf8nv7AgGW4X6nt1/rM/SMyv7S0
t6HUyppa0Gwp1ON1orna3jDVO8Fd9Q56h9dax2YpylVnRb/5WHnBv2O1+6A6F1So
T6D4f0OLdhbhKJMF7nTo7Djtjq+G0KJkm5mo4noyBB5kXmhsBt8AroM4MCo4MZOs
QWlKZDD9ztDYdhncaYgDnbIwJ47iE7E2kUw9Cdrf31U/fCS+80F3UnoGyv+d+ncF
Fwzm8qljEXzTzQ7+G+2W5zmaLZ10TmB300bUxDlz8+pU5/Jy79qgcslimVcE5i1G
t58spKlizaarYuS6U3oV2G6PeNMs3Z7qjX5YRA+VG14qEv7+GcKUm3b0Jt7sYza+
2jHd1/4Gk/Iqn/1jCv29asHtmt63azo+y+v8RRFxutbZwwmT1DeE3VtaUWS4dnmo
dW2CuAEAVnSHkY7wJHvRZx1hDMYagwv0vn7e6KjL45/WTTgnB9s93CI5UztneNUp
nySJ+vLpa/jeJea4S7FlW7COTDPMQWmemJyctfvfg1aGBbChSRMWbVmAQgUucWjM
qHS5IQFtKtplRM0a5EFmgGISXIU2w9EZDewgZj72z+AmgJaKwCYGVoYko51nLCpb
AQO51p6mscHZKLHJFzE/fARjbcJqvwVakBACaIHVJqVlfK26gE3OrD/TYc+hRUu7
3xWrrslEg1KTSjSjkC0HJJsjzJV+7aIiGKMNL7QORRpHVmizKyXzazkrS4tmySul
Wr3smky73qOLa+XbDlVYJL612jb9aXHj57lVf8xv+/XpjoBdTb+JN44Tmq/hp6fr
PiVe+bEo74PevHdEJR/VECJd3m7OWmd3tJl93cjZ7CeF1dRVRLQ2QgjPUKMTjctq
26zUFEG6Y2bNOtsd5tnWNRaj0eu2GOdUuiG+aUomH3Q6RiwGE6Mfcc7btkyya3rl
cpt6uQkJMWedym37pNITIBRdOpeUkvVvQcuD0KaqUJNVGNETWXOWypilMWWhZE/J
KkM6bD/B2hQHntHXoOxBuxA7jhqKIyK2JCVKh62zwZYkAnJjW6JpDH9WhVbDKhMw
7l16d8JqAbQgjfouDvn/3JODWPvGB2xcWsYOBT2MsGl15wnjzMDzvLGwyu1z9kt9
K73OKHcgwvOEFd41Vt9K8+B6x/Bsx0y4bnGxfnameWY8d2mJMT38Tj4xQpgfYm+7
BVF79+qoPuwUbs10rNwpJ/2yuPy35ZU/u9i2ImQxlqWc2S5yvHt2ouPXpOoPaaWf
EUp/Q8395HLLePNsHe8Gi7ppIEXdlEiwZc3bvW7lxoYpq7O0yIRwpW1uRKxa9YvX
VdpV/MR669Cq22ZzD/IVbpdF7vOKB5TcKbF2yeQZNQ05pROamTH1pp6zJZPN1VtC
JFOYuTjp8ujtpKyEegGqf/O9oMXu48mxWlsSmhujKQ8sOqGUtcqYgR7GZUCYzVlq
cxo8WkcbGrDStabCcz2Aqw0US5lQmNaWDFIwjSVLb09BrLAE0sKoDDwBDuWuhz+l
NqVorCnoNubXs1Ffbw98i9V+8UD83w+EtxMOGU5Pp2IfCzV0nKeqKTMNhpVed8yi
8UsRH1PsVxvnLeZ5uWWKOLFYt7DaMzxtss0GVbMLzPVF8gh3ZHRW7FisGZmlri4w
IiPdUfCR8nu3TYKrPysjvtnR8lpD4x+Ot6yru7pHKd3bTNI14cg2ITp9YW2l+IVw
00tDdRsamrNrwcSIX68bnmpeULHiw60rANE59vqK5OqoblM26+tcHNGLNzy0OZV8
USiNSu3LCvec3zA+LlabVWYLMjeuXViRDU3pJqWBWWXfgmHAqZo2z3mt1wzauEoT
YrOWG9jM01d2WhZJyd/PasEP7OFJcVo445IG0dXj0EFwkDeBggcHmWMghzWw1LRE
6aKFXapkrSVD74CeFnpsPfCu0CFrrYkD3UyDEw3MjgydMxlCi57qq/Qpci1kRkcs
u3U2UARjpE5vzP4VtFrYOoY6P0/er02wmL935xvEYEj7av17OvvYFpdn2mLrU2q9
rUKPFllR2JbLBkPE6Zk+5+S4eHSOMxGhzM90rM11jrkmPFtG6VTv3GRPeIwTX2DN
GTlhMveGibX+q7KWj2tr3ugi/PrClRtCknyOQb3OJC/x6LqmxrpDrS0ndNrzS2M1
i1qliTYXoKy9Vu6cIK3quuPTTauLrOi6KDKEXFf5J5kghZqc5+tWva1r9p45q3pN
jazz7Ctyz7zdNOGT+YKaCa9xck0yPFyKEJvEhZZ+W/8YbdIjWfRuaVzP2Tyj5O7a
46ePpz4FoU35msX87z3kuw/FiZbFFw+gKOEX9xTwU4LQ7givYbN7xRBalSkDplHG
ZHjsAxGFcVeuS0xWpCY6xmgHCrKNoH8FYKdoLcmwh2UAIRlURAkieoArHMYA+bDW
DttV6HFhphr6AKi1p4XOOUXvxsgcvpjj0SNOYrUBQPtt+7VPghZ1U6cPPFV15mzN
xZx2ArlFZaZ6FtrGw7kzc07n+Cx/aFgytSAeWert94jH9N5x/6JhdkS9PSxcFPrG
CQuDHSvD7HUTM04TXd9ud/28gPSHoou/LSr87akzMXIbz0w8a6lLKzqbSMXR57SG
3NYflo8sdM6MdU37ySva3muLVYvrlMisetvuWOWNBAiLHtLgotuyyAuO063rmp4t
IyHswYfM7LhSvCUxLjICY5yBUaVlVo/ME+SqXjFBJG+tHre1B+fIBksBMOtGHr7i
8uOV+HRswkv9G9BiNXAjLwNmUgloDVjVThUEe78AUbT+gYkS1POBAzSJLmMq7Dab
0T6zAQ5aqOB5/g60cIULtinApVCrhTKb4DlFY0xS6NJ0Tozc6d90PNo5r0Xr2m9h
Vn0CtJASBotNS87KPXiy5WIhk8HleUYIUysd47M6/6RXNhKQTnrV/Q6p16rtV3un
vAuG+XnVhHXqll05RxkZaloZrV0Yx4cF7KvdwqshvPGFNvPvCvM/y73w+9KcCPlK
IxN/SF6RcnZHKS8tbU/hxUpmLfuV6tmZtkUXfkndtaFjxBfbVsdkcatlgz42xFry
1k9O6m1bcX6gz+YvHJytc8U4wqva7i19z7aDEbX1rmt1ixaf3+QfVJoXuMGt3uCS
qW9S6dPTjbJaMq2gsvzE0TNZu/ehtUCi+4Z9zPb23aHFJe3mSbAaaK/pO0Utkqh8
oLOFp+gAbCN6TgDXPdKUsAO8Gz2636UyZauN2Tq4dZmqtuyCdwCktM7UO1IRGIDT
dS60kwVFKjKUCV0uKNOVii7aYuSOvrjjH4XX/g1od7RCMLiM5AxyyiFlUfGYyDnT
oPewRs2caYdmIOj2Wa0Gm0MLyskpl35YMzkqXVoTDazSppfFvoGuFWfTqrMzREau
dmluesXzy6z+j3IqPi6p+FVF/n8WlDHqqlIbTmIzsnYaubhk1emuH9fOrFUGNtpm
tjvXR7kxD287KJ+hrHjo60bi/Ei3e31ccWNZunWTPb5JCy6xJjzmUZlnYtQ4bNRG
e+RbUvG2WHxVy7tuYcbUhqhaN2M3D3D98z2TU84RuXXWYh0Z0NSwLqWfRP9NSMWf
9He2t+8HrRRCq9CnweIEasCAKiXpcdYDgy5wy5A/05ACNZ6QfXrrXsSSDnVizNlw
yQAqEsMxR5Az/90h24C9wlirNsNbBI21CauF8xswzTZjpNa++N/3a/9NaB9LJxYc
yeu9gFc394YIA3M1nlH6eFAVHDBJw4aeG0F+zCe6atQsGybHFYtzKs91oXmCN+8x
j5iUc/rmlT7ihpkfx5uuG6UL61THh+dqbhdUvnPpwo/2FdQeOgapXyDlGqpzisG6
8yU32pc26tyvN89s0SJuyZabsz2sXu6dnu2eG+3tX5rWbC1ptno8C15kelo6PMOf
nhL3KyxzV3sHQ+Jxn2HFicTV0oiRd83dHQ+wNkcE0TBzYkoya/Asq30j2tUpoX6I
d7LtWMoBFFpQ5u3g+j2hxWCyuRJYZSqQBLTo2o8BfPSQCxWOShlwidM9NTwC2q01
7NWZ9+qAjUKRYaiipjFC7Vt06AKnQOUpYJvCAuwyA3EkWlo4OdSS2auz7kFAnIbX
gY1GkckfNf/tL5y7aF37+T3xn/6VGMw3OGT4oUNPlZ5yoORoafGz9f4G+wsixXU6
d6peMtAhG6Y5Q+zouGDdawxNCee3uO559dAksuRxug2OAerYPMcUddROLdYt+2Vb
Iv3WdO/ET6rod9pb32rPn2ST2HXljwMe/FeyUvZTz1O8l4k/quZssXw2TcQtujGq
DvlcE1rDJsXx3BhyVebZaHFMt46EkdEhz+DgsHe43zlrNc3E22dfqJq4SRq5xQxu
04dusIavsV3rZGSw2eNjuyLs+Rcapl+nj7OKu/8e15N3uqrwJt7hjfp+0IofQ4ug
GbIeVCwpGhNUcZJpIcDoqFuGGla6GYgJaqEilixDQgcR2Csq3KUyZ8IlXTjJnA77
GzBDBmkUrHxUcMEkLWHl8DgPDkSmqPVwvzZiAtDe29Eykfwb0KIOORmzE5AwT2ee
masQW2oqBfk9qjOKQIV3mjK1JJpaNjvXDf4l+sSYZrDfNOLzu/kOYw1XLJ0crgqE
R2qX1ukL/bwtkv7qvKD/LYLsdQb3V4SWeTXilDkPlzXucNnCE1N4COHKufyrJrUX
WZchN/tlz/lsUcS1zDU/LzJuKpzhjsAcfnKhaSFk7R+QBBcdA+O24YERx/A10sz1
0tnl1rkoaeoWafRlet8tsm+jx+Gv5LCKGg14/khjnyGfU3isfAdL7I5sZsJh4LA7
s1HfPY3C7f6/oNUlQ8Zx2HfEKeDcDDBEtCelT4eLBVBrLwmduMhAq1j4LtqmAE54
l84OCftAqmxwwvMDxA6gxaGFUzKUtoXopiqQJGDo4F2tESsyJKw2AS3A74//BrQ7
QtI7fACVZ4s0ldXQP5++WHAur7elYVaJj+mEL0uDw2SvwBYctrmmbBNCpq6da8/J
y8UPjPNUy/NdoX5JbJId7XMuvyKW/LKdGWvjrRbRPzhXM3ep6sVOYnMJHpOZkYRL
lp/MH8ppeLlBs8peVcieV1vDdlNEbLvZa9+y6mMeRQjvjiqWXbz+ZdnQonVgsmB8
scMbdlujipkhXf/ErH41ThlfbV2Ybl6Zr1teq1+K1SzG8AsmQvfRZw4dwj6D3VHC
3BGOA79gUkKwNWlHxvP7QZvJRdMouGmpw8oRXGKMRoYeBKF2nKxCBy1QvwonioH9
qY37DXZQz8AxY5UxA52JwaFbthkqc7LOgdXa0vSuJJA/o0afojamqPSJi8DUDNw6
aiNGbPBsWB59Jfj8bmI2Sv7FfcG3Q/vj22yoGLIDbUIoJQWbIBdH+1Onj5zJP5uX
kpSRmZ5dUXhaQc5d6mGH+PaxLlNvt0PrnJiz2d38/qYDVcx6Uxu+jWUdtZKXhylR
JWcL4Wz6RudHfN4PyZyXqllD+V2vXS6rP18wWZ4bIMmxz5wC1x8trPqvdt1rlBGD
clOt3VJ61zSWmE4Ro1ufcxsiXOei0RoyTpp0w4PcobBurK91aoI+tORyrbity8hQ
0GscDPNjEcrYcsuIo2msr3n+avnCeuPcgtrs410uPXcukQtjvnZIX8uFfE+C+oIE
tFkwjYI9ozSU/xSHzlqkQs8JfTIcvQB4y2ErGDyAZacAgNUwcMI2JJyLs2RA8ECZ
a0wG8VXnTtXBVjPkVAUmLoMKEsAJp2vNmVp0uBxyXhshtBKTL2b7akcxRPYl2kz5
/tA+VqXd0dTAPhaqS8XhcPRycoQ0oq8T9lD8du16yGoVcJGWPXUNl6mncguoUosT
vzLE25wWbwd1iwL+soizblye8vV73mdyf9QpHsypqioseubcxfzDB3fOIQ6der/L
qtbGRrizM71xP2fLKN2WWjYVti25d8nqmhhwDbE9E0JfgD822b2ywnP4ub6p1rE1
myk+LlnWUOuLKqqHJctuprGxkaBt6j6x95TwFEN8id56pfLkkYNpUAMZi8Ol/BvQ
fgORXxZPhtWaIbSw5kkMQ8G5VEiYCZNbOPYGnhPnrJmw/oGJbjYqcAvy3ixou8DN
WjJ0MHXKQtxpOhucfNM40WNgeK8kJsvTQFSGa7g7l8LILMEtx1//IkrMRt19oPgC
Dhv/S2jT/59uFKz8Er//3yWQ0rCoSMCpgzniyzzqBbKkzTEjGRqy2Ykt8s5zPWfO
nD9bVcFXj49Uz40rIj22kMoZ4ugXaPiI2begnZ/dlEnvFHeq80r2JWVg9hxMempf
IrWpffbcusgvl8/NEvz9jGU7e1ltiJB9Syrntto9M2gbNw2N9yCTItekbLa/cXYM
7/NSJTr62AJ/eH1AtjZikBKKLlVWt1eXtGCy93YUNSanpJ/be7766Ss5JyCbNi4l
/Wu5kH8P2oePxD98pXdnohGFFvaMMhLzbGhOtDMABTsVOzOIsEehMu3VOcC7wLXC
zgNsSSLA06IcJYZ0HaQPytBCbjc4Cwf5MWDMhg94NbST/LiOStcYMfLH0EJEZegy
4feGFmXnT975ONAwlajxYdqBDj6e2X+BfKiTdKDNb3FS8Jr64sbTZZcLCfSaobGW
0SkXe1PSNIwhK3MCMfJykMFaVRJWLYMh5eLMhN1/vawWf/TU46uhTMhJKfWN9VPc
sQHNCxpbyOPx2YNBhXVebV+zOVbt/ZMCzZRaNiBY9DWKO8vtnOrxwS6f9wqD2DI0
3BucsQWmZoxjCwRE3cqlNTAIOaS2842JmgqNrKmYx8Ln/1tWK31stYavrTYBAPSc
ip3h8sRO+269MxUApoKnQyDLTVHpHkOrh3MXAFrEmaJ3JyGOFDg3Y4UxG1XQQwM2
SLtgLgY1ukB0l5r64PGA8M/3hf8DaHeE5x6rnSajEoOJzwV+Fg2HKyVPMX3Vbolr
vqCh5Vxb5dGKuktNpPLl8SvTfaCKlOUpsVcI+YNbTYtDIukMuzOsMq7x/GG5ceOX
ZLro1IVEFE9CBwqzD+/rLr60LJ/h2eP+vuD6qNQ07NWaVhxIzOGKis0TIs68PLjQ
NKQupF24gvSW6ZUtq6s5LFqriscJ9DsHVhzj2yO+lSX+0KTCPaV1UBsYO3dkQvEF
l+Dlzfwfxtqdk5+sRMtCrs9UJGItVBaHThjt/eIgm5AWnv8o9dlwptWAdqb0GWjs
zIBu1pymSQzIwdQ6A3HDfEprS9F7gUNOBjFbi54DquDRb0IrPgO2lPVYsR4doOH/
D6BN6K4//uW/VrFCc2ZU2gNb83T1evEYv5i15/Q5THJK4rM7d6W0adRPmrByJP2E
w02Hk59KFliKFtfYAxMMYqSHvT4pG/hZW2O4paTg2ZOo9gzKcJ2aWbJ/t6+OQHNv
jzq8Y9Mm9XzQEVh29MQl6gm5Z1KhHFbO2ytGTSXy9iMd+acY+PTSS7kyBS+y0qno
aaXiK6mk6vpmWq9dph+QqAJSvWPCR2TRLuxkT2h9hcOl7hQ/3wda2M77pzQKu4eH
tizkif1aBCoMw6EIqI2WKG1TwUOOgOIH1LVJMHbCuXNQ2qZrQMhEbVoFzB3ORCYp
TWk6N8ieYIZs8AGTTUfg4GOC5xpcNhUtcLNUUNwYhRbUtd8J2i/uie4/kP0ztKj7
xe7Izz0W9UUteCdnLj5cTDzZthu3C7PTeoCFadbBQ11yOmvak9/UmYJJAT+cUUu8
srJJGhkUcSJE0ppXMPw7VtVC7YUsKMeFDoriUjKT0muyD3czeHyFZyTg168EjNMr
ZmTeQl/WBgcl8xrE6eSueDtGdccI5WfwlYfaavfX5J3oJpPicapTW1hVn/30IVz2
ruMXS0ur2MVX8Pl5tQV5R2tKjuNwKTv6u9Ahp0J0/zesFrd7B1ptBspRgoOqaLok
KCENCiEQJqGdpav0wNSytCY4BgXSXZAb66wg3MLkGT1CgDcBSjgFzwNApg3MV+9C
y1xUm1yzMzuXrjKAR6bakKnQ4ES6QMz8P4Q2UQWiuusJKXFU8/Rr1HcUgXYUkR6f
4WPLGgqoFmmDQ73/6OHE+xlHzp33jZUOzTYNrzVMjgF/W8EbOXt+pxWFQxUZgUmd
LbyYdzmXw28dC1uM/mljYJDT53NZJqwLrMnpQen8QLdjhD3nz+kqPYUv3XUxL632
4mlae8tG9DKT/birlVCPz8Qk/10xBE3pE6EkDf3//6+kUVgsujoN69p0OBKFoNuS
0C2jlSgCR/4VepAV74KnArCDCH0sXIA3JqkNO5atgvvRKVIVOkThgJfSOfb9/7U9
aXNU15W9r+pWq5EQJoAxQxxjBvUmBI5tsIMdgj0YEAi11Dvq/S29SlhCYjUQVxKX
JYHscpxK2Jdh6cZ24pqZGle2cuIJ9lTsKScFAqm7JRm7ZvwX5pxzX7fERGRmPkR1
6tXrp/fuve+ed5Z7z5Y9QIn/qNA4pUwAgKWwgctgtjf4mIL8wVPp//qy+xaZ88Yx
K5h7ErPnzgOlUnh6OvrLX+3W6LFKIvpGKWgipCpW1epk1Z8PBJg4taF1U9tT7S/Y
OnYaH18pTe/i5U3t/sf7M1ve+uFLo0eCA28/FTusfnKjcqEVGDt0RDY1+eLmpkRo
o/BqrO9Ho4Ba76vJ8Kuv9OeOHzqRPTSwzz26z3toZPdrP7Lvdix9waZ3bbCse9S8
/cUNhw+t2eWe3bAktz0MmZ1bWvp+qL1R9auVvuNN3237+isgBu94KTZRcgN2y1PC
nckQ2rxLiOap6fD773hsjtkti6yEWiJW8lrllKgiiaoE1njX11AbZ2shgSWqIRJH
wtWjq42I3jM87knpU/2NfUfIUisiJFIgjwHQSJDAtEVqUMIjucOnsl/PdN8uxUsV
YbLClyv+O5Sm/i9hcipQroR/87uASqeT1UpYzRav/T8D+lVJpLziySeWOVYTDamX
tGxSmhZp1thaj/U/++ZB/+hA/PUfrPf1yOoXy6Xi8/LlTYv2u5++xnuv9r3845hb
fLPn4CX38e97Yr1vhcPB+o0rng5ufmL/68Efv779zUxT23K1bd3fd7dbv/Oc4pFF
K57dpF/6sLT+Vuur2oBm7hd5H1RX7bK5lYplsmefd375hXdyGiYKMBq/XfbfvhO4
O5W8OxVkXhaVmT0/f7erxfnY/4JaZYJFYyJqjYRa5LoRDjCKBhwMzhSQb8eoMC2X
QgdHYa8c84f1WrL7iUsLDLtI6LC6jYHMFoxkaALUghr11YznzlTobik8UYnfnQzd
RV+ZeWBiOj4+GfjXX7vVeh0FwEglYe4r71rD3wNIQarPrdSw6hsaa7N2QTObR0Ud
mlmUpuZl7d/bmO9wn/y+9439O6IJeVNzTXF1PLy0kO98T+x6o/P5V4IvDb+962dj
Lx57LRAfGrNt2yxrrlvidK1K7t1y/GjoJ684ujerm7+xqHPbQhta1HXLlmubHpL2
hJnxVSqtVh02C/2obcLU3oiO+B0zhrx53b0v4rcmu2+Vg5NT3O1y5PZE5zimtwwC
57uLyWlC791wr3E89mCGDLSYwKKzrBCeHs0DaROfYfvA6AfD4a6FEakQdy3goi7O
Y7IEYa+CLL56vo/YNXwf0lYlNAgymzRkjC8CNWrwzNBX94K3yt7bpdDtSuROmRsv
R+eFWxMBkCIf/NqtRKQqq3JINZf9zmXID6IGpuvKWUFj2t9gkwu8UaHFMjN1y1aq
FxnbUvbAP28XT3dsj2w1NZgl7UytWblIt261ZejA2sLY4/62pVueeeroD4bXb31K
tcqiNi2WKXRNLod1/ROPbn122TNObVPTorZvLWlbJwl7OjK9T6HSVzcUq2OTUFsb
6tyXQtQy3yig2nvTsYmyl+gBpFgcd5LLIXSPqiRBBldmou/d8KwhhvwgWUukRmoU
k7W4YkmQRZ3ywuniAvuJbjGIWtB+k6qoiL4WIEphOZvIgUCt0SseCbU6dKUTNPGM
zJccOLVvZsb/p1JgssKh90yZm8TcYPPARCk2MxP9lw/cOpOBisPTHMnnsq//wc0e
wOjY7pVU71czazJj0X/AqzXoPrh882OR0y8GL2zYwn9bZ9TLpFohePM/7LQVzq3a
5Hpk5ZJl23xdz23a0ti2XG61Shv6Wp1+2YqHvr3WvGqZaeVS1QKNZpVNxorxsaVa
rQ66vFbocl7BoZj7FlWhIHvue857U567JQ8gslRJ3inhmrA8ncTNWpC+leD0TM8v
bnS1OB7MkBW0wEU1qopaLeYc4YmIkV0rmAodQ+JWkeMjlglHN5p+HUZbp+WoEqdw
AxnWPMywD3w7ilsWAFboIhg7eK7v6y87xsu+6TJfnvJVpj2oLc8LpURlyvPhRwGF
mgUlKueol/9fmA3lowZUkusrE+Fy9ey5sm71821yrZYh1Wip8/mX7Nz48OqVj+3w
dtm/s6HqLTW3Qfmc4/1XSGBXKVhe3YR6EMz/ahueWfuf98JTM523JvdMzcT/POEv
lf2A4NK0H2lgyjfzReD9dzptrr+GWkIboRYzasYzhFqBUEvsOiZZ/ZSkJGvJRQY9
p4SXAbUqHhOXKEkMwyOaRJoZfXV4GwlmzAeZ6vtJ38wX3lul4J07ickpD2kH8Xlh
Yspfmfb/4p8CVTTI/mIG/zZ/1Vhe1pe1CWX8iha7/ekn/+Zdz/f3zPOuW5+HStMh
oAdY8IxXEpSvESuFjoM4q4RL09Gfv+trcf2VxY+EWtzyVaKWBFhBuiSnC5HtMKMH
RUQy/GliaQMy8IyK0qcytze22EX3jCSSrILZ8xPI2zHjfU/v9kHug9+E/+1PiY//
mLz5efi3n4gf/TE6L3z474FPPkv+/pPO8wXuVKHrfHH3uasdF290XCi454WLhd3z
wgV48HrnhRv+M1fdF4udFwsdl250nS90nyr6r13rOFOI/uOVHVff3Xa64D1f9F8s
wiM7Lhf8ZwrtF4ovnb0WuHTde77g/unF3W+f33qmELjyTvvpq93Xb3guFHZdKXac
L3ovFLsvFtzX3+s6fdV7qeg+c6370vXQ2eKu84Wus0U3dH216L5U6PzZNfe5oudK
oetcsetcwQ1wloCdw8VLRRhY54UCjBBeZ9elYuflG91nr3Rffj80fjfw4U3xo89C
Nz8N3fyc+93HgT98Grv5H5E/fJb8+LOeT/8cu3zZ9601pEaZsfZAhjZ7Mas1EC6S
JhUTZrv5SK9VIL848rOhdNi1E7LY53QYRt0LUlZHSd5w+4ky0MCHoonyBswGmDEl
U6Y4B7xaHxUfSXAbh7IvHc1sP5LZdiTTfjS17fjerUd7tx3Jth/N73gl234st/NY
L8COY3hx5/Fe7/BQcOxQ4MQB/8hgYGTId2J/YOyg/+RBz8hQ8I3DgbFD/hP7/aOD
nuFBuOId2cfANzoIR8/wABz9J4e8eAOee0fxX74TcGXIM7yPHhn0jQxBI4GTQwz8
0rMEI4MIw/t8I4Nw3X9iMHASj96Rfu9wPzTlP3mAgZfOfScGu1/v94wMeIcHfCMD
1BTeGTyxL3RyMDA6sGfsQHB0CFqjIeFgQif3A3hhJMP9PWP7Im8dCI7hAOD+8NhQ
12v9O4/nYboAdh6HCcnuOJKG8xcO57cdS79wOO3/YX5r757mR7+JutpCFjotxeVR
nvkwz8iXvBuFmlY1S9C0lsUjmWMR2OMUlycDUubyaqEPKFsWwwAhdFXHMM6MIY7K
tgG6A8A09cCugW9nZZGUPJyWhbOyWE4WzWI5C0yWkJfHMrKIKO8R5OEU3hOlOLOI
oAjz6KwTEfBiIi+LZuR7BExwlKSoJLwzLYukMdF2WMQ4QYCwIO/hsSm8nsYGCaSf
sQx2F8/KpI5w5xUfgdagqTC0I0gQSRGI1IuIfAumCwGoIoW1OGAMcISfXB9+6Bhr
k8UBREUZjkdgdyKwpzDOKk1hkhRIF8WE41TlI6MSelWpl7FoUg/HSk4CXWELPawR
dJ3ARqBZvMLLcHs4q+sKyZbSVky9d4+cz+oivDoiaGE5G+X0MTIMMLFa87IgdUkh
aViidBJh2EVXN7Tbc3mMuoRek7m61F6Ko8UIAwVxYwUzD5DlR53MaNFZLqOMY04M
JS6ciFtQ+IKJyzRn+xvTfQ181pxMa1DeY+8aqjMP2pwOEx9l6zHXI8WqcHn4SjQc
JY/EuBVJtKtIrgNoQWTgsg3Ve1itGXDBhpnPDAnRQOs3HXx2Yp8xidtqGBETR2cS
NaiNyUy1qWpsi5QXjU7QlsUW7pIDKLypWdzL3EBNqX4zVTfS8Xnc0kEn+wwNRtTS
EeYc819ymTouDbOhTaZhSHBuTfUqkjkMoxLzcM42dOERq5AzJnDpCI3gzg+NX09v
pEugWNTFOCChel9I+/AKNP6qPHtkHIu9JGbLRKkkaKWdZA2mF0E1CskaA78yaANI
MCrHKyBNlVFWawKnG6O+qHaEOs7DChj6poStvD7GGzA7r7AgIRijSVgW6/isQcxr
kiLbu5YTPzBx2QXpPngTi9iL7hwYtJ9h08omWoMJXjFOEO+nrwf96zDAMIfukjBs
6J1tmMwCvgsu0gDBZMvCWcY1m4D2D/Ll05FLHroMEL61NCSWgIeJIfryGIJZIBOL
o0FrNKEW5ZqOYtfgoobPq0l+KaQjOSHFhNqsKmgZCb0o4wImgYjhkZaUAkZeIap4
I7VP0yKYONrdQ6JKkbE1jduFZKMzYgb6tCaCtXnqfQHTN/4OqfYhb48hmanbk9BG
BFRwgHDDnBqwEhN0EU4X5RHCHALLLSW9UqqqUuHKFUaAvjWY4jFj4PJGPo/Goghn
igtmLkW5WQUzgmhOgKwVFiYES5QzJcR6SsdrSMLXx4P0RXYdTxnjqQYuA7dZkhmL
0FvP542xlCEGjeB/ycKIiTUMoKmhUEDnHgP8BJogzKnCST3tjbAEwHq0fMAnhSRi
ikPvoJ8LdTHRlEiznyZAM265iHDdDD1y2QaMTsvB8ADrNT1Dw9YFaDuhPRwULlX/
aqb8o4MRdIp7OOhXlMyqw5yGPqMau4LhqckSY8Dp5QElcDTgN4dDhbcDMIG6Q978
hggHd+rJP8KIQ0W7GXYRTelYQEYC+wVO0xBH0WACMuMyQLXGxY+gD5G+OwSy1hxP
KzFKAOlGj9pvlfVLJ6J0HkvNBlbPPWe3sfhrzDjUx6hZRZkdpXuQP2draWzkSZTN
sjiGG6m4lJ7H/LtI63H8rmGi1fh182g35HKGVF9dGkEvZIlQBAoNzWI8P5qecpjh
BqQ7iYBZ/YDRCi3AVMm0msvq+Qy0oKUqGQjJNBZUAI5H6zrMk4U5gHMNqb1NuX6L
gEp+1Td7Npxc4lvsE0eeweZNlBOvJl+wXJ24V8HlmBuhovq4QmKKYk1k6JgfYJyF
V2XIQpo1odMLogBngOkxyZyKg08ZXllyQdRIIwcGhm6m2khSAYI5IYKA1wd6dCvI
g07f4lTanWZHq87m1NudRoervsVhsTkb7C483g8LbE5ri6PR5my0uxrpJwN4BP5r
IbDaWxuday10pQlus7usLXCPq8Hmootw4jTBCVy3tTY71jXb1zbZW+G8fk2r1dlW
b281r8H/1rc4zS0ui31tvaOtydUGbeLR1WZxtMLjphZnvc1lsrmMaxxwW72tFe40
21xmm7OuegV+QiMA1KkL2mywwdjWWe1r4cTSAoBX4Ce9KY3QBqNyLXSta25d3+ho
tTjW4nigIxgMNu4y43iooxb8WW9HgB6xU2gB/tWCRwbSIwSsBTiyEytNL/S1AO60
t+Lr2FsbEFxNzrY6eoRQ4KprwdeEt250ti6AicWXwusLHK1WGCFiCh+sg1mFKXWu
b1htV6lM/w2hJyGcLv3BVAAAAABJRU5ErkJggg==">
<p style="top:730.3pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">http://dx.doi.org/10.1016/j.pnpbp.2017.01.001</span></p>
<p style="top:738.8pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0278-5846/&#xa9; 2017 Elsevier Inc. All rights reserved.</span></p>
<img style="position:absolute;transform:matrix(.47999198,0,-0,.47763369,13.532669,36.445985)" src="data:image/png;base64,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">
<p style="top:63.6pt;left:232.6pt;line-height:8.0pt"><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt">Contents lists available at</span><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt;color:#2e3092"> ScienceDirect</span></p>
<p style="top:85.5pt;left:139.4pt;line-height:13.9pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.9pt">Progress in Neuro-Psychopharmacology &amp; Biological</span></p>
<p style="top:103.4pt;left:270.9pt;line-height:13.9pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.9pt">Psychiatry</span></p>
<p style="top:119.3pt;left:192.9pt;line-height:8.0pt"><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt">journal homepage:</span><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt;color:#2e3092"> www.elsevier.com/locate/pnp</span></p>


<p style="top:57.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">established</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7-signaling de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cit, or independently enhance cognition</span></p>
<p style="top:67.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">through complementary mechanisms.</span></p>
<p style="top:78.2pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The majority of evidence supporting the therapeutic use of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7</span></p>
<p style="top:88.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChR-selective drugs for cognitive impairment derives from rodent</span></p>
<p style="top:99.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">preclinical tasks in genetic, environmental, or pharmacological models</span></p>
<p style="top:109.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of cognitive impairment (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Levin, 2012</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">)</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> however, pharmaceutical de-</span></p>
<p style="top:120.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">velopment of compounds targeting neuronal nAChRs has been chal-</span></p>
<p style="top:130.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">lenging. For instance, the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">4</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">2* nAChR-selective agonist TC-1734/</span></p>
<p style="top:141.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">AZD3480 (ispronicline) showed ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cacy in early clinical trials for mild,</span></p>
<p style="top:151.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">age-associated memory loss (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Dunbar et al., 2011</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) but failed to show</span></p>
<p style="top:161.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clear ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cacy in follow-up studies for cognitive impairment in AD</span></p>
<p style="top:172.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Frolich et al., 2011</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) or SCZ (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Velligan et al., 2012</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). The ultimate failure</span></p>
<p style="top:182.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of drugs such as ispronicline in large clinical trials despite encouraging</span></p>
<p style="top:193.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">preclinical and early clinical data suggests that the translational path-</span></p>
<p style="top:203.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">way for drugs targeting neuronal nAChRs may bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t from a reapprais-</span></p>
<p style="top:214.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">al to identify speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">c barriers. With this goal in mind, the past ten years</span></p>
<p style="top:224.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">have witnessed the assessment of multiple drugs active at</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs in</span></p>
<p style="top:235.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">randomized, placebo-controlled clinical trials for cognitive impairment</span></p>
<p style="top:245.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in SCZ and AD, most of which have extensive preclinical assessment.</span></p>
<p style="top:256.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">We thus sought to apply the technique of meta-analysis to this collec-</span></p>
<p style="top:266.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion of rodent and human data to evaluate the strategy of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR</span></p>
<p style="top:277.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">targeting for cognitive symptoms in SCZ and AD. Speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cally, we com-</span></p>
<p style="top:287.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pare evidence of ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cacy for this strategy in humans with that from</span></p>
<p style="top:297.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the preclinical rodent models which supported initial drug develop-</span></p>
<p style="top:308.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ment of these compounds. Taken together, our overall objective is to</span></p>
<p style="top:318.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">quantitatively evaluate preclinical and clinical data seeking to alleviate</span></p>
<p style="top:329.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">a major unanswered clinical burden and facilitate the successful devel-</span></p>
<p style="top:339.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">opment of therapeutics targeting nAChRs.</span></p>
<p style="top:360.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">2. Methods and materials</span></p>
<p style="top:381.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">2.1. Identi</span><span style="font-family:AdvTT94c8263f.I+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">cation of studies</span></p>
<p style="top:402.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">2.1.1. Search strategy</span></p>
<p style="top:413.0pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">PubMed was searched on April 1, 2016 for relevant studies using the</span></p>
<p style="top:423.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">search term: (alpha7 OR alpha-7) AND (nicotinic receptor OR nicotinic</span></p>
<p style="top:433.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">acetylcholine receptor) AND (agonist OR positive allosteric modulator)</span></p>
<p style="top:444.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">AND placebo. References from appropriate papers and</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> clinicaltrials.gov</span></p>
<p style="top:454.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were searched for additional relevant publications or unpublished stud-</span></p>
<p style="top:465.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ies that might contribute to the meta-analysis. The Cochrane Library</span></p>
<p style="top:475.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">was also searched using the same search terms and no new additional</span></p>
<p style="top:486.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">references were identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed. Upon identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cation of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR-targeting</span></p>
<p style="top:496.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">compounds used in clinical trials, PubMed was again searched to iden-</span></p>
<p style="top:507.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tify rodent studies of these compounds using the search term: ((choline</span></p>
<p style="top:517.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">AND galantamine) OR (ABT-126) OR (DMXB-A OR GTS-21) OR</span></p>
<p style="top:528.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(encenicline OR EVP-6124) OR RG3487 OR TC-5619 OR tropisetron OR</span></p>
<p style="top:538.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">varenicline) AND (rat OR mouse) AND (cognition OR cognitive). Refer-</span></p>
<p style="top:548.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ences were reviewed for additional relevant published and unpublished</span></p>
<p style="top:559.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">research.</span></p>
<p style="top:580.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">2.1.2. Selection of studies</span></p>
<p style="top:590.8pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Two reviewers examined the titles, abstracts, and in some cases</span></p>
<p style="top:601.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">texts of studies obtained by the above search strategies to determine in-</span></p>
<p style="top:611.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clusion in the meta-analyses. Discrepancies were resolved by a</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nal re-</span></p>
<p style="top:622.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">viewer. Eligibility for inclusion in the human meta-analysis was based</span></p>
<p style="top:632.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">upon analysis of the full articles for the following criteria: randomized,</span></p>
<p style="top:643.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">double-blind, placebo-controlled trials of single drug or drug combina-</span></p>
<p style="top:653.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion with a potential mechanism of action targeting the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR, com-</span></p>
<p style="top:664.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pared with placebo; and subject diagnosis of SCZ or AD. Studies were</span></p>
<p style="top:674.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">excluded if no cognitive outcomes were measured or reported. We ex-</span></p>
<p style="top:684.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cluded studies solely of galantamine (without an additional</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7-selec-</span></p>
<p style="top:695.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tive agonist) on the basis of its relative non-speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">city as a positive</span></p>
<p style="top:705.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">allosteric modulator (PAM) at</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Samochocki et al., 2003</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Study eligi-</span></p>
<p style="top:716.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">bility for inclusion in the rodent meta-analysis was based upon analysis</span></p>
<p style="top:726.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of the full articles for the following criteria: study tested</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 compound</span></p>
<p style="top:737.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">or combination used in clinical trials; reported outcome of cognitive</span></p>
<p style="top:57.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">behavioral task(s); adequate statistical description of sample size and</span></p>
<p style="top:67.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">outcomes to calculate effect size (ES). Studies were excluded if only ju-</span></p>
<p style="top:78.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">venile animals were examined, rats or mice were not used, or the paper</span></p>
<p style="top:88.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">was solely a review article.</span></p>
<p style="top:109.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">2.2. Meta-analytic procedures</span></p>
<p style="top:130.5pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Data were extracted by the</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rst author and corroborated indepen-</span></p>
<p style="top:141.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dently by a second reviewer. The primary outcome measure for clinical</span></p>
<p style="top:151.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">trials was performance on cognitive tasks. To standardize the cognitive</span></p>
<p style="top:161.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">measures across trials for ES calculation, we created nine cognitive</span></p>
<p style="top:172.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">subdomains relevant to assessment of cognition in SCZ and AD (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Keefe</span></p>
<p style="top:182.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">et al., 1999</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">): overall cognitive index, attention, working memory, exec-</span></p>
<p style="top:193.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">utive function, speed of processing, verbal learning, visual learning, so-</span></p>
<p style="top:203.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cial cognition, and language (Supplemental Table 1). Reviewers also</span></p>
<p style="top:214.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">gathered data on dose, trial design, smoking status, number of partici-</span></p>
<p style="top:224.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pants, duration of active treatment, and other relevant attributes of</span></p>
<p style="top:235.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the studies. When additional information was required for analysis, a</span></p>
<p style="top:245.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">request for the data was made to the corresponding author of the</span></p>
<p style="top:256.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">study by email. For the rodent studies, primary outcome measure was</span></p>
<p style="top:266.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">performance on behavioral tasks relevant to human cognition. For</span></p>
<p style="top:277.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">water maze (WM) tasks, results from the probe trial were preferentially</span></p>
<p style="top:287.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">used to calculate ES. If these data were not available, group differences</span></p>
<p style="top:297.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in learning were used. Data was gathered on behavioral task, dose, du-</span></p>
<p style="top:308.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ration of treatment, method of drug delivery (oral, intraperitoneal, sub-</span></p>
<p style="top:318.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cutaneous, intraventricular), sample size, and other relevant attributes.</span></p>
<p style="top:329.3pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Meta-analysis was conducted using Open Meta-Analyst (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Wallace et</span></p>
<p style="top:339.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">al., 2012</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Effect sizes of drug treatment were calculated as Cohen&apos;s d</span></p>
<p style="top:350.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">using Open Meta-Analyst, freely available web tools for ES calculation</span></p>
<p style="top:360.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Lipsey and Wilson, 2001; Wilson, 2010</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), and Microsoft Excel. Egger&apos;s</span></p>
<p style="top:371.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">test and Duval and Tweedie&apos;s trim and</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ll correction were performed</span></p>
<p style="top:381.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">using Comprehensive Meta-Analysis (Biostat, Englewood, NJ). The con-</span></p>
<p style="top:392.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">vention throughout the study is negative ES favor drug treatment,</span></p>
<p style="top:402.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">whereas positive ES favor placebo/vehicle. Effect sizes from clinical trials</span></p>
<p style="top:413.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were calculated using one of the following: 1) Group mean change from</span></p>
<p style="top:423.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">baseline to trial endpoint, sample size, and SD; 2) trial endpoint group</span></p>
<p style="top:433.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">means, sample size, and SD; 3)</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-value between groups and sample</span></p>
<p style="top:444.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">size, or; 4) ES for outcome and duration of interest reported directly</span></p>
<p style="top:454.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">from the study text. For all ES, 95% con</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dence intervals (CIs) were cal-</span></p>
<p style="top:465.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">culated. In the case of multiple doses of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonist, ES of each compar-</span></p>
<p style="top:475.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ison to placebo were weighted by participant number and averaged to</span></p>
<p style="top:486.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">create a single ES with the exception of subgroup analysis examining ef-</span></p>
<p style="top:496.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">fect sizes of the highest doses used or the doses corresponding to the</span></p>
<p style="top:507.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">largest ES. When studies reported the results of multiple cognitive</span></p>
<p style="top:517.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tasks that fell within the same cognitive subdomain without a</span></p>
<p style="top:528.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">subdomain index, we utilized a task hierarchy ordered by the most</span></p>
<p style="top:538.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">commonly used tasks across trials.</span></p>
<p style="top:549.0pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">For meta-analysis of the rodent studies, ES were calculated using 1)</span></p>
<p style="top:559.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t-statistic and sample size; 2) F-test and sample size; 3)</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-value be-</span></p>
<p style="top:569.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tween groups and sample size. When a range of</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-values (i.e.</span></p>
<p style="top:580.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt">&#x201c;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.05</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt">&#x201d;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) was reported, the least signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-value was used to calcu-</span></p>
<p style="top:590.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">late the ES for statistically signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant results, and a</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-value of 0.50 was</span></p>
<p style="top:601.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">used when the</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-value was simply reported as</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x201c;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">non-signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt">&#x201d;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> with-</span></p>
<p style="top:611.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">out further speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cation (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Moran et al., 2016</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). The effect direction was</span></p>
<p style="top:622.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">concluded by visual inspection of graphical results. As in the analysis</span></p>
<p style="top:632.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of human studies, a weighted average was performed across doses to</span></p>
<p style="top:643.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">obtain a single ES. No additional correction for multiple comparisons be-</span></p>
<p style="top:653.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">yond what was employed in the source data was performed. For meta-</span></p>
<p style="top:664.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">analysis within a single rodent cognitive task (i.e., novel object recogni-</span></p>
<p style="top:674.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion (NOR) task or WM task, a single ES was calculated for each inde-</span></p>
<p style="top:684.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pendent cognitive de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cit model and entered into the meta-analysis.</span></p>
<p style="top:695.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">For both human and rodent studies, a random-effects model for meta-</span></p>
<p style="top:705.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">analysis was used. Publication bias was assessed by visual inspection</span></p>
<p style="top:716.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of funnel plots and Egger&apos;s test. We assessed the association between</span></p>
<p style="top:726.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sample size and ES using meta-regression. For secondary analyses of</span></p>
<p style="top:737.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">human trials we performed subgroup analysis based on the diagnosis</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">46</span></p>
<p style="top:37.7pt;left:160.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:57.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of patient group (SCZ vs. AD).</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.05 were considered statistically</span></p>
<p style="top:67.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant.</span></p>
<p style="top:88.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">3. Results</span></p>
<p style="top:109.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1. Included studies</span></p>
<p style="top:130.5pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Fig. 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> depicts the selection strategy of studies for inclusion in the</span></p>
<p style="top:141.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">human and rodent meta-analyses. Thirty-six potential references were</span></p>
<p style="top:151.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed in PubMed of placebo-controlled clinical trials of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR</span></p>
<p style="top:161.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">agonists or PAMs for cognitive impairment in SCZ and AD. After trial ex-</span></p>
<p style="top:172.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clusion and addition of eligible trials from review of references and</span></p>
<p style="top:182.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">, 18 trials were eligible for inclusion. Of these, 16 trials</span></p>
<p style="top:193.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">provided data sets within the publication, and we were able to ascertain</span></p>
<p style="top:203.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">additional cognitive subdomain data from two trials via email request.</span></p>
<p style="top:214.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Altogether, we included 18 studies involving 2670 participants testing</span></p>
<p style="top:224.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">eight drugs or drug combinations, all of which have agonist activity at</span></p>
<p style="top:235.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">, Supplemental Table 2). No new references</span></p>
<p style="top:245.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed from a Cochrane Library search using the same terms.</span></p>
<p style="top:256.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">We then searched PubMed for rodent studies using cognitive tasks fol-</span></p>
<p style="top:266.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">lowing treatment with these eight drugs or drug combinations. We</span></p>
<p style="top:277.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed 67 potential rodent studies, and after study exclusion and ad-</span></p>
<p style="top:287.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dition of studies identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed from the study references, included 29 stud-</span></p>
<p style="top:297.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ies in our rodent meta-analysis (Supplemental Table 3). We were</span></p>
<p style="top:308.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">unable to identify any published rodent studies of ABT-126.</span></p>
<p style="top:329.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2.</span><span style="font-family:AdvTT94c8263f.I+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">7 agonist ef</span><span style="font-family:AdvTT94c8263f.I+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">cacy in two common rodent tasks of cognition</span></p>
<p style="top:350.2pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The two most commonly used preclinical cognitive models were the</span></p>
<p style="top:360.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">NOR task, a test of rodent non-spatial memory, and the Morris WM or</span></p>
<p style="top:371.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">water labyrinth, tests of rodent spatial memory, used in 10/29 (34%)</span></p>
<p style="top:381.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and 11/29 studies (38%), respectively (Supplemental Table 3). The re-</span></p>
<p style="top:392.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mainder included tests of social interaction, fear conditioning, passive</span></p>
<p style="top:402.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and active avoidance, additional tests of spatial memory, impulsivity,</span></p>
<p style="top:413.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and attention. Models of cognitive impairment were diverse (listed in</span></p>
<p style="top:423.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Supplemental Table 3), and included pharmacological, genetic, neuro-</span></p>
<p style="top:433.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">degenerative, and acquired injury models. Cognitive enhancement in</span></p>
<p style="top:444.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">unmanipulated animals was also commonly tested. To determine the</span></p>
<p style="top:454.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ES of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists in the most common paradigms, NOR and</span></p>
<p style="top:57.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">WM, random-effects meta-analysis was performed. Large ES were</span></p>
<p style="top:67.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">found for both NOR (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.73, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">1.00 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.45,</span></p>
<p style="top:78.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.001,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Fig. 2</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">A) and WM (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">1.18, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">1.69 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.66,</span></p>
<p style="top:88.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.001,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Fig. 2</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">B). There was minimal heterogeneity between studies</span></p>
<p style="top:99.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">for the NOR (I</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">= 18%,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.26), though heterogeneity was signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span></p>
<p style="top:109.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in studies using WM (I</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">= 56%,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.015). Visual inspection of funnel</span></p>
<p style="top:120.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">plots revealed asymmetry for both paradigms (Supplemental Fig. 1),</span></p>
<p style="top:130.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and Egger&apos;s test provided evidence of publication bias for WM studies</span></p>
<p style="top:141.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.0092) but not for NOR studies (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.24). Correction for publica-</span></p>
<p style="top:151.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion bias in the WM using Duval and Tweedie&apos;s trim and</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ll yielded an</span></p>
<p style="top:161.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">effect size similar to that derived from the NOR studies (corrected</span></p>
<p style="top:172.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.84, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">1.39 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.51). Taken together, we found</span></p>
<p style="top:182.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">that rodent preclinical testing of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR drugs focused on tests of</span></p>
<p style="top:193.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">spatial and non-spatial memory across a wide variety of cognitive im-</span></p>
<p style="top:203.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pairment models, with published results demonstrating large ES of</span></p>
<p style="top:214.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">these agents.</span></p>
<p style="top:235.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.3.</span><span style="font-family:AdvTT94c8263f.I+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">7 agonists for cognitive impairment in clinical trials of SCZ and AD</span></p>
<p style="top:256.1pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Cognitive outcomes in the clinical trials were grouped into nine cog-</span></p>
<p style="top:266.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nitive subdomains (Supplemental Table 1). Meta-analysis of studies</span></p>
<p style="top:277.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">reporting an overall cognitive index (13/18, 72%) demonstrated no sig-</span></p>
<p style="top:287.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ni</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists over placebo (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.057, 95%</span></p>
<p style="top:297.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.16 to 0.044,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.27;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Fig. 3</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">A). No signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant heterogeneity</span></p>
<p style="top:308.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">was found (I</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">= 0,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.72). Visual inspection of the funnel plot sug-</span></p>
<p style="top:318.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">gested minimal publication bias (Supplemental Fig. 2A). Varenicline&apos;s</span></p>
<p style="top:329.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">af</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nity at</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR is many orders of magnitude lower than at</span></p>
<p style="top:339.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">4</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">2* nAChRs and at low doses may exert insigni</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant agonism at</span></p>
<p style="top:350.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Coe et al., 2005; Hong et al., 2011</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). We thus performed a subgroup</span></p>
<p style="top:360.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">analysis of studies leaving out varenicline. Random-effect meta-analysis</span></p>
<p style="top:371.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">again revealed a small, non-signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant ES of remaining</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists on</span></p>
<p style="top:381.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">overall cognition (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.097, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.21 to 0.012,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> =</span></p>
<p style="top:392.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.081). Subgroup analysis by patient diagnosis found no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant dif-</span></p>
<p style="top:402.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ference in effect of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists on overall cognitive index in patients</span></p>
<p style="top:413.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with SCZ (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.062, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.19 to 0.061,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.32) and AD</span></p>
<p style="top:423.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.046, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.22 to 1.29,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.61). Meta-regression</span></p>
<p style="top:433.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">demonstrated no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant association between trial size and ES on</span></p>
<p style="top:444.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">overall cognitive index (</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.000, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.001 to 0.001,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> =</span></p>
<p style="top:454.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.75). The results of the individual rodent studies demonstrate cognitive</span></p>
<img style="position:absolute;transform:matrix(.48003204,0,-0,.46144004,240.8324,935.348)" src="data:image/png;base64,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">
<p style="top:738.5pt;left:178.6pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Fig. 1.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> Study selection for clinical trial and rodent preclinical meta-analytic calculations.</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">47</span></p>
<p style="top:37.7pt;left:168.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:433.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">effects of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists are highly dose-dependent. We thus re-</span></p>
<p style="top:443.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">peated the meta-analysis using two additional subgroups: 1) the</span></p>
<p style="top:454.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">highest dose employed in each study, and 2) the highest ES in each</span></p>
<p style="top:464.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">study. Meta-analysis of the highest dose in each study did not meaning-</span></p>
<p style="top:475.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">fully change the overall ES (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.055, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.16 to 0.046,</span></p>
<p style="top:485.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.28). However, when only the most effective doses were included</span></p>
<p style="top:496.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in the meta-analysis, we detected a small but signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant effect of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 ag-</span></p>
<p style="top:506.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">onists on overall cognitive index (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.12, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.22 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span></p>
<p style="top:517.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.02,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.020).</span></p>
<p style="top:527.4pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Random effects meta-analysis on the most commonly reported cog-</span></p>
<p style="top:537.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nitive outcome, attention (14/18 studies, 78%), again found that</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 ag-</span></p>
<p style="top:548.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">onists did not signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly differ from placebo (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.077, 95%</span></p>
<p style="top:558.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.20 to 0.047,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.22;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Fig. 3</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">B). No signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant heterogeneity</span></p>
<p style="top:569.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">was found (I</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">= 0,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.65) or evidence of publication bias by inspec-</span></p>
<p style="top:579.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion of funnel plot (Supplemental Fig. 2B). Subgroup analysis of non-</span></p>
<p style="top:590.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">varenicline studies was of small, non-signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant ES (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.13, 95%</span></p>
<p style="top:600.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.30 to 0.044,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.15). Only one study reported attentional</span></p>
<p style="top:611.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">measures in subjects with AD and thus subgroup analysis by disorder</span></p>
<p style="top:621.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">was not performed. Meta-regression demonstrated no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant asso-</span></p>
<p style="top:632.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ciation between trial size and ES on attentional measures (</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.000,</span></p>
<p style="top:642.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.002 to 0.001,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.55). Similar to overall cognitive index,</span></p>
<p style="top:653.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">subgroup analysis taking only the highest dose of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonist did</span></p>
<p style="top:663.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">not substantially alter the result of the meta-analysis for attention</span></p>
<p style="top:673.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.033, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.17 to 0.11,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.65), while meta-analysis</span></p>
<p style="top:684.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">incorporating only the most effective doses found a small but signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span></p>
<p style="top:694.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">effect of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists on attention (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.13, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.25 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span></p>
<p style="top:705.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.00,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 0.049). Meta-analysis incorporating all doses of the remaining</span></p>
<p style="top:715.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">seven cognitive subdomains failed to demonstrate signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant effects of</span></p>
<p style="top:726.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR drugs (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Table 2</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), with some subdomains including only a</span></p>
<p style="top:736.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">small number of studies.</span></p>
<p style="top:433.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">4. Discussion</span></p>
<p style="top:454.2pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The main</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ndings of our meta-analyses are that</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR ago-</span></p>
<p style="top:464.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nists show large ES in commonly used preclinical behavioral tests</span></p>
<p style="top:475.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of cognition in rodents, yet do not demonstrate commensurate</span></p>
<p style="top:485.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">large effects on cognition in humans with SCZ and AD. In most</span></p>
<p style="top:496.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">subdomains of cognition, including attention,</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR drugs</span></p>
<p style="top:506.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">across a range of tested doses showed extremely modest bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cial</span></p>
<p style="top:517.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">effects that did not approach statistical or clinical signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cance. Such</span></p>
<p style="top:527.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">results were consistent in subgroup analyses by diagnosis and</span></p>
<p style="top:537.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">when varenicline was excluded. Even when the most effective</span></p>
<p style="top:548.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">doses were entered into a subgroup meta-analysis, only small ES</span></p>
<p style="top:558.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of uncertain clinical signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cance were found. The discrepancy be-</span></p>
<p style="top:569.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tween results of preclinical animal models demonstrating large ES</span></p>
<p style="top:579.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and those of clinical trials demonstrating non-signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant or small</span></p>
<p style="top:590.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">magnitude ES further illuminates the challenges of translating</span></p>
<p style="top:600.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChR-based drugs for psychiatric and neurocognitive disorders.</span></p>
<p style="top:622.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.1. Challenges of</span><span style="font-family:AdvTT94c8263f.I+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">7 nAChR agonists as human therapeutics and alterna-</span></p>
<p style="top:632.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">tive pharmacological options</span></p>
<p style="top:653.6pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Our search strategy identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed eight pharmacological compounds or</span></p>
<p style="top:664.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">combinations, all of which were used as exogenous partial or full ago-</span></p>
<p style="top:674.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nists at</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs. Multiple pharmacological properties of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR</span></p>
<p style="top:684.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">agonists complicate their use as therapeutic compounds. Most impor-</span></p>
<p style="top:695.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tantly, the proclivity of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs to rapidly desensitize in the presence</span></p>
<p style="top:705.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of agonists, including nicotine, is well described (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Amar et al., 1993</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">),</span></p>
<p style="top:716.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">which may interfere with repeated dosing, and some studies suggest</span></p>
<p style="top:726.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">that desensitization varies between agonists (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Stevens et al., 1998</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Fur-</span></p>
<p style="top:737.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">thermore,</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists frequently demonstrate inverted U-</span></p>
<p style="top:57.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span></p>
<p style="top:66.2pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Included trials in the meta-analysis of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7 nicotinic agonists for cognitive dysfunction in schizophrenia and Alzheimer&apos;s disease. Abbreviations: OCI, overall cognitive index. P, speed of pro-</span></p>
<p style="top:74.8pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cessing, VeL, verbal learning; ViL, visual learning; WM, working memory; EF, executive function; A, attention; SC, social cognition; L, language; NS, non-smoking; S, all smokers; AD,</span></p>
<p style="top:83.3pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s disease; SCZ, schizophrenia.</span></p>
<p style="top:97.9pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">First</span></p>
<p style="top:106.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">author</span></p>
<p style="top:97.9pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Year</span></p>
<p style="top:97.9pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Agonist</span></p>
<p style="top:97.9pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Dose(s) (total</span></p>
<p style="top:106.5pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg/day)</span></p>
<p style="top:97.9pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Design</span></p>
<p style="top:97.9pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Duration</span></p>
<p style="top:97.9pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">N</span></p>
<p style="top:97.9pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Subject</span></p>
<p style="top:106.5pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diagnosis</span></p>
<p style="top:97.9pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Smoking</span></p>
<p style="top:106.5pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">status</span></p>
<p style="top:97.9pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cognitive outcomes in</span></p>
<p style="top:106.5pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">meta-analysis</span></p>
<p style="top:97.9pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">References</span></p>
<p style="top:119.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Haig</span></p>
<p style="top:119.5pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2016</span></p>
<p style="top:119.5pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ABT-126</span></p>
<p style="top:119.5pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10, 25</span></p>
<p style="top:119.5pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:119.5pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 weeks</span></p>
<p style="top:119.5pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">207</span></p>
<p style="top:119.5pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:119.5pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:119.5pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, P, VeL, ViL, WM, EF, A,</span></p>
<p style="top:128.1pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SC</span></p>
<p style="top:119.5pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Haig et al., 2016</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:136.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Florian</span></p>
<p style="top:136.7pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2016</span></p>
<p style="top:136.7pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ABT-126</span></p>
<p style="top:136.7pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">25, 75</span></p>
<p style="top:136.7pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:136.7pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">24 weeks</span></p>
<p style="top:136.7pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">434</span></p>
<p style="top:136.7pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">AD</span></p>
<p style="top:136.7pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:136.7pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI</span></p>
<p style="top:136.7pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Florian et al.,</span></p>
<p style="top:145.2pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2016</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:153.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Gault</span></p>
<p style="top:153.8pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2015</span></p>
<p style="top:153.8pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ABT-126</span></p>
<p style="top:153.8pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5, 25</span></p>
<p style="top:153.8pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:153.8pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 weeks</span></p>
<p style="top:153.8pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">274</span></p>
<p style="top:153.8pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">AD</span></p>
<p style="top:153.8pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:153.8pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI</span></p>
<p style="top:153.8pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Gault et al., 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:162.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Keefe</span></p>
<p style="top:162.4pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2015</span></p>
<p style="top:162.4pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">EVP-6124</span></p>
<p style="top:162.4pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.27, 0.90</span></p>
<p style="top:162.4pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:162.4pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 weeks</span></p>
<p style="top:162.4pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">319</span></p>
<p style="top:162.4pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:162.4pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:162.4pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, P, A, WM, VeL, ViL, EF,</span></p>
<p style="top:170.9pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SC</span></p>
<p style="top:162.4pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Keefe et al., 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:179.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Preskorn</span></p>
<p style="top:179.5pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2014</span></p>
<p style="top:179.5pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">EVP-6124</span></p>
<p style="top:179.5pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.30, 1.0</span></p>
<p style="top:179.5pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:179.5pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3 weeks</span></p>
<p style="top:179.5pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">21</span></p>
<p style="top:179.5pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:179.5pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:179.5pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, WM, EF, SC, ViL</span></p>
<p style="top:179.5pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Preskorn et al.,</span></p>
<p style="top:188.1pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:196.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Deutsch</span></p>
<p style="top:196.7pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2013</span></p>
<p style="top:196.7pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Galantamine + choline</span></p>
<p style="top:196.7pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Gal: 24</span></p>
<p style="top:205.2pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Chol: 2000</span></p>
<p style="top:196.7pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:196.7pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">16 weeks</span></p>
<p style="top:196.7pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">43</span></p>
<p style="top:196.7pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:196.7pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:196.7pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">P, A, WM, VeL, ViL</span></p>
<p style="top:196.7pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Deutsch et al.,</span></p>
<p style="top:205.2pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2013</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:213.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Freedman</span></p>
<p style="top:213.8pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2008</span></p>
<p style="top:213.8pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">GTS-21</span></p>
<p style="top:213.8pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">150, 300</span></p>
<p style="top:213.8pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Crossover</span></p>
<p style="top:213.8pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4 weeks</span></p>
<p style="top:213.8pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">31</span></p>
<p style="top:213.8pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:213.8pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">NS</span></p>
<p style="top:213.8pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">P, A, WM, VeL, ViL, EF</span></p>
<p style="top:213.8pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Freedman et al.,</span></p>
<p style="top:222.3pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2008</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:230.9pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Olincy</span></p>
<p style="top:230.9pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2006</span></p>
<p style="top:230.9pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">GTS-21</span></p>
<p style="top:230.9pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">112.5, 225</span></p>
<p style="top:230.9pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Crossover</span></p>
<p style="top:230.9pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1 day</span></p>
<p style="top:230.9pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12</span></p>
<p style="top:230.9pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:230.9pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">NS</span></p>
<p style="top:230.9pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, A, WM, VeL, ViL, P, L</span></p>
<p style="top:230.9pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Olincy et al.,</span></p>
<p style="top:239.5pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2006</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:248.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Umbricht</span></p>
<p style="top:248.0pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2014</span></p>
<p style="top:248.0pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RG3487</span></p>
<p style="top:248.0pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5, 15, 50</span></p>
<p style="top:248.0pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:248.0pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">8 weeks</span></p>
<p style="top:248.0pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">215</span></p>
<p style="top:248.0pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:248.0pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:248.0pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, P, A, VeL, ViL, EF, SC</span></p>
<p style="top:248.0pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Umbricht et al.,</span></p>
<p style="top:256.6pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:265.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Lieberman</span></p>
<p style="top:265.2pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2013</span></p>
<p style="top:265.2pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">TC-5619</span></p>
<p style="top:265.2pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">25</span></p>
<p style="top:265.2pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:265.2pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 weeks</span></p>
<p style="top:265.2pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">185</span></p>
<p style="top:265.2pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:265.2pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:265.2pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, EF, P, A, VeL, ViL, WM,</span></p>
<p style="top:273.8pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SC</span></p>
<p style="top:265.2pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Lieberman et al.,</span></p>
<p style="top:273.8pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2013</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:282.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Walling</span></p>
<p style="top:282.3pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2016</span></p>
<p style="top:282.3pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">TC-5619</span></p>
<p style="top:282.3pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5, 50</span></p>
<p style="top:282.3pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:282.3pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">24 weeks</span></p>
<p style="top:282.3pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">477</span></p>
<p style="top:282.3pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:282.3pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:282.3pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI</span></p>
<p style="top:282.3pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Walling et al.,</span></p>
<p style="top:290.9pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2016</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:299.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shiina</span></p>
<p style="top:299.5pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2010</span></p>
<p style="top:299.5pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Tropisetron</span></p>
<p style="top:299.5pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10</span></p>
<p style="top:299.5pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:299.5pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">8 weeks</span></p>
<p style="top:299.5pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">40</span></p>
<p style="top:299.5pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:299.5pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:299.5pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">WM, EF, A</span></p>
<p style="top:299.5pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Shiina et al.,</span></p>
<p style="top:308.0pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2010</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:316.6pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Zhang</span></p>
<p style="top:316.6pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2012</span></p>
<p style="top:316.6pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Tropisetron</span></p>
<p style="top:316.6pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5, 10, 20</span></p>
<p style="top:316.6pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:316.6pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10 days</span></p>
<p style="top:316.6pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">40</span></p>
<p style="top:316.6pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:316.6pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">NS</span></p>
<p style="top:316.6pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, WM, P, L, A, VeL, ViL</span></p>
<p style="top:316.6pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Zhang et al.,</span></p>
<p style="top:325.2pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2012</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:333.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shim</span></p>
<p style="top:333.7pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2012</span></p>
<p style="top:333.7pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Varenicline</span></p>
<p style="top:333.7pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2</span></p>
<p style="top:333.7pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:333.7pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">8 weeks</span></p>
<p style="top:333.7pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">120</span></p>
<p style="top:333.7pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:333.7pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:333.7pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">A, P, WM, EF</span></p>
<p style="top:333.7pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Shim et al., 2012</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:342.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Kim</span></p>
<p style="top:342.3pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2014</span></p>
<p style="top:342.3pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Varenicline</span></p>
<p style="top:342.3pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2</span></p>
<p style="top:342.3pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Crossover</span></p>
<p style="top:342.3pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">6 weeks</span></p>
<p style="top:342.3pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">66</span></p>
<p style="top:342.3pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">AD</span></p>
<p style="top:342.3pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">NS</span></p>
<p style="top:342.3pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, ViL, P, A, WM</span></p>
<p style="top:342.3pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Kim et al., 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:350.9pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Smith</span></p>
<p style="top:350.9pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2016</span></p>
<p style="top:350.9pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Varenicline</span></p>
<p style="top:350.9pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2</span></p>
<p style="top:350.9pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:350.9pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">8 weeks</span></p>
<p style="top:350.9pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">87</span></p>
<p style="top:350.9pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:350.9pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">S</span></p>
<p style="top:350.9pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, P, A, WM, VeL, ViL, EF</span></p>
<p style="top:350.9pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Smith et al.,</span></p>
<p style="top:359.4pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2016</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:368.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Roh</span></p>
<p style="top:368.0pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2014</span></p>
<p style="top:368.0pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Varenicline</span></p>
<p style="top:368.0pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1</span></p>
<p style="top:368.0pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Crossover</span></p>
<p style="top:368.0pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1 day</span></p>
<p style="top:368.0pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">30</span></p>
<p style="top:368.0pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:368.0pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">NS</span></p>
<p style="top:368.0pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">A, P, WM</span></p>
<p style="top:368.0pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Roh et al., 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:376.6pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Hong</span></p>
<p style="top:376.6pt;left:76.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2011</span></p>
<p style="top:376.6pt;left:97.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Varenicline</span></p>
<p style="top:376.6pt;left:172.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1</span></p>
<p style="top:376.6pt;left:230.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Parallel</span></p>
<p style="top:376.6pt;left:265.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">8 weeks</span></p>
<p style="top:376.6pt;left:299.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">69</span></p>
<p style="top:376.6pt;left:316.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SCZ</span></p>
<p style="top:376.6pt;left:361.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mix</span></p>
<p style="top:376.6pt;left:402.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">OCI, A, P</span></p>
<p style="top:376.6pt;left:492.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Hong et al., 2011</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">48</span></p>
<p style="top:37.7pt;left:160.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:516.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">shaped curves in cognitive tasks, exempli</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed in a recent study of work-</span></p>
<p style="top:527.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ing memory in non-human primates (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Yang et al., 2013</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). These proper-</span></p>
<p style="top:537.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ties enhance the dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">culty of dose choices in human trials. Finally, many</span></p>
<p style="top:548.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of the agonists studied have activity at non-</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs, especially 5-</span></p>
<p style="top:558.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HT</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">3</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">, complicating the interpretation of their effects. An alternative strat-</span></p>
<p style="top:569.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">egy to target the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR is through the use of PAMs (reviewed in</span></p>
<p style="top:579.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Uteshev, 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">)), which are compounds that do not activate the recep-</span></p>
<p style="top:590.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tor on their own, but rather increase the peak current amplitude (type I</span></p>
<p style="top:600.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">PAM) or both increase the peak current amplitude and in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uence desen-</span></p>
<p style="top:611.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sitization kinetics (type II PAM) in response to the endogenous agonists</span></p>
<p style="top:621.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">acetylcholine and choline. Thus, unlike</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists, PAMs preserve the</span></p>
<p style="top:631.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">endogenous spatial and temporal properties of cholinergic signaling</span></p>
<p style="top:642.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">through</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs and minimize off-target effects. Similar to</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 ago-</span></p>
<p style="top:652.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nists, PAMs such as PNU-120596 can improve the auditory gating ab-</span></p>
<p style="top:663.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">normality in rodents, yet do not cause desensitization and do not</span></p>
<p style="top:673.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">generally exhibit U-shaped dosing curves (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Uteshev, 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Pharmaceu-</span></p>
<p style="top:684.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tical development of PAMs for cognitive outcomes has not been as ro-</span></p>
<p style="top:694.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">bust as for</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists for cognition, though both galantamine</span></p>
<p style="top:705.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">monotherapy and JNJ-39393406 have been examined in small human</span></p>
<p style="top:715.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">studies with mixed results (reviewed in (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Rowe et al., 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">)). Larger</span></p>
<p style="top:726.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">scale trials of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 PAMs may overcome some of the challenges presented</span></p>
<p style="top:736.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">by</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists for cognitive enhancement.</span></p>
<p style="top:516.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.2. Translational barriers between rodent and human studies</span></p>
<p style="top:537.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.2.1. Dosing paradigms between rodent preclinical studies and clinical trials</span></p>
<p style="top:548.2pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The choice of dose and dosing frequency are critical to the demonstra-</span></p>
<p style="top:558.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion of therapeutic effects in clinical trials. Many of the rodent studies in-</span></p>
<p style="top:569.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cluded in our meta-analysis employed acute or sub-acute dosing of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7</span></p>
<p style="top:579.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChR agonists, in stark contrast to many of the larger clinical trials,</span></p>
<p style="top:590.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">which were conducted over months. As noted above, repeated doses of</span></p>
<p style="top:600.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists can induce receptor desensitization, potentially even</span></p>
<p style="top:611.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">resulting in functional antagonism. Thus, the results of acute dosing in ro-</span></p>
<p style="top:621.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dent behavioral tasks of many</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists may not accurately pre-</span></p>
<p style="top:631.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dict their effects in chronic dosing paradigms. Furthermore, the speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">c</span></p>
<p style="top:642.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">choice of dose in clinical trials is extremely challenging given the wide</span></p>
<p style="top:652.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">range of receptor activation in conjunction with the demonstration of</span></p>
<p style="top:663.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the inverted U-shape curve. These challenges are mitigated in rodent</span></p>
<p style="top:673.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tasks, especially tasks with acute administration, as such studies can rela-</span></p>
<p style="top:684.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tively quickly generate dose-response curves using numerous doses. Ad-</span></p>
<p style="top:694.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ditionally, such acute studies are not hampered by drug intolerances or</span></p>
<p style="top:705.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">side effects that might develop over time. For logistical and</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nancial rea-</span></p>
<p style="top:715.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sons and to maintain statistical power, clinical trials can at most study a</span></p>
<p style="top:726.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">few doses, with doses frequently chosen from earlier tolerability data, cog-</span></p>
<p style="top:736.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nitive</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ndings in healthy subjects, or from in vitro studies using binding</span></p>
<p style="top:55.0pt;left:75.1pt;line-height:12.0pt"><span style="font-family:Arial,serif;font-size:12.0pt;color:#111111">A</span></p>
<p style="top:285.8pt;left:75.1pt;line-height:12.0pt"><span style="font-family:Arial,serif;font-size:12.0pt;color:#111111">B</span></p>
<p style="top:473.6pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Fig. 2.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> Forest plot of effect sizes of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7 nicotinic agonists on the novel object recognition task and water maze tasks in rodent models of cognitive impairment. Meta-analysis demonstrated a</span></p>
<p style="top:482.1pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant effect in the novel object recognition task (A) compared to vehicle (Effect size (ES) =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.73, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.00 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.45,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001), and a signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant effect in the water maze task</span></p>
<p style="top:490.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(B) compared to vehicle (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 1.18, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.69 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.66,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001). Note: negative effect size favors drug treatment.</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">49</span></p>
<p style="top:37.7pt;left:168.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:559.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and activation data with human</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR. For instance, the doses of TC-</span></p>
<p style="top:569.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">5619 were chosen based on phase I tolerability data, improvement in at-</span></p>
<p style="top:580.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tentional measures in healthy controls, and oocyte electrophysiological</span></p>
<p style="top:590.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">studies expressing human</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Lieberman et al., 2013</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). The exqui-</span></p>
<p style="top:601.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">site sensitivity of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists to dose for cognitive outcomes is illustrated</span></p>
<p style="top:559.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">by two subgroup meta-analyses. Meta-analysis incorporating the highest</span></p>
<p style="top:569.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dose of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonist within each trial failed to demonstrate any signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span></p>
<p style="top:580.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">drug effects on overall cognitive index or attention. The sub-group analysis</span></p>
<p style="top:590.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">incorporating only the most effective doses, which can be considered an</span></p>
<p style="top:601.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">estimate of the upper bound of ES, calculated only small effect sizes on</span></p>
<p style="top:55.2pt;left:65.8pt;line-height:12.0pt"><span style="font-family:Arial,serif;font-size:12.0pt">A</span></p>
<p style="top:278.5pt;left:65.8pt;line-height:12.0pt"><span style="font-family:Arial,serif;font-size:12.0pt">B</span></p>
<p style="top:518.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Fig. 3.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> Forest plot of effect sizes of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7 nicotinic agonists on overall cognitive index and attention for subjects with schizophrenia and Alzheimer&apos;s disease. Meta-analysis demonstrated no</span></p>
<p style="top:527.1pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant effect on overall cognition (A) compared to placebo (Effect size (ES) =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.057, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.16 to 0.044,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.27), and no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant effect on attention (B) compared to</span></p>
<p style="top:535.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.077, 95% CI =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.20 to 0.047,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.22). Note: negative effect size favors drug treatment.</span></p>
<p style="top:629.1pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 2</span></p>
<p style="top:637.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Summary of results from random-effects meta-analysis for all cognitive subdomains across all drug doses studied. Note: negative effect size favors drug.</span></p>
<p style="top:652.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cognitive subdomain</span></p>
<p style="top:652.3pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Effect size (95% CI)</span></p>
<p style="top:652.3pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">I</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-value)</span></p>
<p style="top:652.3pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Number of studies included</span></p>
<p style="top:665.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Overall cognitive index</span></p>
<p style="top:665.3pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.057 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.16, 0.044)</span></p>
<p style="top:665.3pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0 (0.72)</span></p>
<p style="top:665.3pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">13</span></p>
<p style="top:673.9pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Attention</span></p>
<p style="top:673.9pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.077 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.20, 0.047)</span></p>
<p style="top:673.9pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0 (0.65)</span></p>
<p style="top:673.9pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">14</span></p>
<p style="top:682.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Working memory</span></p>
<p style="top:682.5pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.011 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.14, 0.12)</span></p>
<p style="top:682.5pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3 (0.42)</span></p>
<p style="top:682.5pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">14</span></p>
<p style="top:691.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Executive function</span></p>
<p style="top:691.0pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.006 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.18, 0.19)</span></p>
<p style="top:691.0pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">32 (0.16)</span></p>
<p style="top:691.0pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">9</span></p>
<p style="top:699.6pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Speed of processing</span></p>
<p style="top:699.6pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.015 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.14, 0.11)</span></p>
<p style="top:699.6pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0 (0.98)</span></p>
<p style="top:699.6pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">13</span></p>
<p style="top:708.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Verbal learning</span></p>
<p style="top:708.2pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.076 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.25, 0.096)</span></p>
<p style="top:708.2pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">16 (0.30)</span></p>
<p style="top:708.2pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">9</span></p>
<p style="top:716.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Visual learning</span></p>
<p style="top:716.7pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.048 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.19, 0.092)</span></p>
<p style="top:716.7pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0 (0.57)</span></p>
<p style="top:716.7pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span></p>
<p style="top:725.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Social cognition</span></p>
<p style="top:725.3pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.031 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.15, 0.21)</span></p>
<p style="top:725.3pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0 (0.95)</span></p>
<p style="top:725.3pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5</span></p>
<p style="top:733.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Language</span></p>
<p style="top:733.8pt;left:193.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.12 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.49, 0.72)</span></p>
<p style="top:733.8pt;left:346.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0 (0.38)</span></p>
<p style="top:733.8pt;left:466.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">50</span></p>
<p style="top:37.7pt;left:160.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:57.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">overall cognitive index or attention (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">0.12 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.13). These ES are of</span></p>
<p style="top:67.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">unclear clinical signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cance and differ substantially from the large ES found</span></p>
<p style="top:78.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in rodent cognitive studies (ES =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:8.0pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">1.18 to</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> 0.73). The results of these</span></p>
<p style="top:88.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">analyses clearly illustrate that dose selection is a dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cult barrier to over-</span></p>
<p style="top:99.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">come in the translation of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR agonists into human treatments.</span></p>
<p style="top:120.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.2.2. Relevance and predictive validity of rodent models and tasks to hu-</span></p>
<p style="top:130.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">man cognitive enhancement</span></p>
<p style="top:141.0pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Many preclinical studies performed the NOR task, a test of nonspatial</span></p>
<p style="top:151.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">learning and memory, and/or the Morris WM or related tests of spatial</span></p>
<p style="top:161.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">learning and memory. Other tasks more speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cally examining atten-</span></p>
<p style="top:172.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion, social interaction, executive function, or processing, represented</span></p>
<p style="top:182.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">a minority. Both the NOR and WM map onto multiple domains of</span></p>
<p style="top:193.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">human cognition in addition to learning and memory, recruiting atten-</span></p>
<p style="top:203.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tional processes as well as executive functioning and working memory.</span></p>
<p style="top:214.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">We thus reasoned that focusing on the NOR and WM were appropriate</span></p>
<p style="top:224.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rodent paradigms to include in a meta-analysis not only because of the</span></p>
<p style="top:235.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">quantity of published studies reporting these tests, but also because</span></p>
<p style="top:245.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">they involve similar cognitive processes as tested in humans. It should</span></p>
<p style="top:256.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">be noted that the NOR and WM have predictive validity for</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> de</span><span style="font-family:AdvTT94c8263f.I+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">cits</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> in</span></p>
<p style="top:266.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cognition in humans (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Cohen and Stackman, 2015; Terry, 2009</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), but it</span></p>
<p style="top:277.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">is poorly understood whether predictive validity in these tasks is bidi-</span></p>
<p style="top:287.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rectional, whereby</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> improved</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> performance predicts improvement in</span></p>
<p style="top:297.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">human cognition, either in healthy controls or in clinical populations.</span></p>
<p style="top:308.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">As opposed to the rather narrowly focused set of behavioral tasks, we</span></p>
<p style="top:318.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed a large range of pharmacological, environmental, and genetic</span></p>
<p style="top:329.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">preclinical models of cognitive de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cits. Most pharmacological models</span></p>
<p style="top:339.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">involved acute or sub-chronic systemic administration of muscarinic</span></p>
<p style="top:350.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">AChR or NMDA receptor antagonists. In especially the case of glutamate</span></p>
<p style="top:360.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">receptor-antagonists such as PCP, MK-801, and ketamine, these com-</span></p>
<p style="top:371.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pounds can mimic some of the positive and cognitive symptoms of psy-</span></p>
<p style="top:381.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">chotic illness and model pathological network effects that arise within</span></p>
<p style="top:392.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">patients with SCZ through changes in excitatory-inhibitory balance</span></p>
<p style="top:402.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Meltzer et al., 2013</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). However, unlike genetic models and environmen-</span></p>
<p style="top:413.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tal models with early-life insults, acute and sub-chronic pharmacologi-</span></p>
<p style="top:423.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cal models do not model de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cits in neural development or migration, a</span></p>
<p style="top:433.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">critical aspect of SCZ pathogenesis. Thus, dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">culty in recapitulating crit-</span></p>
<p style="top:444.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ical aspects of underlying pathophysiology might represent an addition-</span></p>
<p style="top:454.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">al roadblock to translation.</span></p>
<p style="top:475.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.2.3.</span><span style="font-family:AdvTT94c8263f.I+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">7 nAChR genetic, pharmacological, and expression differences be-</span></p>
<p style="top:486.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">tween rodent and human</span></p>
<p style="top:496.7pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Important differences exist in the genetics, pharmacology, biophys-</span></p>
<p style="top:507.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ical properties, and neuronal localization of the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR between ro-</span></p>
<p style="top:517.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dents and humans, some of which might mediate the observed</span></p>
<p style="top:528.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">differences between preclinical studies and clinical trials. In humans</span></p>
<p style="top:538.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">but not rodents,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> CHRNA7</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">, the gene coding for</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR protein, is par-</span></p>
<p style="top:549.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tially duplicated and known as</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> CHRFAM7A</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Bertrand et al., 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). The</span></p>
<p style="top:559.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">partially duplicated gene can coassemble with full-length</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR</span></p>
<p style="top:569.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to potentially regulate its expression and function, which might differ-</span></p>
<p style="top:580.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">entially in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uence agonist effects between human and rodent. Addition-</span></p>
<p style="top:590.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">al complexities of the human genetics of</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> CHRNA7</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> include a highly</span></p>
<p style="top:601.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">unstable localization on chromosome 15 that predisposes to inversions,</span></p>
<p style="top:611.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">deletions, and duplications, as well as polymorphisms in the promoter</span></p>
<p style="top:622.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">region resulting in differential expression levels of the protein</span></p>
<p style="top:632.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Bertrand et al., 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). The complexity of genetics of</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt"> CHRNA7</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> in humans</span></p>
<p style="top:643.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">as compared to the analogous gene in rodents might in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uence the</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nd-</span></p>
<p style="top:653.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ings in clinical trials. Along similar lines, the pharmacology of speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">c</span></p>
<p style="top:664.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">agonists differs between human and rodents sequences coding for</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7</span></p>
<p style="top:674.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChRs. For example, the partial agonist GTS-21 activates the rat</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7</span></p>
<p style="top:684.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChR to a maximal response greater than twice that of the human</span></p>
<p style="top:695.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR, and the K</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">i</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> of GTS-21 at the rat receptor is roughly an order</span></p>
<p style="top:705.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of magnitude less than at the human receptor (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Meyer et al., 1998</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), sug-</span></p>
<p style="top:716.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">gesting that similar serum levels might have strongly disparate effects</span></p>
<p style="top:726.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">between species. Finally, localization differences of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs may dif-</span></p>
<p style="top:737.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">fer between rodents and humans, as suggested by a recent study in non-</span></p>
<p style="top:57.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">human primates demonstrating postsynaptic localization of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs</span></p>
<p style="top:67.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in glutamatergic synapses of layer III dorsolateral prefrontal cortex</span></p>
<p style="top:78.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Yang et al., 2013</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). The authors suggest that higher evolved organisms</span></p>
<p style="top:88.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with enhanced cognitive capacity, such as primates, may place increas-</span></p>
<p style="top:99.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ing importance on</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs localized to the post-synaptic spine as</span></p>
<p style="top:109.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">compared to rodents. Thus, the mechanism of functional interaction</span></p>
<p style="top:120.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with other receptors critical for cognition, such as NMDA receptors,</span></p>
<p style="top:130.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">may differ between rodents and humans.</span></p>
<p style="top:151.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.3. Study limitations</span></p>
<p style="top:172.4pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Our human meta-analysis, despite studying 18 trials, synthesized</span></p>
<p style="top:182.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">heterogeneous trial designs and was of modest overall subject size,</span></p>
<p style="top:193.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">which precluded the possibility of performing many meaningful sub-</span></p>
<p style="top:203.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">group analyses that may be informative as to which groups of patients</span></p>
<p style="top:214.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">may truly bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t from</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists. Studies of cognitive enhancement</span></p>
<p style="top:224.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">require very large sample sizes to</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nd small ES, and thus there exists</span></p>
<p style="top:235.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the possibility of type II error in our clinical trial meta-analysis. Further-</span></p>
<p style="top:245.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">more, only three of 18 studies enrolled subjects with AD, with the two</span></p>
<p style="top:256.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">largest AD trials reporting only composite cognitive outcomes but not</span></p>
<p style="top:266.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cognitive subdomains, limiting our power to assess</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 drugs in this</span></p>
<p style="top:277.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clinical population. We nonetheless felt it was important to perform</span></p>
<p style="top:287.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">meta-analysis combining SCZ and AD populations because post-</span></p>
<p style="top:297.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mortem evidence suggests similar loss of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR expression in corti-</span></p>
<p style="top:308.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cal and other brain regions (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Burghaus et al., 2000; Marutle et al., 2001</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">).</span></p>
<p style="top:318.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">It is unknown however to what extent this misregulation plays a causal</span></p>
<p style="top:329.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">role in the pathophysiology of these two disorders. We were unable to</span></p>
<p style="top:339.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">include a robust dataset of a phase II trial of EVP-6124 for cognition as</span></p>
<p style="top:350.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">an adjunct to cholinesterase inhibitors for subjects with mild-moderate</span></p>
<p style="top:360.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">AD because to our knowledge this study was not published or publicly</span></p>
<p style="top:371.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">available (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Anon, 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). Subsequent phase III studies were unfortunately</span></p>
<p style="top:381.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">put on hold due to gastrointestinal side effects. Thus, it is possible that</span></p>
<p style="top:392.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists and/or PAMs may indeed be more effective for AD than</span></p>
<p style="top:402.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">SCZ, but additional data is needed to support this assertion.</span></p>
<p style="top:423.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">4.4. Future directions and conclusions</span></p>
<p style="top:444.4pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Closing the translational gap that appears to exist between animal</span></p>
<p style="top:454.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">studies and human clinical trials is challenging. One</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rst step that</span></p>
<p style="top:465.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">stems from our</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ndings is the more consistent use of chronic dosing</span></p>
<p style="top:475.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">paradigms in animal studies to parallel chronic administration in clinical</span></p>
<p style="top:486.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">populations. Along similar lines, successful translation of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChR ag-</span></p>
<p style="top:496.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">onists might be facilitated by the incorporation of intermediate stages of</span></p>
<p style="top:507.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">testing that employ human paradigms with increased face validity to</span></p>
<p style="top:517.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">animal paradigms, including virtual WM (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Astur et al., 2002</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) or human</span></p>
<p style="top:528.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">object recognition tasks (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Raber, 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">). These human studies could be</span></p>
<p style="top:538.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">performed after both acute and chronic dosing, and only if improve-</span></p>
<p style="top:549.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ments are found on chronic dosing would the compound progress to</span></p>
<p style="top:559.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">larger scale clinical trials using more traditional cognitive outcomes</span></p>
<p style="top:569.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">for SCZ and AD cohorts.</span></p>
<p style="top:580.3pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">A small subset of the included clinical trials performed subgroup anal-</span></p>
<p style="top:590.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">yses to further pinpoint the clinical characteristics of patients who might</span></p>
<p style="top:601.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t preferentially from these agents. Given the relatively limited num-</span></p>
<p style="top:611.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">bers of patients within these subgroups and post-hoc nature of some of</span></p>
<p style="top:622.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">these analyses, we did not perform meta-analysis using these subgroups,</span></p>
<p style="top:632.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">however, certain themes arise. Smoking status may play an important</span></p>
<p style="top:643.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mediating role in the effects of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 agonists, though the direction of its ef-</span></p>
<p style="top:653.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">fect seems to be compound-speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">c, with some studies</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nding no effect</span></p>
<p style="top:664.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of smoking. In addition to cognitive outcomes, negative symptoms were</span></p>
<p style="top:674.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">often a primary or secondary outcome, with some trials, including GTS-</span></p>
<p style="top:684.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">21 (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Freedman et al., 2008</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), encenicline (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Keefe et al., 2015</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">), and RG3487</span></p>
<p style="top:695.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">Umbricht et al., 2014</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">) showing some ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cacy in secondary outcome or</span></p>
<p style="top:705.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">post-hoc subgroup analyses. Similar to cognitive dysfunction, negative</span></p>
<p style="top:716.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">symptoms of SCZ are disabling without any highly effective pharmacolog-</span></p>
<p style="top:726.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ical treatments, and thus further investigation into the possible use of</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7</span></p>
<p style="top:737.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nAChR-targeting compounds for this constellation of symptoms is</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">51</span></p>
<p style="top:37.7pt;left:168.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:57.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">warranted. Finally, most compounds were well tolerated in humans,</span></p>
<p style="top:67.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">which may allow for further trials in these subgroups or for other indica-</span></p>
<p style="top:78.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tions. The preclinical ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cacy of compounds targeting</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">7 nAChRs is en-</span></p>
<p style="top:88.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">couraging. However, the aggregate lack of effect in clinical trials</span></p>
<p style="top:99.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">reinforces the importance of identifying the major translational road-</span></p>
<p style="top:109.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">blocks, which may occur at multiple steps in the drug development</span></p>
<p style="top:120.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pipeline.</span></p>
<p style="top:147.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Funding</span></p>
<p style="top:167.9pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">This work was supported by Autism Speaks Grant # 9699 (ASL). The</span></p>
<p style="top:178.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">funding agency had no in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uence on data collection, analysis, or</span></p>
<p style="top:188.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">reporting.</span></p>
<p style="top:215.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Acknowledgements</span></p>
<p style="top:236.7pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The authors would like to acknowledge Marina R. Picciotto, PhD for</span></p>
<p style="top:247.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">helpful comments on the manuscript.</span></p>
<p style="top:268.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Appendix A. Supplementary data</span></p>
<p style="top:289.0pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Supplementary data to this article can be found online at</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> http://dx.</span></p>
<p style="top:299.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">doi.org/10.1016/j.pnpbp.2017.01.001</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">.</span></p>
<p style="top:326.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">References</span></p>
<p style="top:343.6pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Anon, 2015.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Rare but Severe Side Effects Sideline Some Phase 3 Encenicline Trials</span></p>
<p style="top:351.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Alzforum (Access date: 10/02/2016) URL: http://www.alzforum.org/news/research-</span></p>
<p style="top:359.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">news/rare-severe-side-effects-sideline-some-phase-3-encenicline-trials.</span></p>
<p style="top:367.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Adler, L.E., Hoffer, L.D., Wiser, A., Freedman, R., 1993.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Normalization of auditory physiolo-</span></p>
<p style="top:375.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">gy by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 150, 1856</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1861.</span></p>
<p style="top:383.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Amar, M., Thomas, P., Johnson, C., Lunt, G.G., Wonnacott, S., 1993.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Agonist pharmacology</span></p>
<p style="top:391.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">of the neuronal alpha7 nicotinic receptor expressed in Xenopus oocytes. FEBS Lett.</span></p>
<p style="top:399.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">327, 284</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">288.</span></p>
<p style="top:407.4pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Astur, R.S., Taylor, L.B., Mamelak, A.N., Philpott, L., Sutherland, R.J., 2002.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Humans with</span></p>
<p style="top:415.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hippocampus damage display severe spatial memory impairments in a virtual Morris</span></p>
<p style="top:423.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">water task. Behav. Brain Res. 132, 77</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">84.</span></p>
<p style="top:431.3pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Bertrand, D., Lee, C.H., Flood, D., Marger, F., Donnelly-Roberts, D., 2015.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Therapeutic po-</span></p>
<p style="top:439.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tential of alpha7 nicotinic acetylcholine receptors. Pharmacol. Rev. 67, 1025</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1073.</span></p>
<p style="top:447.3pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Bitner, R.S., Bunnelle, W.H., Anderson, D.J., Briggs, C.A., Buccafusco, J., Curzon, P., et al.,</span></p>
<p style="top:455.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2007.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Broad-spectrum ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy across cognitive domains by alpha7 nicotinic acetyl-</span></p>
<p style="top:463.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">choline receptor agonism correlates with activation of ERK1/2 and CREB phosphory-</span></p>
<p style="top:471.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">lation pathways. J. Neurosci. 27, 10578</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">10587.</span></p>
<p style="top:479.1pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Bowie, C.R., Harvey, P.D., 2005.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Cognition in schizophrenia: impairments, determinants,</span></p>
<p style="top:487.1pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and functional importance. Psychiatr. Clin. North Am. 28, 613</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">633 (26).</span></p>
<p style="top:495.0pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Burghaus, L., Schutz, U., Krempel, U., de Vos, R.A., Jansen Steur, E.N., Wevers, A., et al.,</span></p>
<p style="top:503.0pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2000.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Quantitative assessment of nicotinic acetylcholine receptor proteins in the ce-</span></p>
<p style="top:511.0pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">rebral cortex of Alzheimer patients. Brain Res. Mol. Brain Res. 76, 385</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">388.</span></p>
<p style="top:519.0pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Chu, L.W., Ma, E.S., Lam, K.K., Chan, M.F., Lee, D.H., 2005.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Increased alpha 7 nicotinic ace-</span></p>
<p style="top:527.0pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tylcholine receptor protein levels in Alzheimer&apos;s disease patients. Dement. Geriatr.</span></p>
<p style="top:534.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Cogn. Disord. 19, 106</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">112.</span></p>
<p style="top:542.9pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Coe, J.W., Brooks, P.R., Vetelino, M.G., Wirtz, M.C., Arnold, E.P., Huang, J., et al., 2005.</span></p>
<p style="top:550.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.</span></p>
<p style="top:558.8pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">J. Med. Chem. 48, 3474</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">3477.</span></p>
<p style="top:566.8pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cohen, S.J., Stackman Jr., R.W., 2015.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Assessing rodent hippocampal involvement in the</span></p>
<p style="top:574.8pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">novel object recognition task. A review. Behav. Brain Res. 285, 105</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">117.</span></p>
<p style="top:582.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Deutsch, S.I., Schwartz, B.L., Schooler, N.R., Brown, C.H., Rosse, R.B., Rosse, S.M., 2013.</span></p>
<p style="top:590.7pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist</span></p>
<p style="top:598.7pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">strategy. Schizophr. Res. 148, 138</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">144.</span></p>
<p style="top:606.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Dunbar, G.C., Kuchibhatla, R.V., Lee, G., Group T-ACS, 2011.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> A randomized double-blind</span></p>
<p style="top:614.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects</span></p>
<p style="top:622.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with age-associated memory impairment. J. Psychopharmacol. 25, 1020</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1029.</span></p>
<p style="top:630.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Florian, H., Meier, A., Gauthier, S., Lipschitz, S., Lin, Y., Tang, Q., et al., 2016.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy and</span></p>
<p style="top:638.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">safety of ABT-126 in subjects with mild-to-moderate Alzheimer&apos;s disease on stable</span></p>
<p style="top:646.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">doses of acetylcholinesterase inhibitors: a randomized, double-blind, placebo-con-</span></p>
<p style="top:654.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">trolled study. J. Alzheimers Dis. 51, 1237</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1247.</span></p>
<p style="top:662.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Freedman, R., 2014.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Alpha7-nicotinic acetylcholine receptor agonists for cognitive en-</span></p>
<p style="top:670.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hancement in schizophrenia. Annu. Rev. Med. 65, 245</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">261.</span></p>
<p style="top:678.4pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Freedman, R., Hall, M., Adler, L.E., Leonard, S., 1995.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Evidence in postmortem brain tissue</span></p>
<p style="top:686.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psy-</span></p>
<p style="top:694.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">chiatry 38, 22</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">33.</span></p>
<p style="top:702.3pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Freedman, R., Olincy, A., Ross, R.G., Waldo, M.C., Stevens, K.E., Adler, L.E., et al., 2003.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> The</span></p>
<p style="top:710.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">genetics of sensory gating de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cits in schizophrenia. Curr. Psychiatry Rep. 5, 155</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">161.</span></p>
<p style="top:718.2pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Freedman, R., Olincy, A., Buchanan, R.W., Harris, J.G., Gold, J.M., Johnson, L., et al., 2008.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Ini-</span></p>
<p style="top:726.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165,</span></p>
<p style="top:734.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1040</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1047.</span></p>
<p style="top:56.1pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Frolich, L., Ashwood, T., Nilsson, J., Eckerwall, G., Sirocco, I., 2011.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Effects of AZD3480 on</span></p>
<p style="top:64.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cognition in patients with mild-to-moderate Alzheimer&apos;s disease: a phase IIb dose-</span></p>
<p style="top:72.0pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nding study. J. Alzheimers Dis. 24, 363</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">374.</span></p>
<p style="top:80.0pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Gault, L.M., Ritchie, C.W., Robieson, W.Z., Pritchett, Y., Othman, A.A., Lenz, R.A., 2015.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> A</span></p>
<p style="top:87.9pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">phase 2 randomized, controlled trial of the</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092"> &#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7 agonist ABT-126 in mild-to-moderate</span></p>
<p style="top:95.9pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Alzheimer&apos;s dementia. Alzheimers Dement. Transl. Res. Clin. Interv. 1, 81</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">90.</span></p>
<p style="top:103.9pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Gu, Z., Yakel, J.L., 2011.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Timing-dependent septal cholinergic induction of dynamic hippo-</span></p>
<p style="top:111.9pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">campal synaptic plasticity. Neuron 71, 155</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">165.</span></p>
<p style="top:119.8pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Haig, G.M., Bain, E.E., Robieson, W.Z., Baker, J.D., Othman, A.A., 2016.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> A randomized trial to</span></p>
<p style="top:127.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">assess the ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy and safety of ABT-126, a selective alpha7 nicotinic acetylcholine</span></p>
<p style="top:135.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">receptor agonist, in the treatment of cognitive impairment in schizophrenia. Am.</span></p>
<p style="top:143.7pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">J. Psychiatry (appiajp201515010093).</span></p>
<p style="top:151.7pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Hong, L.E., Thaker, G.K., McMahon, R.P., Summerfelt, A., Rachbeisel, J., Fuller, R.L., et al.,</span></p>
<p style="top:159.7pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2011.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Effects of moderate-dose treatment with varenicline on neurobiological and</span></p>
<p style="top:167.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cognitive biomarkers in smokers and nonsmokers with schizophrenia or</span></p>
<p style="top:175.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">schizoaffective disorder. Arch. Gen. Psychiatry 68, 1195</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1206.</span></p>
<p style="top:183.6pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Keefe, R.S., Silva, S.G., Perkins, D.O., Lieberman, J.A., 1999.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> The effects of atypical antipsy-</span></p>
<p style="top:191.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">chotic drugs on neurocognitive impairment in schizophrenia: a review and meta-</span></p>
<p style="top:199.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">analysis. Schizophr. Bull. 25, 201</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">222.</span></p>
<p style="top:207.5pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Keefe, R.S., Meltzer, H.A., Dgetluck, N., Gawryl, M., Koenig, G., Moebius, H.J., et al., 2015.</span></p>
<p style="top:215.5pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nico-</span></p>
<p style="top:223.4pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tinic acetylcholine receptor agonist, as a treatment for cognitive impairment in</span></p>
<p style="top:231.4pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">schizophrenia. Neuropsychopharmacology 40, 3053</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">3060.</span></p>
<p style="top:239.4pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Kim, S.Y., Choi, S.H., Rollema, H., Schwam, E.M., McRae, T., Dubrava, S., et al., 2014.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Phase II</span></p>
<p style="top:247.3pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">crossover trial of varenicline in mild-to-moderate Alzheimer&apos;s disease. Dement.</span></p>
<p style="top:255.3pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Geriatr. Cogn. Disord. 37, 232</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">245.</span></p>
<p style="top:263.3pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Levin, E.D., 2012.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Alpha7-nicotinic receptors and cognition. Curr. Drug Targets 13,</span></p>
<p style="top:271.3pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">602</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">606.</span></p>
<p style="top:279.2pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Lieberman, J.A., Dunbar, G., Segreti, A.C., Girgis, R.R., Seoane, F., Beaver, J.S., et al., 2013.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> A</span></p>
<p style="top:287.2pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for</span></p>
<p style="top:295.2pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cognitive enhancement in schizophrenia. Neuropsychopharmacology 38, 968</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">975.</span></p>
<p style="top:303.1pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Lipsey, M.W., Wilson, D.B., 2001.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Practical Meta-Analysis. Sage Publications, Thousand</span></p>
<p style="top:311.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Oaks, Calif.</span></p>
<p style="top:319.1pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., et al., 2001.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Laminar dis-</span></p>
<p style="top:327.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J. Chem.</span></p>
<p style="top:335.0pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Neuroanat. 22, 115</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">126.</span></p>
<p style="top:343.0pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Meltzer, H.Y., Rajagopal, L., Huang, M., Oyamada, Y., Kwon, S., Horiguchi, M., 2013.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Translating</span></p>
<p style="top:351.0pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">the</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt;color:#2e3092"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-methyl-</span><span style="font-family:AdvTT5235d5a9,serif;font-size:4.8pt;color:#2e3092">D</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-aspartate receptor antagonist model of schizophrenia to treatments for</span></p>
<p style="top:358.9pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 16, 2181</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2194.</span></p>
<p style="top:366.9pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Meyer, E.M., Kuryatov, A., Gerzanich, V., Lindstrom, J., Papke, R.L., 1998.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Analysis of 3-(4-</span></p>
<p style="top:374.9pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and</span></p>
<p style="top:382.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">rat alpha-7 nicotinic receptors. J. Pharmacol. Exp. Ther. 287, 918</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">925.</span></p>
<p style="top:390.8pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moran, T.P., Schroder, H.S., Kneip, C., Moser, J.S., 2016.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Meta-analysis and psychophysiol-</span></p>
<p style="top:398.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ogy: a tutorial using depression and action-monitoring event-related potentials. Int.</span></p>
<p style="top:406.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">J. Psychophysiol.</span></p>
<p style="top:414.7pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Olincy, A., Harris, J.G., Johnson, L.L., Pender, V., Kongs, S., Allensworth, D., et al., 2006.</span></p>
<p style="top:422.7pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psy-</span></p>
<p style="top:430.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">chiatry 63, 630</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">638.</span></p>
<p style="top:438.6pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Preskorn, S.H., Gawryl, M., Dgetluck, N., Palfreyman, M., Bauer, L.O., Hilt, D.C., 2014.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Nor-</span></p>
<p style="top:446.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">malizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related</span></p>
<p style="top:454.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">potentials and cognition: a proof of concept, randomized trial in patients with schizo-</span></p>
<p style="top:462.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">phrenia. J. Psychiatr. Pract. 20, 12</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">24.</span></p>
<p style="top:470.5pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Raber, J., 2015.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Novel images and novel locations of familiar images as sensitive transla-</span></p>
<p style="top:478.5pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tional cognitive tests in humans. Behav. Brain Res. 285, 53</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">59.</span></p>
<p style="top:486.5pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Roh, S., Hoeppner, S.S., Schoenfeld, D., Fullerton, C.A., Stoeckel, L.E., Evins, A.E., 2014.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Acute</span></p>
<p style="top:494.4pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">effects of mecamylamine and varenicline on cognitive performance in non-smokers</span></p>
<p style="top:502.4pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with and without schizophrenia. Psychopharmacology 231, 765</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">775.</span></p>
<p style="top:510.3pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Rowe, A.R., Mercer, L., Casetti, V., Sendt, K.V., Giaroli, G., Shergill, S.S., et al., 2015.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Dementia</span></p>
<p style="top:518.3pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">praecox redux: a systematic review of the nicotinic receptor as a target for cognitive</span></p>
<p style="top:526.3pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">symptoms of schizophrenia. J. Psychopharmacol. 29, 197</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">211.</span></p>
<p style="top:534.3pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Samochocki, M., Hof</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">e, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., et al.,</span></p>
<p style="top:542.3pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2003.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Galantamine is an allosterically potentiating ligand of neuronal nicotinic but</span></p>
<p style="top:550.2pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 305, 1024</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1036.</span></p>
<p style="top:558.2pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., et al., 2010.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> A</span></p>
<p style="top:566.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">randomised, double-blind, placebo-controlled trial of tropisetron in patients with</span></p>
<p style="top:574.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">schizophrenia. Ann. General Psychiatry 9, 27.</span></p>
<p style="top:582.1pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shim, J.C., Jung, D.U., Jung, S.S., Seo, Y.S., Cho, D.M., Lee, J.H., et al., 2012.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Adjunctive</span></p>
<p style="top:590.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">varenicline treatment with antipsychotic medications for cognitive impairments in</span></p>
<p style="top:598.1pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">people with schizophrenia: a randomized double-blind placebo-controlled trial.</span></p>
<p style="top:606.0pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Neuropsychopharmacology 37, 660</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">668.</span></p>
<p style="top:614.0pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Smith, R.C., Amiaz, R., Si, T.M., Maayan, L., Jin, H., Boules, S., et al., 2016.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Varenicline effects</span></p>
<p style="top:622.0pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind</span></p>
<p style="top:629.9pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">randomized trial. PLoS One 11, e0143490.</span></p>
<p style="top:637.9pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Stevens, K.E., Kem, W.R., Mahnir, V.M., Freedman, R., 1998.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Selective alpha7-nicotinic ago-</span></p>
<p style="top:645.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nists normalize inhibition of auditory response in DBA mice. Psychopharmacology</span></p>
<p style="top:653.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">136, 320</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">327.</span></p>
<p style="top:661.8pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Terry Jr., A.V., 2009.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Spatial Navigation (Water Maze) Tasks. In: Buccafusco, J.J. (Ed.),</span></p>
<p style="top:669.8pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Methods of Behavior Analysis in Neuroscience, second ed. (Boca Raton (FL)).</span></p>
<p style="top:677.8pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Umbricht, D., Keefe, R.S., Murray, S., Lowe, D.A., Porter, R., Garibaldi, G., et al., 2014.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> A ran-</span></p>
<p style="top:685.7pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">domized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487,</span></p>
<p style="top:693.7pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">for cognitive de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cits in schizophrenia. Neuropsychopharmacology 39, 1568</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1577.</span></p>
<p style="top:701.6pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Uteshev, V.V., 2014.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> The therapeutic promise of positive allosteric modulation of nicotinic</span></p>
<p style="top:709.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">receptors. Eur. J. Pharmacol. 727, 181</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">185.</span></p>
<p style="top:717.6pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Velligan, D., Brenner, R., Sicuro, F., Walling, D., Riesenberg, R., Sfera, A., et al., 2012.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Assess-</span></p>
<p style="top:725.6pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ment of the effects of AZD3480 on cognitive function in patients with schizophrenia.</span></p>
<p style="top:733.5pt;left:313.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Schizophr. Res. 134, 59</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">64.</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">52</span></p>
<p style="top:37.7pt;left:160.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>


<p style="top:56.1pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wallace, B.C., Dahabreh, I.J., Trikalinos, T.A., Lau, J., Trow, P., Schmid, C.H., 2012.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Closing the</span></p>
<p style="top:64.1pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">gap between methodologists and end-users: R as a computational back-end. J. Stat.</span></p>
<p style="top:72.0pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Softw. 49, 1</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">15.</span></p>
<p style="top:80.0pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Walling, D., Marder, S.R., Kane, J., Fleischhacker, W.W., Keefe, R.S., Hosford, D.A., et al.,</span></p>
<p style="top:87.9pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2016.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative</span></p>
<p style="top:95.9pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and cognitive symptoms of schizophrenia. Schizophr. Bull. 42, 335</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">343.</span></p>
<p style="top:103.9pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wilson, D.B., 2010.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Practical Meta-Analysis Effect Size Calculator URL: http://</span></p>
<p style="top:111.9pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">www.campbellcollaboration.org/escalc/html/EffectSizeCalculator-SMD-main.php.</span></p>
<p style="top:119.8pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wonnacott, S., Barik, J., Dickinson, J., Jones, I.W., 2006.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Nicotinic receptors modulate trans-</span></p>
<p style="top:127.8pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">mitter cross talk in the CNS: nicotinic modulation of transmitters. J. Mol. Neurosci. 30,</span></p>
<p style="top:56.1pt;left:322.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">137</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">140.</span></p>
<p style="top:64.1pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Yang, Y., Paspalas, C.D., Jin, L.E., Picciotto, M.R., Arnsten, A.F., Wang, M., 2013.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Nicotinic</span></p>
<p style="top:72.0pt;left:322.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">alpha7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex.</span></p>
<p style="top:80.0pt;left:322.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Proc. Natl. Acad. Sci. U. S. A. 110, 12078</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">12083.</span></p>
<p style="top:87.9pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Zhang, X.Y., Liu, L., Liu, S., Hong, X., Chen da, C., Xiu, M.H., et al., 2012.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Short-term</span></p>
<p style="top:95.9pt;left:322.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tropisetron treatment and cognitive and P50 auditory gating de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cits in schizophre-</span></p>
<p style="top:103.9pt;left:322.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nia. Am. J. Psychiatry 169, 974</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">981.</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">53</span></p>
<p style="top:37.7pt;left:168.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">A.S. Lewis et al. / Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry 75 (2017) 45</span><span style="font-family:AdvTT94c8263f.I+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">53</span></p>

</div>
